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Executive summary 
Concerns about long-term prescribing 
There has been concern about levels of prescribing of medicines with the potential to 
create dependence (BMA, 2015). Most research on trends in the prevalence of 
prescribing has been based on volume of medicines prescribed. One such study 
identified that increases in opioid prescribing have been most pronounced for 
stronger opioids (Curtis et al., 2018).  
 
It is also important, however, to use patient-level data so that the proportion of the 
population prescribed to, their individual characteristics, and the length of time 
medicines are prescribed for can be examined (McManus, 2018). While short-term 
use of potentially dependence forming medicines (DFM) may be clinically appropriate, 
long-term use - especially for the management of chronic pain - is generally not (FPM, 
2019).  
 
Commissioning of the 2017 report 
This need to understand trends in long-term DFM prescribing prompted the 
Department of Health and Social Care (DHSC) to commission an analysis of primary 
care data at the patient-level. An extract from the Clinical Practice Research Datalink 
(CPRD; Herrett et al., 2015) was examined to produce trends in the proportion of 
people prescribed DFM and to calculate the length of continuous prescribing periods.  
 
Continuous prescribing periods here refers to the length of an initial individual 
prescription, combined with the length of any repeat prescriptions within a particular 
time frame. The results were published in a report: Prescribing Patterns in 
Dependence Forming Medicines (Cartagena Farias et al., 2017).1  
 
Key findings from the 2017 report 
The 2017 analysis showed that the proportion of patients prescribed at least one of 
four types of DFM increased in England from 6.3% in 2000 to 9.5% in 2015. 
Benzodiazepines were the only type examined to see a reduction in prescribing. The 
other types all at least doubled in the proportion of the population prescribed to.  
 
The report also showed that the mean number of days that DFM were continuously 
prescribed for increased. In particular, the length of opioid continuous prescribing 
periods nearly doubled, from 64 days in 2000 to a peak of 102 days in 2013/2014. In 
2015, over half of prescribing periods for GABAergic medicines exceeded 30 days, as 
did around a third of benzodiazepine, opioid and Z drug prescribing periods.  
  
                                            
1 The full report includes a research of research, detailed CPRD methodology, and can be 
downloaded here: http://phrc.lshtm.ac.uk/papers/PHRC_014_Final_Report.pdf  
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The current report builds on and extends the previous analyses 
• While the previous report focused on prescribing periods exceeding 30 days, 
this report presents trends for three thresholds: 30 days, 6 months and 12 
months. This addresses a critical gap in knowledge about the extent of very 
long-term DFM prescribing in England. 
 
• In the previous report people with an epilepsy or cancer diagnosis were 
analysed separately. In the current analysis those who had ever been 
diagnosed with cancer were excluded from the sample for opioid prescribing 
trends only, and those who had ever been diagnosed with epilepsy were 
excluded for trends in GABAergic medicines only. 
 
• The current analyses additionally examine two individual medicines: 
gabapentin and pregabalin. It is important to consider trends in these 
separately as pregabalin was not introduced to the market until 2004. 
 
• This report also includes trends in the volume of sales of over-the-counter 
(OTC) medicinal products containing codeine and dihydrocodeine (2015-
2018). 
Aims 
• Estimate the proportion of individual prescriptions for each type of DFM to 
exceed 30 days, 6 months and 12 months each year, 2000 to 2015. 
 
• Estimate the proportion of continuous prescribing periods for each type of 
DFM to exceed 30 days, 6 months and 12 months each year, 2000 to 2015. 
 
• Compare the demographic and area-level characteristics of people prescribed 
DFM short- and long-term. 
 
• Explore time trends in sales of OTC medicine products containing codeine and 
dihydrocodeine, 2015 to 2018. 
 
• Review some published estimates of the number of people in England 
prescribed DFM long term. 
 
The estimates in this report draw on a relatively small data extract, the 
descriptive trend lines presented should not be viewed as definitive or 
exhaustive. This analysis is one of several studies taking place on related 
topics. Public Health England (PHE) have conducted a fuller review of the 
evidence, including detailed analyses of other data sources (Tayler et al., 
2019). 
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Methods 
The current study reanalysed the same CPRD data extract. The extract consists of a 
sample of patients prescribed at least one of the four types of DFM between 2000 
and 2015. The CPRD contains information about individual prescriptions issued by 
GPs (including the specific product and number of tablets prescribed) and about the 
patients prescribed to (such as age, sex, and area).  
 
The length of individual prescriptions was calculated. The length of continuous 
prescribing periods was estimated by combining the length of the initial prescription 
with that of all repeat prescriptions for a medicine of the same DFM type within a 
relatively short period. The estimates presented should be considered conservative. A 
range of approaches can be used to estimate what proportion of prescribing periods 
exceeded particular thresholds. The approach taken in this report was to calculate the 
prevalence of long-term prescribing in all prescribing periods occurring in a given 
year. This is ideal for understanding temporal trends, maximises the relatively small 
sample, and is consistent with the approach taken in the previous report.  
 
Time trends for longer-term prescribing periods (6 months or more) are presented for 
2001 to 2014. This is because prescribing at the start (2000) and end (2015) of the 
CPRD data extract period may not fully capture the completed period of continuous 
prescribing. Data on over the counter (OTC) sales of codeine and dihydrocodeine-
containing medicines were acquired from IRI Group Ltd. 
 
Definitions 
The following definitions are used in this report:  
 
• Prescriptions: individual prescriptions not linked at the patient level. 
 
• Continuous prescribing periods: a series of one or more prescriptions (an 
initial prescription combined with all repeat prescriptions) making up a 
continuous episode of prescribing. 
 
Key findings 
Patterns for the proportions of prescriptions and prescribing periods exceeding 30 
days were broadly consistent with the previous report, they are summarised here for 
completeness. The more nuanced sample inclusion criteria (relating to those with a 
cancer or epilepsy diagnosis) had relatively minimal effects on the results.  
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Trends in length of individual prescriptions  
A downward trend has been evident for benzodiazepines and - since 2004 - for 
GABAergic medicines in the proportion of individual prescriptions to exceed 30 days. 
The rate has been more stable for opioids and Z drugs. As expected, individual 
prescriptions exceeding 6 months were too rare for trends to be reliably examined 
with this data extract. 
 
Proportion of individual prescriptions to exceed 30 days, by DFM type 
 
 
When the two main GABAergic medicines were examined separately, we can see 
that the overall fall in 2004 in the proportion of prescriptions exceeding 30 days was 
due to the introduction of pregabalin in that year. The proportion of pregabalin 
prescriptions to exceed 30 days has remained about half the rate for gabapentin. 
Trends for GABAergic medicines as a whole are likely to reflect changes in how much 
of the total prescribing was for pregabalin and how much was for gabapentin widely 
prescribed (Montastruc et al., 2018). 
 
Proportion of individual prescriptions to exceed 30 days, gabapentin and pregabalin   
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Trends in length of continuous prescribing periods  
 
Benzodiazepines: continuous prescribing periods 
While there has been a steep fall in the proportion of benzodiazepine prescribing 
periods to exceed 30 days (from about half of prescribing periods in 2001 to a third in 
2014), reductions in the proportions of prescribing periods to exceed 6 and 12 months 
have been less clear.  
 
Benzodiazepines: Proportion of continuous prescribing periods to exceed 30 days 
 
 
In 2014, 12% of continuous benzodiazepine prescribing periods exceeded 6 months. 
Half of these (6% of prescribing periods that year) exceeded 12 months. There are 
indications of a slight downward trend over time. Around 13% of prescribing periods 
exceeded 6 months in 2001 to 2003, while since 2007 10% to 12% were prescribed 
at this level. 
 
Benzodiazepine: proportion of continuous prescribing periods to exceed 6 and 12 
months 
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Z drugs: continuous prescribing periods 
In 2014, 37% of continuous Z drug prescribing periods exceeded 30 days. The rate 
has had a slight downward trend over time.  
 
Z-drugs: Proportion of continuous prescribing periods to exceed 30 days 
 
 
Similar to benzodiazepines, in 2014 13% of Z drug continuous prescribing periods 
exceeded 6 months, and 6% exceeded a year. While the rate exceeding 30 days 
appears to have decreased, the rate exceeding these longer thresholds may be 
increasing. 
 
Z-drugs: proportion of continuous prescribing periods to exceed 6 and 12 months 
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Opioids: continuous prescribing periods 
Similarly, while the proportion of continuous prescribing periods to exceed 30 days 
reduced (from 38% in 2001 to 34% in 2014) no reduction was evident at the longer 
thresholds. Rather, the results were indicative of a slight upward trend over time. 
 
Opioids: Proportion of continuous prescribing periods to exceed 30 days 
 
 
Opioids: proportion of continuous prescribing periods to exceed 6 and 12 months 
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Gabapentin: continuous prescribing periods 
Since 2010, the proportion of gabapentin prescribing periods to exceed 30 days fell 
from 76% to 60% in 2014.  
to 2014 (Figure 14). 
 
Gabapentin: Proportion of continuous prescribing periods to exceed 30 days  
 
 
The rates exceeding 6 and 12 months fluctuate in the data but are not consistent with 
a pattern of long-time decline. 
 
Gabapentin: proportion of continuous prescribing periods to exceed 6 and 12 months  
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Pregabalin: continuous prescribing periods 
While the proportion of pregabalin prescribing periods to exceed 30 days remained 
around 60% between 2004 and 2014, the proportion to exceed longer thresholds 
steadily grew over this period. In 2014, 16% of continuous pregabalin prescribing 
periods exceed 6 months and 8% exceeded a year. 
 
Pregabalin: Proportion of continuous prescribing thresholds to exceed 30 days 
 
 
 
Pregabalin: proportion of continuous prescribing periods to exceed 6 and 12 months 
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Among those prescribed DFM: characteristics of people prescribed 
DFM long-term:  
Among those patients prescribed DFM, the characteristics of those prescribed to 
longer-term can be compared with the characteristics of those prescribed to shorter-
term. It is important to bear in mind, however, that these comparisons do not take 
account of the characteristics associated with being prescribed DFM at all. 
 
Older people  
For most types of DFM (except opioids), older people prescribed the drug were more 
likely than younger people to be prescribed it for more than 6 months. For example, in 
2014 18.7% of those aged 81 and over who were prescribed Z drugs were prescribed 
to for more than six months, compared with 5.1% of those prescribed the drug who 
were 18 to 40-year olds.  
 
Z drugs: proportion of continuous prescribing periods to exceed 6 months, by age 
 
Men 
In 2014, for all types of DFM, continuous prescribing periods in excess of 12 months 
were more likely among men prescribed the drug than among women who were 
prescribed to. Differences by sex, however, were not evident at other prescribing 
thresholds or in earlier years.  
 
North of England 
The sample was grouped into five regions: North of England, Midlands and East of 
England, London, South East, and South West. People prescribed DFM and living in 
the North were more likely than those living in other regions to be prescribed to for 
periods in excess of 6 and 12 months. This was the case for all classes of DFM.  
 
Deprived neighbourhoods 
Among people prescribed DFM, those living in deprived areas were generally more 
likely to be prescribed to for longer. This association, for example, has remained 
evident and pronounced among those prescribed opioids in every year of the data 
extract. 
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Opioids: proportion of continuous prescribing periods to exceed 6 months, in areas of 
least (Q1) and most (Q5) deprivation  
Trends sales of over the counter (OTC) medicines  
There was a small reduction in the volume of OTC sales of medicines containing 
codeine or dihydrocodeine between 2015/2016 and 2017/2018. Apart from a slight 
increase in sales of ibuprofen and codeine combinations, all products showed a small 
fall in sales volume between 2015/6 and 2017/18.  
 
Total counts of sales of individual codeine and dihydrocodeine-containing medicines 
 
 
 
Estimates of the prevalence of prescribed medicine dependence 
We need to be cautious about drawing conclusions about dependence on prescribed 
medicines from primary care data, even where the analyses take account of length of 
prescribing. We discuss three papers that have been used to extrapolate such a 
prevalence and conclude that they should not be used in this way. 
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Limitations 
The analyses presented in this report have limitations, including that they: 
• Examine trends by broad class of medicine, and do not take account of 
medicine strength or variations in dose.  
 
• Are based on a relatively small sample (<50,000 patients).  
 
• Relate to prescribing practice: these data do not indicate whether medicines 
were dispensed, whether they were taken, and whether they were taken by 
the patient they were prescribed to or by someone else. 
 
• Cannot tell us whether long-term prescribing was clinically appropriate in 
individual cases, nor whether patients were dependent on prescribed 
medicines. 
 
• Apply strict rules on what constitutes a continuous prescribing period; 
estimates should be regarded as conservative. 
 
• Do not capture recent trends (since 2015). 
 
 
Conclusions and implications 
Prevalence: Individual DFM prescriptions almost never exceeded 12 months. 
However, once repeat prescribing is accounted for a sizeable minority of continuous 
prescribing periods exceed this level: about one in twenty in 2014 lasted more than a 
year. This ranged from about 4% of prescribing periods for opioids and gabapentin, to 
6% for benzodiazepines and gabapentin, and 8% for pregabalin.  
 
Change over time: While the prevalence of continuous prescribing over 30 days 
tended to show signs of decline, there is little evidence of any decline at longer-term 
thresholds.  
 
Pregabalin trends: Prescribing for periods in excess of 12 months increased 
particularly sharply for pregabalin since its introduction in 2004. As pregabalin and 
gabapentin become controlled as class C drugs (Home Office, 2018), it will be 
important to monitor the impact of reclassification on prescribing practice (Torjesen, 
2019). Awareness of this steep increase in long-term pregabalin prescribing is 
relevant across sectors, and should inform service provision in primary care, 
specialist services (such as pain management), and psychiatry. 
 
Variation: Those most likely to be prescribed DFM at this level were older, living in 
deprived neighbourhoods, and living in the North of England. In 2014 being male 
emerged as associated with prescribing for periods exceeding 12 months. It is 
possible that changing prescribing practices are not addressing the issue of very 
long-term prescribing in some groups of men. 
 
  
 13 
 
Further research 
• The current analyses drew on a relatively small extract of data from the 
CPRD. There is a need for further research with larger CPRD extracts which 
explore patterns in long-term prescribing for individual medicines.  
 
• In relation to the monitoring of opioid prescribing periods, this should include 
taking account of oral morphine equivalence (OME) (Curtis et al., 2019). 
 
• Further analyses could draw on other information available in the CPRD, both 
to more fully profile the extent of DFM prescribing and the characteristics of 
who is prescribed to long term. As information on diagnoses and symptom 
recording improves, this could include exploring psychiatric comorbidities in 
this population. 
 
• Different methods can be used to calculate the length of continuous 
prescribing periods and to monitor change over time in these. The analyses in 
this report should be replicated using other approaches.  
 
• OTC sales data can be used to examine trends at the aggregate level. Further 
work exploring individual level purchasing and use of OTC products containing 
codeine and dihydrocodeine is needed, and could be achieved with the 
inclusion of questions on general population surveys such as the Health 
Survey for England (HSE) and the Adult Psychiatric Morbidity Survey (APMS). 
 
• Up-to-date monitoring of duration of prescribing is essential, in particular 
review of current trends in the long-term prescribing of pregabalin. 
 
• Alongside monitoring prescribing data, other types of research are also 
needed to understand the nature and extent of dependence on prescription 
medicines. 
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1 Introduction 
1.1 Background 
There has been concern about levels of prescribing (Curtis et al. 2019), particularly 
the risks associated with long-term prescribing (McManus, 2018), of medicines with 
the potential to create dependence. Dependence here refers to the need to continue 
taking a medicine to maintain a state of feeling normal and to avoid symptoms of 
withdrawal.  
 
In response to this concern, a report was commissioned through the Public Health 
Research Consortium (PHRC) by the National Institute for Health Research (NIHR) 
Policy Research Programme: Prescribing Patterns in Dependence Forming Medicines 
(Cartagena Farias et al., 2017).2 The National Centre for Social Research - with 
clinical and methodological support from the Institute of Psychiatry, Psychology and 
Neuroscience and University of Bristol - undertook the descriptive study of prescribing 
trends. This report included a rapid review of literature and should be referred to for 
details of previous research on the topic. It also included analysis of an extract from 
the Clinical Practice Research Datalink (CPRD) and methodological details about that 
extract. The report described: 
 
• Trends (2000-2015) in the proportion of people prescribed medicines known to 
have the potential to be dependence forming, and prescribing trends for four 
different types of dependence forming medicines (benzodiazepines, Z-drugs, 
opioids and GABAergic medicines). 
• Trends in the characteristics of prescribing periods: mean number of days 
prescribed for and the proportion exceeding 30 days. 
• Trends in the characteristics of people prescribed dependence forming 
medicines long term: age, sex, region, health, and area-level deprivation. 
 
The report produced new information at the patient level necessary to understand 
trends in prescribing practice. It confirmed falls at the patient level in the extent and 
length of benzodiazepine prescribing, but also found increases in the prescribing of 
other types of dependence forming medicines (DFM).  
 
The findings raised additional questions at Department of Health and Social Care 
(DHSC), Public Health England (PHE) and for the All Party Parliamentary Group 
(APPG) for prescribed drug dependence, specifically around continuous prescribing 
periods to exceed even longer thresholds. 
1.2 New analyses in this report  
The following definitions are used in this report: 
 
Prescriptions: individual prescriptions that are not linked at the patient level.  
Continuous prescribing periods: a series of one or more prescriptions (an initial 
prescription combined with all repeat prescriptions) making up a continuous episode 
of prescribing. 
 
The current study revisits the same data extract as that used in the previous report, 
but builds on the analysis in several new ways: 
                                            
2 http://phrc.lshtm.ac.uk/papers/PHRC_014_Final_Report.pdf 
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Different thresholds of long-term prescribing 
The previous report presented the proportion of prescriptions and the proportion of 
continuous prescribing periods of benzodiazepines, Z-drugs, opioids or GABAergic 
medicines to exceed 30 days (the recommended maximum for some drug classes). 
The current analyses extend this by presenting the proportion of prescriptions and 
continuous prescribing periods to exceed three different prescribing length thresholds: 
30 days, 6 months, and 12 months.  
 
Differently defined patient population 
People with a diagnosis of epilepsy or cancer were analysed separately from other 
people in the previous analysis. This was done to reduce the inclusion of prescribing 
linked to the management of epilepsy and cancer-related pain and the use of 
medicines in community-based palliative care. In the current analysis, however, a 
more nuanced approach has been taken. Those with a cancer diagnosis were 
excluded from the analyses of opioid prescribing trends only (and retained in the 
sample for other drug classes), and those with an epilepsy diagnosis were excluded 
from the analysis of GABAergic medicines (and retained in the sample for the other 
drug classes). 
 
Separate focus on gabapentin and pregabalin  
The previous report examined prescribing for four classes of drugs: benzodiazepines, 
Z-drugs, opioids, and GABAergic medicines. The current analyses also examine two 
individual medicines included in that combined GABAergic medicine grouping - 
gabapentin and pregabalin – separately. It is important to examine trends in these 
separately as pregabalin was not introduced to the market until 2004. 
 
Inclusion of separate analysis of over-the-counter (OTC) opioid sales 
The previous report drew only on analysis of primary care prescribing data, while this 
report includes analysis of scale and trends in sales of OTC medicinal products 
containing codeine and dihydrocodeine (2015-2018). 
1.3 Objectives 
The main objectives were to examine the extent to which DFM are prescribed long-
term and to profile the characteristics of people who are prescribed to long-term. We 
also include analysis of the sales of over-the-counter medicines containing 
(dihydro)codeine and evaluate some published estimates of the extent of long-term 
DFM prescribing (see Appendix B). 
 
Objective 1 
Estimate the proportion of individual prescriptions for each type of DFM to exceed 30 
days, 6 months and 12 months each year between 2000 and 2015 (Chapters 3 and 
4). 
 
Objective 2 
Estimate the proportion of continuous prescribing periods for each type of DFM to 
exceed 30 days, 6 months and 12 months each year between 2000 and 2015 
(Chapters 3 and 4). 
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Objective 3 
Describe the demographic (age, sex) and area-level (deprivation and region) 
characteristics of people prescribed DFMs short- and longer-term each year between 
2000 and 2015 (Chapters 5 and 6). 
 
Objective 4 
Produce time trends in the volume of annual sales of OTC medicine products 
containing codeine and dihydrocodeine, between 2015 and 2018 (Chapter 7). 
 
Objective 5 
Extrapolate from the proportion of prescribing periods in 2014/5 to estimate the 
proportion of the population to be prescribed each type of DFM continuously in 
excess of 30 days, 6 months and 12 months (Chapter 8). 
 
Objective 6 
Review some published estimates of the number of people in England who are 
dependent on prescribed medicines (Appendix B).  
 
Data tables are presented in Appendix A. Methods are described in Chapter 2, with 
further detail about the CPRD extract in Appendix D and the medicines included in 
the analysis listed in Appendix E.   
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2  Methods 
2.1 Data extraction 
The Clinical Practice Research Datalink (CPRD) contains primary care data for 
approximately 8% of the UK population (Herrett at el., 2015). A geographically 
representative random sample of 49,999 individuals living in England and prescribed 
any benzodiazepine, Z-drug, opioid or GABAergic medicines between 2000 and 2015 
was extracted for analysis.  
 
Further detail about the CPRD extract are provided in Appendix D and a list of all 
medicines included in each of DFM groups examined is provided in Appendix E. A full 
description of the structure, content and generalisability of the CPRD dataset can also 
be found in the previous report (Cartagena Farias et al., 2017), including  further 
description of the data extract used for analysis.  
2.2 Estimating length of individual prescriptions 
The length of an individual prescription was defined as the number of treatment days 
a drug is prescribed for a specific therapy event on a specific occasion. Each 
consultation provided information regarding the total dose and numeric daily dose of a 
particular drug. To calculate the length of each individual prescription, the total 
quantity of drug prescribed was divided by the numeric daily dose for each given 
therapy (e.g. 90 tablets / 3 tablets per day = 30 days duration). Variations in dose 
levels were not accounted for. 
2.3 Estimating length of continuous prescribing 
periods 
The number of days for which a particular class of drug was continuously prescribed 
to a person for was estimated by adding the length of an initial prescription to the 
length of any repeat prescriptions. A repeat prescription was identified when the same 
drug (or another drug in the same class) was prescribed to the same person within a 
period. To identify a series of prescriptions that could reliably be classified as repeat 
prescriptions, the following rules were applied:  
 
1. The number of days between each consultation is less than or equal to 35 days, or 
the length of the previous prescription is equal to, or less than, the number of the 
days between consultations (plus 5 days). This ensured that a repeat prescription 
was identified, as opposed to multiple prescriptions over a longer period. 
 
2. In some instances, consultation identifiers varied despite being held on the same 
day; it was assumed that all events that occurred on the same day were part of the 
same consultation. 
 
3. For analyses of the four major classes of drugs (benzodiazepines, Z-drugs, opioids 
and GABAergic medicines): if a patient switched from one type of benzodiazepine to 
another type of benzodiazepine, this still counted as a continuous prescribing period; 
the same applied to other classes of drug.   
 
4. If two different drugs belonging to the same class of drug were prescribed in the 
same consultation (e.g. diazepam and lorazepam), the longer of the two derived 
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prescription lengths was used. Similarly, if two different prescription lengths were 
prescribed in the same consultation then the longer length was used. 
 
5. The first consultation date when a drug was prescribed was noted as the start date 
of a continuous prescribing period; this ensured that repeat prescriptions following 
from one year to the next were counted from the original start date. 
 
When reporting on prescribing periods that span two calendar years, duration length 
is based on when the prescribing period ends as opposed to curtailing periods at the 
end of a calendar year. As a result, periods spanning more than one calendar year 
are effectively reported twice, in both consecutive years. Likewise, periods spanning 
three years are captured in the data for each of those years. For example, if someone 
was prescribed opioids from May 2001 to August 2002, that would be counted as a 
continuous prescribing period exceeding 12 months in both 2001 and 2002. This 
phenomenon will affect longer prescribing periods more than shorter term prescribing. 
Because prevalence per year is reported, the validity of rates of longer-term 
prescribing is maintained as the relevant prescribing period did indeed occur in both 
consecutive years. 
It is important to note that the CPRD data extract is cut off at the end of 2015, so it is 
likely that a proportion of people had not yet completed their continuous prescribing 
period. This is an issue when estimating the proportion of prescribing periods 
exceeding the longer thresholds, such as 6 or 12 months. Because of this, estimates 
for the final year of data (2015) have not been fully presented, and are given in grey 
text in the tables. Similarly, a significant proportion of people would not have their full 
continuous prescribing period captured at the start of the study period. For instance, 
we would expect low estimates of the proportion of people with a continuous 
prescribing period of 12 months within the first 12 months of the data as many people 
would have received their initial prescription before the start date of the extract. This 
report shows the rates for 2001 to 2014 for continuous prescribing periods exceeding 
6 months and 12 months due to concern about the reliability of longer-term estimates 
for 2000 and 2015; rates for prescriptions, however, include estimates for 2000 as 
truncation should not affect this estimate. 
We use the following conventions in all results tables, ‘-‘ denotes no observations 
(zero value), and ‘0’ denotes non-zero values of less than 0.05% and are thus 
rounded to zero. 
2.4 Base population 
The unit of analysis in the tables varied according to the subject being examined and 
is referred to in the text. Analyses examining trends over time used either 
prescriptions or continuous prescribing periods, where appropriate, whereas analyses 
of the characteristics of long-term prescribing in 2014 refers to people. For the latter 
analyses, prescribing patterns were investigated by area level deprivation of the GP 
practice, region and by the gender and age of the person prescribed to. When 
examining the characteristics of people prescribed to for periods in excess of six or 12 
months, some age bands were combined due to small base sizes.   
2.5 Analysis 
The mean length of prescriptions and continuous prescribing periods for each class of 
DFM and for two types of GABAergic medicines – pregabalin and gabapentin – were 
derived for each year of the data. The results presenting trends over time in 
prescriptions and continuous prescribing periods are descriptive, unadjusted, and not 
tested for statistical significance. 
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Further analysis estimated the proportion of prescriptions and continuous prescribing 
periods for each class of DFM which were in excess of 30 days, 6 months, and 12 
months. These thresholds are not mutually exclusive, meaning that a continuous 
prescribing period in excess of 12 months was also counted as a prescribing period in 
excess of 30 days and in excess of 6 months.  
 
The unit of analysis for the trends described above was prescribing events. These 
were also used to extrapolate a crude estimate of the proportion of the total 
population in 2014 to be prescribed each DFM long-term. For example, we know that 
5.2% of the total CPRD population were prescribed opioids in 2014. We also know 
that 33.7% of continuous opioid prescribing periods in 2014 exceeded 30 days. 
Extrapolating from this, we can estimate that approximately 33.7% of the people 
prescribed opioids were prescribed long-term (33.7% of 5.2% = 1.8% of the total 
population). The key assumption here is that there was little association between the 
number of continuous prescribing periods someone experienced in a year and the 
length of each of those continuous prescribing periods. The mean number of 
prescribing periods per person prescribed to was less than 2 for all types of DFM. 
Because of the uncertainty and scope for systematic undercounting, we recommend 
that these proportions are viewed as minimum estimates and indicative only.3 
2.6 Exclusion criteria 
Exclusion criteria differed from those applied in the previous report. Individuals with 
an epilepsy diagnosis (at any point in the data extract) were excluded from the 
analysis of GABAergic medicines (including pregabalin- and gabapentin-specific 
analyses). This was because some GABAergic medicines have been approved for 
the long-term treatment of epilepsy. People with a cancer diagnosis (at any point in 
the data extract) were excluded from the analysis of opioid prescribing as the use of 
opioids in the treatment of severe cancer-related pain is considered standard 
procedure, although their suitability for treating chronic, non-cancer related pain has 
been questioned. These exclusion criteria were not applied to the analysis of 
benzodiazepines and Z-drugs.  
2.7  Missing data 
Overall, variation in the amount of missing data was not pronounced by gender, age 
or practice (see previous report). However, bias resulting from missing data could not 
be ruled out for other characteristics for which we could not make assessments. 
Therefore, missing data need to be acknowledged as a potential limitation which 
could have biased the results. 
2.8 Over-the-counter sales 
Data on the sales of over-the-counter (OTC) medicines containing codeine or 
dihydrocodeine between February 2015 and February 2018 were acquired from IRI 
Worldwide. Total counts of individual tablets were derived for each 12-month period 
from week ending February 28th, 2015. Counts were calculated from the sales 
volume multiplied by the pack size. 
 
                                            
3 These extrapolations are approximate and should be regarded as likely underestimate.  
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3 Trends in DFM prescribing 
This chapter presents trends in the prescribing of four classes of DFM: 
benzodiazepines, Z-drugs, opioids and GABAergic medicines. Trends for each of 
gabapentin and pregabalin (subclasses of GABAergic medicine) are presented 
separately in Chapter 4. 
3.1 Proportion of people prescribed to 
In the previous report analyses of these data showed that the overall proportion of 
people prescribed DFM at any point in the year increased from 6.3% in 2000 to a 
peak of 9.5% in 2012. The pattern varied by type of DFM. Opioids, Z-drugs and 
GABAergic medicines saw pronounced increases in the proportion of people for 
whom they were prescribed. The proportion prescribed opioids and Z-drugs doubled 
between 2000 and 2012. GABAergic medicine prescribing increased even more 
steeply, from 0.2% of people in 2000 (following approval in October 2000) to 2.1% in 
2015. This context should be borne in mind when interpreting trends in the length of 
time medicines were prescribed for. 
3.2 Mean average length of prescribing  
The mean average number of days of individual prescriptions and of continuous 
prescribing periods are presented for each type of DFM in Appendices 1 and 2. 
These were produced using different exclusion criteria from the previous report (see 
Section 2.5). The revised mean lengths are similar to the results previously reported. 
GABAergic medicine prescriptions tended to be issued for longer than the other types 
of DFM; benzodiazepines, Z-drug and opioid prescriptions averaged a mean length of 
between 24-25 days in 2014 compared with 31 days for GABAergic medicines. The 
average length of prescriptions for GABAergic medicines remained stable between 
2000 and 2015, but average prescription lengths decreased for all other drugs; 
decreases were particularly marked for opioids (36 days in 2000 to 24 days in 2015).  
 
Continuous periods of DFM prescribing in 2014 averaged between 103 and 123 days. 
The average prescribing period for opioids increased from 64 days in 2000, to a peak 
of 103 days in 2014. The continuous prescribing periods for other DFMs remained 
more stable over time.  
3.3 Prescriptions exceeding thresholds 
The length of prescriptions was examined in relation to three thresholds. Rates were 
calculated for the proportion of prescriptions for benzodiazepines, Z-drugs, opioids 
and GABAergic medicines (including separately for gabapentin and for pregabalin, 
presented in the next chapter) to exceed:  
• 30 days 
• 6 months 
• 12 months 
 
Consistent with the trends presented here, the previous report (Cartagena Farias et 
al., 2017) also showed that the proportion of prescriptions for benzodiazepine and 
GABAergic medicines to exceed 30 days fluctuated but with general downward trends 
over time (Figure 1). For opioids, the proportion of prescriptions exceeding 30 days 
was around 15% from 2000-2007, and between 16-18% from 2007-2015. For Z-
drugs, the proportion of prescriptions exceeding 30 days fluctuated between 10-12% 
between 2000 and 2010 and remained below 10% 2011-2015. 
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Figure 1: Proportion of prescriptions exceeding 30 days by DFM type 
 
Source: CPRD (see Appendix 3) 
 
The proportion of individual prescriptions to exceed 6 months and 12 months by DFM 
type was examined, but as expected, the proportion at each year was close to zero 
for these longer thresholds and no trend in prescribing was detectable. 
3.4 Continuous prescribing periods exceeding 
thresholds 
Cartagena Farias and colleagues (2017) described the proportion of continuous 
prescribing periods to exceed 30 days. The current re-analysis of the same data 
reproduces these trends using the updated set of exclusion criteria, as well as also 
presenting trends for the proportion of continuous prescribing periods to exceed 6 and 
12 months.  
 
Figures 2-5 below show the proportion of continuous prescribing periods for 
benzodiazepines, Z-drugs, opioids and GABAergic medicines to exceed 30 days, 6 
months and 12 months. 
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3.4.1 Benzodiazepines 
The proportion of continuous benzodiazepine prescribing periods to exceed 30 days 
fell from about half in 2001 to about a third in 2011-2014 (Figure 2). The proportion to 
exceed six months was around 12%-13% between 2001 and 2007, and 10%-11% 
between 2008 and 2014 (Figure 3). Prescribing periods exceeding 12 months 
followed a similar pattern: the rate was about 6% between 2001 and 2007, and about 
5% between 2008 and 2014. 
 
Figure 2: Benzodiazepines: Proportion of continuous prescribing periods exceeding 
thresholds 
 
(Source: Appendix 4 to Appendix 6) 
 
 
Figure 3: Benzodiazepines: Proportion of continuous prescribing periods exceeding 6 
and 12 months 
 
(Source: Appendix 4 to Appendix 6) 
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3.4.2 Z-drugs 
Less than half of continuous prescribing periods of Z-drugs were in excess of 30 days 
between 2001 and 2012 (varying between 41% and 44%), and after 2012 the 
prescribing rate varied between 37%-40% (Figure 4). The proportion to exceed 6 
months remained mostly below about 12% between 2001 and 2010, and above 12% 
since 2011 (Figure 5). Prescribing periods exceeding 12 months followed a similar 
pattern: about 4% to 5% between 2001 and 2010, since 2011 the rate was 6%. 
 
Figure 4: Z-drugs: Proportion of continuous prescribing periods exceeding thresholds 
 
 (Source: Appendix 4 to Appendix 6) 
 
Figure 5: Z-drugs: Proportion of continuous prescribing periods exceeding 6 and 12 
months 
 
(Source: Appendix 4 to Appendix 6) 
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3.4.3 Opioids 
The proportion of continuous opioid prescribing periods to exceed 30 days diminished 
from 2012 onwards, following a consistent rate of around 37%-39% between 2001-
2011 (Figure 6). The proportion to exceed 6 months remained around 6%-7% 
between 2001 and 2008, and 7%-8% between 2009 and 2014 (Figure 8). Prescribing 
periods exceeding 12 months followed a similar pattern: about 2%-3% between 2001 
and 2008, and 3%-4% between 2009 and 2014. 
 
Figure 6: Opioids: Proportion of continuous prescribing periods exceeding thresholds 
 
(Source: Appendix 4 to Appendix 6) 
 
Figure 7: Opioids: Proportion of continuous prescribing periods exceeding 6 and 12 
months 
 
(Source: Appendix 4 to Appendix 6) 
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3.4.4 GABAergic medicines 
The proportion of continuous GABAergic medicine prescribing periods to exceed 30 
days increased from 58% in 2001 to 71% in 2005 (Figure 8); this covers the period in 
which pregabalin was first introduced. Prescribing rates diminished from 69% in 2010 
to 58% in 2014. The proportion to exceed 6 months remained around 10%-12% 
between 2001 and 2005, and 13%-14% between 2006 and 2014 (Figure 9). 
Prescribing periods exceeding 12 months diminished slightly from 5% to 3% between 
2001 and 2005, and then increased back up to 5% in 2014. 
 
Figure 8: GABAergic medicines: Proportion of continuous prescribing periods 
exceeding thresholds 
 
 (Source: Appendix 4 to Appendix 6) 
 
Figure 9: GABAergic medicines: Proportion of continuous prescribing periods 
exceeding 6 and 12 months  
(Source: Appendix 4 to Appendix 6) 
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4 Trends in gabapentin and pregabalin 
prescribing 
 
As well as producing trends for the combined category of GABAergic medicines, we 
also examined two of the main individual GABAergic medicines separately: 
gabapentin and pregabalin.  
 
4.1 Items prescribed in England 2008-2018 
Figure 10 draws on recently published NHS Digital data showing the volume of 
prescriptions dispensed in England between 2008 and 2018 (NHSD 2019). These 
figures include prescribing for all indications, while our analysis of GABAergic 
medicines excluded prescribing to those with an epilepsy diagnosis. However, the 
NHS Digital figures do provide useful context on the increasing volume of overall 
GABAergic prescribing and demonstrate that most prescribing is for gabapentin or 
pregabalin.   
 
Figure 10: Number of GABAergic medicine items dispensed in 2008-2018 
 
 
4.2 Average length of prescriptions and 
continuous prescribing periods 
The average number of days individual gabapentin prescription were issued for 
remained stable over time at around 36 days (Figure 11). Average pregabalin 
prescriptions increased in length from 2004 (when pregabalin was first approved for 
use in the European Union) to 2008; from 2008 onwards, the number of days covered 
by individual pregabalin prescriptions remained stable at a mean of around 35 days.  
Figure 11: Average number of days of prescriptions by GABAergic medicine type 
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Source: CPRD (see Appendix 7) 
 
The average number of days that gabapentin was continuously prescribed for 
remained relatively stable, but with some fluctuations (Figure 12). The average 
number of days that pregabalin was prescribed for increased steeply over this time, 
almost doubling between 2004 (67 days) and 2014 (127 days).  
 
Figure 12: Average number of days of continuous prescribing periods by GABAergic 
medicine type 
 
Source: CPRD (see Appendix 8) 
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4.3 Prescriptions exceeding thresholds   
Figure 13 shows the proportions of prescriptions exceeding 30 days for people 
prescribed gabapentin and pregabalin. The proportion of gabapentin prescriptions to 
exceed 30 days increased over time until around 2011, at which time the proportion 
declined from 65% to 52% in 2014. The proportion of pregabalin prescriptions to 
exceed 30 days has also broadly increased over time, from about 13% when the drug 
was first introduced to about 30% in 2013 and 2014. 
 
Figure 13: Proportion of prescriptions exceeding 30 days by GABAergic medicine type   
 
 
Source: CPRD (see Appendix 9) 
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4.4 Continuous prescribing periods exceeding 
thresholds   
 
The figures below show the proportion of continuous prescribing periods for 
gabapentin and pregabalin to exceed 30 days, 6 months and 12 months. 
4.4.1 Gabapentin 
The proportion of continuous prescribing periods exceeding 30 days remained stable 
up to 2010, when rates fell sharply for the next 4 years. Rates of prescribing for 
thresholds exceeding 6 months and 12 months remained relatively stable from 2001 
to 2014 (Figure 14). 
 
Figure 14: Gabapentin: Proportion of continuous prescribing periods exceeding 
thresholds  
 
 
 (Source: CPRD Appendix 10 to Appendix 12) 
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4.4.2 Pregabalin 
The proportion of continuous prescribing periods exceeding 30 days fluctuated from 
2004 to 2014, but there was no particular upward or downward trend over this time 
(Figure 15). Conversely, rates of prescribing exceeding 6 months and 12 months 
steadily increased over time (Figure 16) 
 
Figure 15: Pregabalin: Proportion of continuous prescribing periods exceeding 
thresholds 
 
Source: CPRD (see Appendix 10 to Appendix 12) 
 
 
 
Figure 16: Pregabalin: Proportion of continuous prescribing periods exceeding 6 and 
12 months  
 
Source: CPRD (see Appendix 10 to Appendix 12) 
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5 Characteristics associated with DFM 
prescribing in excess of 6 months 
5.1 Variation in continuous prescribing by age-
group 
Among patients prescribed DFM, the characteristics of those prescribed to 
continuously for six months or more could be compared with the characteristics of 
those prescribed to for less than six months. It is important to bear in mind, however, 
that these comparisons do not take account of the characteristics associated with 
being prescribed DFM at all. Too few patients in the sample were prescribed to for 
more than 12 months for these results to be robust. They are therefore not discussed 
in the text but are presented in the tables in Appendix A for reference.  
5.1.1 Benzodiazepines 
Older people prescribed benzodiazepines were more likely to be prescribed to in 
excess of 6 months than younger people prescribed the drug. This association with 
age has remained consistent over time. 
 
Figure 17: Benzodiazepines: Proportion to exceed continuous prescribing threshold of 
6 months, by age  
 
 
Base: People prescribed benzodiazepines each year. Source: CPRD (see Appendix 
14) 
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5.1.2 Z-drugs 
Similar to benzodiazepine prescribing, older people prescribed Z-drugs were more 
likely than younger people prescribed the drug to be prescribed for periods exceeding 
6 months (and 12 months, see Appendix 18). This pattern has remained consistent 
over time. 
Figure 18: Z-drug: Proportion to exceed continuous prescribing threshold of 6 months, 
by age 
 
 
Base: People prescribed Z-drugs each year. Source: CPRD (see Appendix 17) 
5.1.3 Opioids 
Among people prescribed opioids, the association between age and being prescribed 
to longer-term (6+ months) was less clear cut. While younger people prescribed the 
drug were generally less likely to be prescribed it longer term, the rates for other age 
groups were similar.  
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Figure 19: Opioid: Proportion to exceed continuous prescribing threshold of 6 months, 
by age 
 
Base: People prescribed opioids each year. Source: CPRD (see Appendix 20) 
5.1.4 GABAergic medicines 
Age related differences in prescribing of GABAergic medicines in excess of 6 months 
have changed over the study period. The pattern of prescribing is variable from 2001 
to 2007, but an age association emerged from 2008 with longer-term prescribing 
becoming more common in older than younger people. 
 
Figure 20: GABAergic medicines: Proportion to exceed continuous prescribing 
threshold of 6 months, by age 
 
 
Base: People prescribed GABAergic medicines each year. Source: CPRD (see 
Appendix 23) 
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5.2 Variation in continuous prescribing by 
gender 
 
The previous report found little in terms of an association with gender for any DFM 
prescribing in excess of 30 days. The results from this report largely replicate these 
findings for prescribing exceeding 6 months and 12 months. Notable exceptions to 
this overall pattern include evidence of gender differences in prescribing exceeding 6 
months up to 2008/2009 for benzodiazepines and GABAergic medicines, and men 
were more likely to be prescribed to in 2014 for periods exceeding 12 months across 
all DFMs (see Appendix 25 to Appendix 27).  
5.3 Variation in continuous prescribing by area 
level deprivation 
 
Variations in continuous prescribing by area level deprivation was examined using 
measures of IMD at the lower level super output area (LSOA) of the patient’s home 
address4. Figure 21 shows that people prescribed DFM who lived in the most 
deprived areas were more likely to be prescribed benzodiazepines, Z-drugs and 
opioids for 6 months or more than those in the least deprived areas; the variation in 
long term prescribing periods exceeding 6 months for GABAergic medicines by 
deprivation level was more mixed. Similarly, people prescribed DFM who lived in the 
most deprived areas were more likely to be prescribed benzodiazepines, Z-drugs and 
opioids for 12 months or more compared to those in the least deprived areas, while 
the pattern for GABAergic medicines by area deprivation level was again more mixed.  
 
Figure 21: Proportion of continuous prescribing periods to exceed 6 months among 
people prescribed DFM and living in the least (Q1) and most (Q5) deprived areas 
Benzodiazepines 
 
                                            
4 Practice level IMD was available in CPRD but we chose to use patient level IMD as we are 
interested in patient characteristics as opposed to those of the GP practice. 
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Z-drugs 
Opioids 
GABAergic medicines 
 
Source: CPRD (see Appendix 29, Appendix 32, Appendix 35, Appendix 38) Based on 
people living in the fifth of areas with the most deprivation (Q5) and the fifth of areas 
with the least deprivation (Q1) according to the 2007 Index of Multiple Deprivation 
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5.4 Characteristics associated with long-term 
prescribing in 2014 
 
CPRD data for 2014 were examined to compare the circumstances of people 
prescribed DFMs short term (that is, for continuous periods of 30 days or less) and 
long-term (more than 6 and 12 months). See Table 1 to Table 4. Comparisons by 
characteristics were made separately for each threshold. 
5.4.1 Gender variations in long-term prescribing 
Among people prescribed DFM, men were more likely than women to be prescribed 
to for more than 12 months; this was the case for every type of DFM. For instance, 
among women prescribed benzodiazepines, 5.1% were prescribed to for periods 
exceeding 12 months, compared to 7.3% of men; gender differences were not evident 
for relatively shorter long-term prescribing periods of over 6 months.   
5.4.2 Age-group variations in long-term prescribing 
A continuous measure of age was used to examine whether there were age-related 
variations in long-term prescribing in excess of 6 months and 12 months, so no 
reference category was assigned. Older people were more likely than younger people 
to be prescribed for longer than 6 months.5; this was the case for all types of DFM 
apart from opioids. Apart from Z-drugs, older people were no more likely than 
younger people to be prescribed DFMs for longer than 12 months. 
5.4.3 Area level deprivation variations in long-term 
prescribing 
Comparisons in the rates of long-term prescribing among people living in the most (V) 
compared to least (I) deprived areas was examined. People prescribed DFM and 
living in the most deprived areas were more likely to prescribed to for periods in 
excess of 6 months. For example, among people prescribed benzodiazepines and 
living in the least deprived neighbourhoods, 8.8% were prescribed to for longer than 6 
months, while among those living in the most deprived neighbourhoods 19.4% were 
prescribed to at this level. For GABAergic medicines, this was evident only in 
prescribing in excess of 12 months.  
5.4.4 Regional variations in long-term prescribing 
The ten available regions in the CPRD were grouped in to five larger regions, North of 
England, Midlands and East of England, London, South East and South West, in 
order to maximise power. North of England was chosen as the reference category as 
it was the most populated region in this sample.  
People prescribed DFM and living in the North of England were the most likely to be 
prescribed to long-term for periods in excess of 6 and 12 months. For instance, 
15.5% of those living in North of England were prescribed to for longer than 6 months 
                                            
5 Mean age (years) for short-term periods lasting under 30 days: 59.3 (benzodiazepines), 58.9 
(Z-drugs), 60.6 (opioids) and 58.2 (GABAergic medicines). 
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compared to 11.7% living in the South East. This was the case for all classes of DFM, 
although the pattern was less pronounced for GABAergic medicines.  
Please refer to Appendix 40 to 44 for related analyses. These present the 
characteristics associated with being prescribed each type of DFM for up to 3 months, 
between 3 to 6 months, between 6 to 12 months and for more than 12 months. 
 
 
Table 1: Characteristics of people prescribed benzodiazepines in excess of 6 months 
and in excess of 12 months, 2014 
 
 
 
 
 
 
 
 
 
 
 
 
     *  P ≤ 0.05, **  P ≤ 0.01,  *** P ≤ 0.001, § - reference category  
        Source: CPRD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Benzodiazepines 
  Long-term 
  Over 6 
months 
Over 12 
months 
Mean age (years) 64.0** 62.3 
IMD quintile (%)     
I (least deprived) § 8.8 3.3 
II 9.6 3.5 
III 12.0* 4.9 
IV 11.5* 7.5*** 
V (most deprived) 19.4*** 10.6*** 
Gender (%)     
Male § 12.9 7.3 
Female 11.7 5.1*** 
Region (%)     
North of England § 15.5 9.7 
Midlands and East of 
England 
11.3*** 4.8*** 
London 9.9*** 7.3 
South East 11.7** 3.7*** 
South West 10.1*** 5.0*** 
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Table 2: Characteristics of people prescribed Z-drugs in excess of 6 months and in 
excess of 12 months, 2014  
Z-drugs 
  Long-term 
  
Over 6 
months 
Over 12 
months 
Mean age (years) 67.9*** 67.5*** 
IMD quintile (%)     
I (least deprived) § 13.0 6.2 
II 13.1 6.0 
III 9.6* 5.4 
IV 11.8 4.8 
V (most deprived 17.6* 8.0 
Gender (%)     
Male § 13.9 7.7 
Female 12.2 5.1** 
Region (%)     
North of England § 16.7 9.5 
Midlands and East of 
England 11.4*** 4.7*** 
London 13.5 5.6* 
South East 11.6*** 5.4*** 
South West 11.7* 4.2*** 
 
  *  P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, § - reference category  
Source: CPRD 
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Table 3: Characteristics of people prescribed opioids in excess of 6 months and in 
excess of 12 months, 2014 
Opioids 
  Long-term 
  
Over 6 
months 
Over 12 
months 
Mean age (years) 63.3 63.1 
IMD quintile (%)     
I (least deprived) § 4.6 0.9 
II 7.4*** 4.6*** 
III 7.1*** 3.7*** 
IV 8.1*** 4.2*** 
V (most deprived 8.3*** 3.8*** 
Gender (%)     
Male § 7.3 4.1 
Female 7.3 3.3** 
Region (%)     
North of England § 9.2 4.7 
Midlands and East of 
England 6.5*** 3.6* 
London 5.3*** 2.2*** 
South East 6.9*** 3.3*** 
South West 5.3*** 2.0*** 
 
*  P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, § - reference category  
Source: CPRD 
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Table 4: Characteristics of people prescribed GABAergic medicines in excess of 6 
months and in excess of 12 months, 2014 
GABAergic medicines 
  Long-term 
  
Over 6 
months 
Over 12 
months 
Mean age (years)     63.2*** 61.1 
IMD quintile (%)     
I (least deprived) § 14.3 3.9 
II 12.0  5.6* 
III 13.0 3.3 
IV 16.2  6.0* 
V (most deprived 14.5   6.0** 
Gender (%)     
Male § 14.3 6.9 
Female 13.8     3.9*** 
Region (%)     
North of England § 15.2 4.8 
Midlands and East of 
England 15.6     7.4*** 
London 12.1  2.2* 
South East 13.6 4.4 
South West      9.0*** 4.8 
  *  P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, § - reference category  
  Source: CPRD 
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6 Characteristics associated with 
gabapentin and pregabalin 
prescribing in excess of 6 months 
6.1 Variation in continuous prescribing by age-
group 
The previous chapter examined the characteristics of people prescribed 
benzodiazepines, opioids, Z-drugs and GABAergic medicines long-term; the focus in 
this chapter is on the characteristics of people prescribed gabapentin and pregabalin. 
One of the reasons why these drugs are looked at separately is because pregabalin 
only entered the market in 2004. Again, due to the small number of people in the 
sample prescribed to for more than 12 months, the focus here is on those prescribed 
to for more than 6 months. Even at this threshold, numbers are relatively low, and 
results should be treated with caution. The data tables for 30 days, 6 months and 12 
months can be found in  Appendix A.  
6.1.1 Gabapentin 
From 2007 older people prescribed gabapentin were more likely than younger people 
prescribed the drug to receive it long-term (Figure 22, and Appendix 45). Prior to 
2007, associations with age were unclear. 
 
Figure 22: Gabapentin: Proportion of continuous prescribing periods to exceed 6 
months, by age 
 
Source: CPRD (see Appendix 48) 
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6.1.2 Pregabalin 
The youngest age group of 18-40 had the lowest rate of pregabalin prescribed for 
longer than 6 months from 2007 onwards (apart from a spike in prescriptions at 
2012); there were no age-related differences in long-term prescribing prior to 2007. 
 
Figure 23: Pregabalin: Proportion of continuous prescribing periods to exceed 6 
months, by age 
 
Source: CPRD (see Appendix 51) 
6.2 Variation in continuous prescribing by 
gender 
The results did not show any clear gender differences over time. However, overall, 
women prescribed gabapentin and pregabalin for periods exceeding 6 months tended 
to have a lower prescription rate for some periods of time. For example, rates 
between 2001-2006 were lower for women prescribed gabapentin, and rates between 
2006-2010 were lower for women prescribed pregabalin. 
6.3 Variation in continuous prescribing by area 
level deprivation 
Rates of continuous gabapentin prescribing exceeding 6 months varied over time 
among people living in the most compared to least deprived areas (Figure 24); a 
similar trend is observed for prescribing periods exceeding 12 months. 
 
Overall, people prescribed pregabalin living in the most compared to least deprived 
areas had a higher rate for continuous prescribing periods exceeding 6 months 
(Figure 25); however, rates of prescribing for people living in the least deprived areas 
spiked in 2008-2009 and were higher than those in the most deprived areas. There 
was no clear trend for prescribing periods exceeding 12 months, as rates between the 
most and least deprived areas varies over time.  
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Figure 24: Proportion of continuous prescribing periods to exceed 6 months among 
people prescribed gabapentin living in the least (Q1) and most (Q5) deprived areas 
 
 
 
Figure 25: Proportion of continuous prescribing periods exceeding 6 months among 
people prescribed pregabalin living in the least (Q1) and most (Q5) deprived areas 
 
 
 
Source: CPRD (see Appendix 57 and Appendix 60) 
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6.4 Characteristics associated with long-term 
prescribing in 2014 
 
CPRD data for 2014 were examined to compare the circumstances of people 
prescribed gabapentin and pregabalin short- and long-term (see Tables 9 to 12 
below).  
6.4.1 Gender variations in long-term prescribing 
There were no gender differences in prescribing rates for long-term prescriptions of 
gabapentin, but women receiving pregabalin were less likely to be prescribed to for 
more than both 6 months and 12 months. For instance, 4.9% of women were 
prescribed to for longer than 12 months compared to 13% of men. 
6.4.2 Age-group variations in long-term prescribing 
Long-term prescribing was more common in older than younger people prescribed 
gabapentin (for periods exceeding 6 months only), but there were no age-related 
differences in long-term pregabalin prescribing6. 
6.4.3 Area level deprivation variations in long-term 
prescribing 
People living in the most compared to least deprived areas were no more likely to be 
prescribed gabapentin or pregabalin long-term. 
6.4.4 Regional variations in long-term prescribing 
Overall, there were no regional differences in long-term prescribing (over 6 and 12 
months) of gabapentin and pregabalin relative to the North of England (Tables 9 and 
10). The one exception was a lower prescribing rate of pregabalin for continuous 
prescribing periods exceeding 12 months in the South East (4%) compared to the 
North of England (11.7%). 
 
Please refer to Appendices 62 and 63 for related analyses. These present the 
characteristics associated with being prescribed gabapentin and pregabalin for up to 
3 months, between 3 to 6 months, between 6 to 12 months and for more than 12 
months. 
  
                                            
6 Mean age (years) for short-term periods lasting under 30 days: 61.0 (gabapentin) and 55.0 
(pregabalin). 
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Table 5: Characteristics of people prescribed gabapentin in excess of 6 months and in 
excess of 12 months, 2014 
Gabapentin 
  Long-term 
  
Over 6 
months 
Over 12 
months 
Mean age (years) 64.0** 64.1 
IMD quintile (%)     
I (least deprived) § 15.2 4.4 
II 12.4 4.6 
III 9.6 1.5 
IV 14.6 7.3 
V (most deprived 10.9 3.4 
Gender (%)     
Male § 10.3 4.5 
Female 13.5 4.1 
Region (%)     
North of England § 12.5 4.1 
Midlands and East of 
England 15.7 5.2 
London 8.1 0 
South East 12.7 5.1 
South West 5.4 3.2 
*  P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, § - reference category 
     Source: CPRD 
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Table 6: Characteristics of people prescribed pregabalin in excess of 6 months and in 
excess of 12 months, 2014 
Pregabalin 
  Long-term 
  
Over 6 
months 
Over 12 
months 
Mean age (years) 60.7 59.4 
IMD quintile (%)     
I (least deprived) § 10.7 3.3 
II 15.1 8.2 
III 16.1 7.1 
IV 22.2* 11.1* 
V (most deprived 14.6 7.9 
Gender (%)     
Male § 19.9 13.0 
Female 13.9* 4.9*** 
Region (%)     
North of England § 19.4 11.7 
Midlands and East of 
England 15.6 6.5 
London 14.0 10.5 
South East 14.3 4.0** 
South West 14.8 11.5 
*  P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, § - reference category 
Source: CPRD 
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7 Time trends in sales of codeine- and 
dihydrocodeine-containing 
medications 
 
A data extract of over the counter (OTC) sales of codeine and dihydrocodeine-
containing medicines was acquired from IRI Group Ltd, a market research company 
which provides market intelligence data.7 Total counts of individual tablets were 
derived for three consecutive 12-month periods, ending in the final week of February 
2016, 2017 and 2018. 
 
Figure 26: Total counts of sales in individual codeine and dihydrocodeine-containing 
medicines 
 
See Appendix 64 for precise counts. 
 
There was a small decrease in total OTC sales of medicines containing codeine or 
dihydrocodeine between 2015/2016 and 2017/2018, broadly consistent across 
categories. Apart from a small increase over time in sales of ibuprofen and codeine 
combinations (1% increase), all types of medicine showed small decreases in sales 
volume between 2015/6 and 2017/18. The largest drop in sales was in aspirin and 
codeine products (15% reduction). 
 
These trends are broadly consistent with those reported for all analgesics in The 
Pharmaceutical Journal using sales data supplied by IRI Ltd (Connelly, 2017), as well 
as by Nielson Scantrack (Connelly, 2018). The more recent article described sales of 
adult oral analgesics as ‘stagnated’. 
                                            
7 Data provided by IRI Group Ltd. Data are for sales of OTC products (including own-
label and generic) from all multiples and independent pharmacies and most 
supermarkets and grocery outlets in Great Britain. These included: Asda, Iceland, 
Morrisons, Sainsburys (inc. local), Tesco (inc. Express, Metro), Co-operative, Waitrose, 
Boots, Superdrug, Lloyds, Wilkinson, and all independent chemists. Independent grocers 
were generally not included in the sales data. This means that trends over time are likely 
to be reliable, but that the total volume is an underestimate. 
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8 Conclusions 
Prevalence 
Individual DFM prescriptions almost never exceeded 12 months. However, once 
repeat prescribing was accounted for a sizeable minority of prescribing periods 
exceed this level: with about one in twenty lasting more than a year. This ranged from 
about 4% of prescribing periods for opioids and gabapentin, to 6% for 
benzodiazepines and gabapentin, and 8% for pregabalin.  
 
Change over time 
While the prevalence of continuous prescribing over 30 days tended to show signs of 
decline, there is little evidence of decline at the longer-term thresholds. Prescribing for 
periods in excess of 12 months increased particularly sharply for pregabalin since its 
introduction in 2004.  
 
Pregabalin trends 
As pregabalin and gabapentin become controlled as class C drugs (Home Office, 
2018), it will be important to monitor the impact of reclassification on prescribing 
practice (Torjesen, 2019). Awareness of this steep increase in long-term pregabalin 
prescribing is relevant across sectors, and should inform service provision in primary 
care, specialist services (such as pain management), and psychiatry. Reclassification 
has made it illegal to supply pregabalin and gabapentin through repeat dispensing 
and restricts prescription lengths to 28 days. In an analysis of the impact of tramadol 
reclassification, which occurred in 2014 due to concerns about potential misuse, 
overprescribing, and increasing numbers of associated deaths, prescriptions and 
related deaths fell (Chen et al., 2018).  
 
Variation 
Among people prescribed DFM, those most likely to end up being prescribed to for 
longer were older, living in deprived neighbourhoods, and living in the North of 
England. In 2014, being male emerged as associated with being prescribing DFM for 
periods exceeding 12 months. It is possible that changing prescribing practices are 
not addressing the issue of very long-term prescribing in some groups of men. 
 
Further research 
The current analyses drew on a relatively small extract of data from the CPRD. There 
is a need for further research with larger extracts which explore patterns in long-term 
prescribing for individual medicines. In relation to the monitoring of opioid prescribing 
periods, this should include taking account of oral morphine equivalence (OME) 
(Curtis et al., 2019). The current research should be viewed as an initial and 
descriptive visualisation of patterns, future work should extend this with more detailed 
analyses. 
 49 
 
9 References 
BMA (2015) Prescribed drugs associated with dependence and withdrawal – building 
a consensus for action. 
http://bmaopac.hosted.exlibrisgroup.com/exlibris/aleph/a23_1/apache_media/H6IB5G
1BL8SX1KJ7VY4MCRCXVG6EV7.pdf  
British Pain Society. Opioids for persistent pain: summary of guidance on good 
practice from the British Pain Society. Br J Pain 2012; 6: 9–10. 
 
Cartagena Farias J, Porter L, McManus S, Strang J, Hickman M, Reed K, Smith N. 
(2017) Prescribing Patterns in Dependence Forming Medicines. London. Available at: 
http://phrc.lshtm.ac.uk/project_2011-2019_014.html. 
 
Chen TC, Chen LC, Knaggs RDA. A 15-year overview of increasing tramadol 
utilisation and associated mortality and the impact of tramadol classification in the 
United Kingdom. Pharmacoepidemiol Drug Saf2018;27:487-94. 
doi:10.1002/pds.4320 pmid:28944519 
 
Connelly D. A breakdown of the over-the-counter medicines market in Britain in 2016. 
The Pharmaceutical Journal, April 2017, Vol 298, No 7900, online | DOI: 
10.1211/PJ.2017.20202662.  
 
Connelly D. A breakdown of the over-the-counter medicines market in Britain in 2017. 
The Pharmaceutical Journal, May 2018, Vol 300, No 7913, 
 
Curtis H, Croker R, Walker AJ, Richards GC, Quinlan J, Goldacre B. Opioid 
Prescribing Trends and geographical variation in England, 1998-2018 a retrospective 
database study. Lancet Psychiatry. 2019, 6: 2; 140-150. 
Faculty of Pain Medicine (2019) Opioids Aware: A resource for patients and healthcare 
professionals to support prescribing of opioid medicines for pain. 
https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware  
Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. 
Data Resource Profile: Clinical Practice Research Datalink (CPRD). International 
Journal of Epidemiology, Volume 44, Issue 3, 1 June 2015, Pages 827–836.  
Home Office. Atkins V. Pregabalin and gabapentin to be controlled as class C drugs. 
15 Oct 2018. www.gov.uk/government/news/pregabalin-and-gabapentin-to-be-
controlled-as-class-c-drugs. 
McManus S. Opioids: long-term prescribing trends. Lancet Psychiatry. 2019, 6: 2; 
140-150doi.or/10.1016/S2215-0366(18)30507-8 
Montastruc F, Loo SY, Renoux C. Trends in First Gabapentin and Pregabalin 
Prescriptions in Primary Care in the United Kingdom, 1993-
2017JAMA. 2018;320(20):2149-2151. doi:10.1001/jama.2018.12358 
NHS Digital (2019). Prescription cost analysis-England 2018. 
https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-
analysis/2018. (Accessed May 9th, 2019)   
Reed K, Bond A, Witton J, Cornish R, Hickman M, Strang J.  (2011) The changing 
use of prescribed benzodiazepines and z-drugs and of over-the-counter codeine-
containing products in England. Kings: London. 
 50 
 
Taylor S, Annand F, Burkinshaw P, Greaves F, Kelleher M, Knight J, Perkins C, Tran 
A, White M, Marsden J. An evidence review of dependence and withdrawal 
associated with some prescribed medicines. 2019. Public Health England, London. 
Torjesen I. Pregabalin and gabapentin: what impact will reclassification have on 
doctors and patients? BMJ 2019; 364: l1107. 
 
 51 
 
Appendix A. Data tables 
Appendix 1 Average number of days of  
prescriptions by DFM type  
Year Benzodiazepines Z-drugs Opioids 
GABAergic 
medicines 
20008 31.0 27.9 35.8 30.9 
2001 30.9 26.8 30.2 32.3 
2002 30.8 26.7 26.2 32.0 
2003 30.0 26.4 22.9 31.9 
2004 29.0 26.6 23.2 32.6 
2005 28.3 26.6 23.0 31.5 
2006 27.1 26.6 22.9 31.1 
2007 26.5 26.2 22.6 31.5 
2008 25.6 26.7 22.8 31.4 
2009 26.2 26.3 23.3 31.7 
2010 25.4 25.7 23.7 31.2 
2011 25.5 25.2 23.8 31.1 
2012 24.8 24.3 23.8 30.9 
2013 23.9 23.7 24.0 31.3 
2014 24.7 24.2 24.2 30.6 
2015 25.5 24.6 23.9 30.7 
 
Appendix 2 Average number of days of continuous 
prescribing periods by DFM type 
Year Benzodiazepines Z-drugs Opioids 
GABAergic 
medicines 
2000 95.0 78.2 64.1 80.2 
2001 106.4 94.9 72.1 112.0 
2002 115.9 94.6 73.9 100.5 
2003 117.8 91.4 77.5 99.6 
2004 113.5 87.3 76.5 98.8 
2005 117.2 107.9 81.7 105.2 
2006 117.5 100.3 83.0 116.8 
2007 113.7 104.1 80.9 111.7 
2008 118.3 104.6 84.8 108.8 
2009 120.7 103.2 90.3 113.5 
2010 121.9 103.4 92.0 121.1 
2011 112.0 109.9 99.4 115.3 
2012 123.2 113.3 96.0 119.4 
2013 110.0 106.6 102.6 122.8 
2014 117.0 107.7 103.2 123.1 
2015 108.9 112.8 93.8 113.5 
                                            
8 In the tables data for 2000 and 2015 are presented but should be treated with caution due to 
the impact of truncation near the start and end of the data extract. To emphasis this, these 
figures are presented in grey. 
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Appendix 3 Proportion of prescriptions exceeding 
30 days by DFM type. 
% Long-term prescriptions (over 30 days) 
Year Benzodiazepines Z-drugs Opioids 
GABAergic 
medicines 
2000 21.7 12.9 15.7 24.7 
2001 21.3 10.0 15.4 29.4 
2002 21.0 11.8 16.0 31.2 
2003 20.7 11.6 15.0 36.9 
2004 19.8 11.0 15.4 38.0 
2005 18.5 11.5 15.3 32.9 
2006 16.7 11.6 15.7 30.8 
2007 14.5 10.5 15.1 32.5 
2008 12.0 10.7 15.3 31.8 
2009 12.9 12.1 15.8 32.4 
2010 12.4 11.8 16.1 31.5 
2011 12.2 9.5 16.2 31.9 
2012 11.5 8.9 16.7 29.0 
2013 11.0 8.6 18.2 26.7 
2014 12.1 9.2 17.5 23.6 
2015 11.7 9.9 15.7 25.0 
 
 
Appendix 4 Proportion of continuous prescribing 
periods exceeding 30 days by DFM type 
% Long-term prescribing (over 30 days) 
Year Benzodiazepines Z-drugs Opioids 
GABAergic 
medicines 
2000 50.7 43.8 37.1 55.8 
2001 49.1 42.7 38.5 58.0 
2002 46.0 44.0 37.9 62.2 
2003 45.6 42.2 37.3 69.3 
2004 44.0 43.7 38.8 67.3 
2005 43.5 42.9 37.8 70.7 
2006 42.6 42.4 37.3 65.5 
2007 39.6 40.6 36.8 66.7 
2008 37.9 41.6 37.0 67.4 
2009 35.5 42.8 37.3 67.8 
2010 34.3 40.7 38.1 69.3 
2011 33.0 41.8 36.7 64.8 
2012 34.2 43.5 35.9   61.6 
2013 32.3 40.2 34.2 58.7 
2014 32.7 37.0 33.7 58.0 
2015 31.8 37.1 32.3 56.3 
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Appendix 5 Proportion of continuous prescribing 
periods exceeding 6 months by DFM type 
% Long-term prescribing (over 6 months) 
Year Benzodiazepines Z-drugs Opioids 
GABAergic 
medicines 
2000 12.3 7.9 5.7 9.1 
2001 12.6 12.3 7.2 10.4 
2002 13.2 10.8 5.7 12.3 
2003 13.2 9.8 6.8 12.5 
2004 11.2 11.2 6.9 11.6 
2005 12.8 11.9 7.4 11.3 
2006 12.7 11.7 7.2 13.5 
2007 11.7 12.6 6.8 13.0 
2008 11.0 11.1 7.1 13.4 
2009 10.6 11.9 8.2 13.3 
2010 11.2 10.7 7.5 14.5 
2011 10.8 12.5 7.5 13.7 
2012 11.5 13.3 7.5 13.6 
2013 10.0 12.1 7.4 14.3 
2014 12.1 12.8 7.3 14.0 
2015 9.0 12.0 6.6 11.9 
 
 
Appendix 6 Proportion of continuous prescribing 
periods exceeding 12 months by DFM type 
 
% Long-term prescribing (over 12 months) 
Year Benzodiazepines Z-drugs Opioids 
GABAergic 
medicines 
2000 3.8 2.8 1.8 1.7 
2001 5.4 5.1 2.5 5.1 
2002 6.4 4.7 2.5 3.4 
2003 6.1 4.7 3.0 4.0 
2004 5.3 4.0 2.4 3.0 
2005 5.8 5.4 2.8 3.1 
2006 5.7 5.1 2.9 5.0 
2007 5.5 5.1 2.6 3.7 
2008 5.2 4.7 2.7 4.3 
2009 5.1 5.5 3.3 4.6 
2010 5.5 4.3 3.0 5.7 
2011 5.0 5.9 3.1 5.0 
2012 5.2 6.2 3.4 4.4 
2013 4.5 6.0 3.3 5.7 
2014 5.9 6.0 3.6 5.0 
2015 4.4 5.5 1.8 3.6 
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Appendix 7 Average number of days of 
prescriptions by GABAergic medicine type  
 
Year Gabapentin Pregabalin 
2000 31.8 - 
2001 35.4 - 
2002 37.0 - 
2003 35.1 - 
2004 35.3 26.6 
2005 36.3 31.1 
2006 36.5 31.6 
2007 35.6 32.9 
2008 35.7 34.9 
2009 36.7 34.3 
2010 37.0 34.9 
2011 36.4 34.5 
2012 36.5 34.7 
2013 36.3 35.1 
2014 36.5 35.3 
2015 35.1 36.3 
 
 
Appendix 8  Average number of days of 
continuous prescribing periods by GABAergic 
medicine type 
 
Year Gabapentin Pregabalin 
2000 75.3 - 
2001 91.4 - 
2002 93.1 - 
2003 95.3 - 
2004 84.7 64.2 
2005 103.4 66.8 
2006 98.2 90.2 
2007 95.2 91.4 
2008 100.8 110.3 
2009 99.4 110.5 
2010 104.5 104.4 
2011 95.2 108.6 
2012 96.9 107.6 
2013 100.2 114.2 
2014 102.4 126.6 
2015 94.0 116.3 
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Appendix 9  Proportion of prescriptions exceeding 
30 days by GABAergic medicine type 
Year Gabapentin Pregabalin 
2000 29.2 - 
2001 49.2 - 
2002 51.4 - 
2003 56.6 - 
2004 55.9 13.3 
2005 57.7 15.6 
2006 57.1 15.6 
2007 58.4 21.6 
2008 59.8 28.8 
2009 64.4 25.4 
2010 64.0 25.4 
2011 65.1 25.6 
2012 58.6 27.5 
2013 54.8 29.6 
2014 52.2 29.6 
2015 49.7 30.1 
 
 
Appendix 10 Proportion of continuous prescribing 
periods exceeding 30 days by GABAergic 
medicine type 
Year Gabapentin Pregabalin 
2000 55.5 - 
2001 68.5 - 
2002 68.2 - 
2003 72.6 - 
2004 71.5 60.0 
2005 75.5 56.7 
2006 73.4 54.6 
2007 72.7 59.5 
2008 74.0 62.6 
2009 74.8 63.9 
2010 75.7 60.8 
2011 71.3 58.5 
2012 68.7 57.3 
2013 62.2 57.6 
2014 59.8 62.7 
2015 58.3 61.8 
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Appendix 11 Proportion of continuous prescribing 
periods exceeding 6 months by GABAergic 
medicine type 
Year Gabapentin Pregabalin 
2000 9.2 - 
2001 9.6 - 
2002 8.0 - 
2003 12.3 - 
2004 8.7 6.7 
2005 11.9 3.0 
2006 11.5 11.4 
2007 10.5 11.3 
2008 11.3 12.2 
2009 12.7 13.2 
2010 11.7 12.0 
2011 9.1 14.1 
2012 11.3 13.7 
2013 11.5 15.9 
2014 12.3 16.0 
2015 9.2 13.8 
 
 
Appendix 12 Proportion of continuous prescribing 
periods exceeding 12 months by GABAergic 
medicine type 
Year Gabapentin Pregabalin 
2000 0.0 - 
2001 4.1 - 
2002 2.6 - 
2003 4.0 - 
2004 2.6 0.0 
2005 4.3 0.8 
2006 3.1 4.0 
2007 3.1 2.8 
2008 4.0 3.8 
2009 3.8 4.5 
2010 3.9 4.7 
2011 3.1 5.7 
2012 3.4 4.5 
2013 4.0 6.1 
2014 4.2 7.7 
2015 1.7 5.2 
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Appendix 13 Benzodiazepines: Proportion of 
continuous prescribing periods exceeding 30 
days, by age 
Year 18-40 41-60 61-80 81+ 
2000 35.9 43.8 52.3 62.1 
2001 34.1 42.5 50.7 60.7 
2002 26.5 37.9 49.5 58.1 
2003 27.5 38.7 46.8 59.9 
2004 28.5 35.9 45.8 56.6 
2005 30.4 35.9 45.2 56.9 
2006 26.6 36.5 44.9 55.5 
2007 26.6 34.7 41.7 51.2 
2008 28.8 31.9 39.5 48.7 
2009 23.4 30.2 36.9 47.0 
2010 23.3 31.1 35.8 41.7 
2011 16.0 28.5 35.7 43.1 
2012 20.8 29.8 37.4 44.0 
2013 16.4 26.9 37.8 42.0 
2014 22.7 31.4 35.6 37.0 
2015 19.2 31.0 33.1 40.9 
  
 
Appendix 14 Benzodiazepines: Proportion of 
continuous prescribing periods exceeding 6 
months, by age 
Year 18-40 41-60 61-80 81+ 
2000 6.5 8.7 13.3 17.4 
2001 8.9 11.1 12.4 16.4 
2002 7.2 10.2 12.5 21.1 
2003 6.5 9.6 13.4 20.2 
2004 5.5 9.5 11.5 15.0 
2005 9.1 11.4 13.1 16.2 
2006 5.9 11.3 13.3 17.1 
2007 8.9 10.1 11.6 16.0 
2008 5.7 8.1 11.7 16.9 
2009 5.4 8.9 10.5 15.9 
2010 9.5 10.3 11.0 13.5 
2011 4.9 9.9 10.4 15.6 
2012 7.7 8.4 12.0 17.5 
2013 2.3 10.0 10.0 16.0 
2014 10.8 10.7 12.5 14.7 
2015 4.7 8.6 8.7 13.6 
 
  
 58 
 
Appendix 15 Benzodiazepines: Proportion of 
continuous prescribing periods exceeding 12 
months, by age 
 
Year 18-40 41-60 61-80 81+ 
2000 2.2 3.2 4.4 4.1 
2001 3.4 4.7 5.6 6.7 
2002 4.0 4.2 6.7 9.7 
2003 3.9 4.0 5.5 10.7 
2004 3.2 5.1 5.5 6.1 
2005 4.0 4.8 6.0 7.8 
2006 2.6 6.3 5.9 6.6 
2007 2.5 4.7 5.5 8.4 
2008 3.6 4.1 5.3 7.6 
2009 3.2 4.0 4.6 8.4 
2010 4.8 5.6 6.1 4.5 
2011 2.2 5.2 4.4 7.2 
2012 3.3 3.7 5.9 7.1 
2013 0.3 3.9 5.4 7.0 
2014 6.3 6.4 5.9 4.6 
2015 0.8 4.8 5.4 4.7 
 
 
Appendix 16  Z-drugs: Proportion of continuous 
prescribing periods exceeding 30 days, by age 
Year 18-40 41-60 61-80 81+ 
2000 30.8 43.7 44.4 61.7 
2001 34.0 37.1 45.0 60.8 
2002 30.5 40.2 47.9 58.5 
2003 35.2 35.9 49.2 50.6 
2004 33.4 36.9 51.8 52.5 
2005 28.4 36.4 49.3 54.5 
2006 31.5 35.8 46.0 61.1 
2007 30.5 37.1 45.6 47.8 
2008 30.5 36.3 45.7 57.7 
2009 29.6 36.9 46.9 59.6 
2010 31.0 34.3 43.1 61.7 
2011 27.9 37.2 50.2 47.4 
2012 30.0 37.6 48.5 56.0 
2013 27.8 32.7 46.2 53.5 
2014 21.8 32.7 41.8 46.0 
2015 21.2 33.7 41.4 45.8 
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Appendix 17 Z-drugs: Proportion of continuous 
prescribing periods exceeding 6 months, by age 
Year 18-40 41-60 61-80 81+ 
2000 5.3 6.3 7.9 14.7 
2001 5.2 10.8 13.6 21.4 
2002 6.6 10.9 10.7 15.4 
2003 8.4 8.5 9.5 15.7 
2004 5.8 9.8 13.4 15.3 
2005 8.7 9.8 12.8 16.9 
2006 5.2 8.7 12.9 22.6 
2007 9.5 11.6 13.2 16.9 
2008 6.7 9.2 11.6 19.0 
2009 5.5 7.9 14.6 21.3 
2010 6.0 8.7 10.7 21.0 
2011 4.5 11.2 13.8 20.4 
2012 8.1 10.8 13.7 22.2 
2013 7.0 11.6 11.4 19.8 
2014 5.1 10.5 14.7 18.7 
2015 6.5 11.1 11.4 18.7 
 
 
Appendix 18  Z-drugs: Proportion of continuous 
prescribing periods exceeding 12 months, by age 
Year 18-40 41-60 61-80 81+ 
2000 2.2 2.1 3.2 4.3 
2001 1.8 4.2 6.0 8.8 
2002 3.5 5.3 4.0 6.6 
2003 4.4 4.0 4.8 6.1 
2004 3.3 3.8 3.9 5.5 
2005 4.6 4.7 5.4 7.9 
2006 3.5 3.2 6.2 8.9 
2007 3.6 5.9 4.9 5.3 
2008 2.3 4.1 5.1 8.0 
2009 2.4 3.9 6.3 10.4 
2010 2.6 4.9 3.6 6.7 
2011 1.7 5.9 6.3 9.1 
2012 5.1 3.9 6.1 12.2 
2013 6.1 5.7 4.5 9.6 
2014 3.0 5.0 6.8 8.2 
2015 3.7 4.6 5.2 9.1 
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Appendix 19 Opioids: Proportion of continuous 
prescribing periods exceeding 30 days, by age 
Year 18-40 41-60 61-80 81+ 
2000 28.5 36.1 39.6 45.3 
2001 28.4 36.3 43.3 42.8 
2002 29.4 37.8 42.6 35.8 
2003 25.6 36.3 40.7 44.7 
2004 27.8 36.2 44.0 41.8 
2005 26.9 36.7 41.1 42.9 
2006 30.6 35.9 38.3 44.6 
2007 28.2 36.0 39.4 39.2 
2008 26.8 38.1 39.9 36.0 
2009 24.6 37.0 40.4 39.7 
2010 26.8 37.1 40.6 41.9 
2011 28.6 36.7 38.2 39.1 
2012 28.9 34.9 37.0 41.3 
2013 28.1 34.6 36.8 31.7 
2014 25.1 35.1 36.0 31.5 
2015 23.4 35.2 33.1 29.7 
 
 
Appendix 20 Opioids: Proportion of continuous 
prescribing periods exceeding 6 months, by age 
Year 18-40 41-60 61-80 81+ 
2000 5.4 5.4 5.8 6.7 
2001 5.9 6.9 7.5 8.6 
2002 4.5 7.1 5.6 4.8 
2003 6.2 7.2 6.7 7.5 
2004 4.8 6.4 8.2 6.5 
2005 6.9 7.3 7.7 7.4 
2006 6.4 7.5 6.6 9.2 
2007 5.1 6.8 7.0 8.3 
2008 5.0 7.0 7.2 8.7 
2009 5.9 7.4 9.5 8.4 
2010 6.0 7.3 7.7 8.5 
2011 5.6 8.3 7.8 6.5 
2012 5.0 6.4 8.4 9.6 
2013 6.7 8.0 7.8 6.1 
2014 6.4 7.5 7.9 6.2 
2015 4.7 6.5 7.3 6.1 
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Appendix 21 Opioids: Proportion of continuous 
prescribing periods exceeding 12 months, by age 
Year 18-40 41-60 61-80 81+ 
2000 1.9 1.6 1.9 1.8 
2001 2.1 2.5 2.8 2.4 
2002 2.5 3.1 2.5 1.2 
2003 2.8 3.6 2.5 3.1 
2004 1.8 2.4 2.6 2.5 
2005 2.9 2.7 3.0 2.6 
2006 2.7 3.0 2.7 3.9 
2007 2.8 3.2 2.1 2.8 
2008 3.0 2.2 2.9 3.2 
2009 2.4 3.5 3.6 2.6 
2010 3.1 3.0 2.8 3.3 
2011 2.4 3.6 3.2 2.6 
2012 2.8 2.9 3.8 3.9 
2013 3.3 4.2 2.9 2.3 
2014 3.8 3.6 4.0 2.7 
2015 2.1 1.9 1.7 2.0 
 
 
Appendix 22 GABAergic medicines: Proportion of 
continuous prescribing periods exceeding 30 
days, by age 
Year 18-40 41-60 61-80 81+ 
2000 38.1 62.1 60.1 76.9 
2001 57.5 66.8 57.8 53.6 
2002 52.0 69.2 74.8 44.2 
2003 63.8 77.9 73.2 65.7 
2004 61.8 68.8 70.3 71.0 
2005 69.8 70.5 75.6 62.5 
2006 62.6 67.5 64.7 64.6 
2007 68.5 68.6 68.2 60.5 
2008 66.0 64.0 74.3 63.2 
2009 64.8 65.3 74.7 61.1 
2010 59.1 68.2 74.9 69.2 
2011 56.1 66.8 66.9 64.8 
2012 50.8 62.6 65.0 61.2 
2013 50.3 58.7 60.7 63.9 
2014 44.2 58.2 61.6 63.9 
2015 56.9 51.8 61.1 58.1 
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Appendix 23 GABAergic medicines: Proportion of 
continuous prescribing periods exceeding 6 
months, by age 
Year 18-40 41-60 61-80 81+ 
2000 5.8 13.0 6.2 0.0 
2001 9.7 10.8 10.4 8.9 
2002 9.7 16.1 9.5 7.2 
2003 9.4 11.3 14.9 14.3 
2004 18.2 8.1 12.0 11.2 
2005 19.0 9.4 10.9 7.1 
2006 20.0 11.7 12.2 14.1 
2007 13.7 16.1 10.6 11.3 
2008 12.0 13.9 12.7 15.0 
2009 7.7 14.0 13.1 21.3 
2010 10.8 15.6 14.3 18.6 
2011 8.5 12.6 16.4 15.9 
2012 12.0 11.3 15.8 15.8 
2013 10.6 11.4 16.5 19.5 
2014 9.5 12.9 14.4 21.0 
2015 15.4 11.0 11.7 12.3 
 
 
Appendix 24 GABAergic medicines: Proportion of 
continuous prescribing periods exceeding 12 
months, by age 
Year 18-40 41-60 61-80 81+ 
2000 0.0 1.9 0.0 0.0 
2001 5.8 5.3 5.8 0.0 
2002 1.6 6.0 1.0 3.6 
2003 0.0 4.9 4.0 5.7 
2004 7.1 0.2 4.5 2.2 
2005 8.5 2.5 2.3 0.4 
2006 5.4 4.0 4.9 7.2 
2007 5.5 3.6 3.3 3.9 
2008 1.8 5.2 4.0 6.7 
2009 3.3 4.5 4.1 9.9 
2010 3.3 6.9 5.0 7.8 
2011 1.8 5.1 5.9 7.1 
2012 3.9 4.0 4.6 5.7 
2013 5.2 4.4 5.9 9.3 
2014 5.0 4.3 5.5 5.9 
2015 2.6 3.6 4.3 2.4 
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Appendix 25 Proportion of continuous prescribing 
periods exceeding 30 days, by DFM type and 
gender 
  Benzodiazepines Z-drugs Opioids GABAergic medicines 
Years Male Female Male Female Male Female Male Female 
2000 48.9 51.5 42.7 44.4 36.2 37.7 54.6 56.8 
2001 47.3 50.0 41.0 43.5 38.5 38.6 60.7 55.7 
2002 44.1 47.0 45.9 43.0 38.0 37.8 65.2 60.3 
2003 44.9 45.9 44.5 41.0 36.7 37.7 73.5 66.9 
2004 41.5 45.2 46.4 42.2 36.0 40.4 73.5 63.2 
2005 41.8 44.3 45.5 41.5 36.2 38.8 75.6 67.5 
2006 41.6 43.1 43.9 41.5 35.3 38.5 72.5 61.2 
2007 39.4 39.7 42.1 39.8 37.3 36.5 68.4 65.7 
2008 38.3 37.7 40.1 42.4 35.1 38.1 72.5 64.6 
2009 34.5 35.9 43.1 42.5 36.4 37.8 68.7 67.3 
2010 35.8 33.5 40.6 40.8 38.5 37.8 69.4 69.2 
2011 33.5 32.7 41.8 41.8 36.1 37.1 67.0 63.2 
2012 33.6 34.6 42.3 44.1 35.3 36.2 63.4 60.3 
2013 34.1 31.3 40.2 40.2 34.2 34.2 59.1 58.5 
2014 36.0 31.0 36.9 37.0 31.9 34.7 56.8 58.7 
2015 32.9 31.2 36.4 37.4 31.5 32.7 55.9 56.5 
 
 
Appendix 26 Proportion of continuous prescribing 
periods exceeding 6 months, by DFM type and 
gender 
  Benzodiazepines Z-drugs Opioids GABAergic medicines 
Years Male Female Male Female Male Female Male Female 
2000 10.5 13.1 7.5 8.0 6.6 5.2 8.5 9.6 
2001 10.4 13.7 12.8 12.1 6.5 7.6 12.5 8.5 
2002 11.9 13.8 11.5 10.4 5.4 5.9 15.8 10.0 
2003 10.6 14.4 10.3 9.5 7.2 6.6 17.1 9.9 
2004 9.6 12.0 11.3 11.2 6.2 7.2 16.8 8.2 
2005 11.7 13.3 11.7 12.0 7.5 7.3 14.5 9.2 
2006 11.6 13.3 10.7 12.3 6.6 7.5 15.8 12.0 
2007 11.3 12.0 13.5 12.1 6.6 7.0 13.6 12.7 
2008 11.0 11.0 10.1 11.5 6.4 7.4 16.2 11.9 
2009 10.5 10.7 10.8 12.5 7.6 8.6 12.5 13.8 
2010 11.6 11.0 10.4 10.8 6.9 7.8 12.7 15.7 
2011 10.0 11.2 11.2 13.1 7.9 7.1 13.5 13.9 
2012 10.8 11.9 13.3 13.3 6.6 8.1 13.3 13.7 
2013 11.1 9.4 11.5 12.5 7.4 7.4 13.9 14.6 
2014 12.9 11.7 13.9 12.2 7.3 7.3 14.3 13.8 
2015 8.2 9.4 9.0 13.6 6.3 6.7 13.0 11.3 
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Appendix 27  Proportion of continuous prescribing 
periods exceeding 12 months, by DFM type and 
gender 
 
Appendix 28 Proportion of continuous 
benzodiazepine prescribing periods exceeding 30 
days, by IMD quintile 
Proportion of benzodiazepine prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 47.4 49.2 52.4 51.0 53.7 
2001 44.9 47.1 50.0 52.2 51.6 
2002 43.0 39.6 51.4 47.9 49.7 
2003 44.4 41.3 48.6 46.8 47.8 
2004 38.3 40.8 44.8 47.0 50.6 
2005 35.8 42.8 44.0 47.0 48.0 
2006 43.9 40.8 43.5 41.8 43.9 
2007 35.9 36.0 44.8 35.9 47.7 
2008 33.2 36.4 40.0 37.7 43.4 
2009 32.3 36.0 36.3 35.1 38.3 
2010 33.0 31.8 35.1 34.3 38.9 
2011 29.4 31.4 36.9 35.0 31.9 
2012 31.7 30.2 40.2 37.7 31.2 
2013 29.4 31.3 34.9 33.9 31.3 
2014 28.1 27.3 36.0 33.4 39.5 
2015 29.8 31.1 31.9 32.4 34.4 
 
 Benzodiazepines Z-drugs Opioids GABAergic medicines 
Years Male Female Male Female Male Female Male Female 
2000 4.0 3.7 3.3 2.6 1.8 1.8 2.4 1.0 
2001 4.6 5.8 5.0 5.1 2.5 2.6 5.6 4.7 
2002 5.0 7.1 5.6 4.3 2.1 2.7 5.4 2.1 
2003 4.8 6.7 4.7 4.6 3.3 2.8 3.9 4.1 
2004 4.4 5.7 4.5 3.7 2.2 2.5 4.4 2.1 
2005 5.8 5.8 5.3 5.5 2.8 2.8 4.1 2.4 
2006 5.7 5.7 4.7 5.4 2.5 3.2 5.8 4.6 
2007 5.3 5.6 6.2 4.5 2.6 2.7 5.0 3.0 
2008 4.1 5.8 3.4 5.4 2.2 3.0 4.9 4.0 
2009 5.3 5.0 5.6 5.4 3.3 3.2 4.2 4.8 
2010 6.6 4.9 3.9 4.5 2.8 3.1 5.6 5.7 
2011 4.2 5.4 5.1 6.3 3.3 2.9 4.6 5.3 
2012 5.5 5.1 6.3 6.2 3.3 3.4 4.0 4.6 
2013 4.2 4.7 6.2 5.8 3.5 3.2 5.6 5.7 
2014 7.3 5.1 7.7 5.1 4.2 3.3 6.9 3.9 
2015 3.8 4.7 4.9 5.8 1.3 2.1 4.2 3.2 
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Appendix 29 Proportion of continuous 
benzodiazepine prescribing periods exceeding 6 
months, by IMD quintile 
Proportion of benzodiazepine prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 9.3 11.2 12.1 14.9 14.2 
2001 9.5 11.3 11.8 13.9 16.9 
2002 9.6 12.5 16.4 12.0 16.3 
2003 11.9 11 12.9 13.7 17.2 
2004 9.5 8.5 12.3 12.3 14.8 
2005 8.9 10.7 14.5 13.7 17.3 
2006 12.9 10.8 12.0 12.7 16.4 
2007 8.3 9.7 13.6 10.8 17.4 
2008 7.1 10.7 11.8 11.6 14.2 
2009 9.5 11.0 11.1 11.2 10.3 
2010 8.7 10.3 11.3 9.9 17.5 
2011 10.5 10.7 8.7 13.3 10.1 
2012 9.7 11.3 13.9 10.4 12.7 
2013 7.3 9.7 10.0 10.8 12.5 
2014 8.8 9.6 12.0 11.5 19.4 
2015 7.9 6.6 7.2 12.9 11.5 
 
Appendix 30 Proportion of continuous 
benzodiazepine prescribing periods exceeding 12 
months, by IMD quintile 
Proportion of benzodiazepine prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 3.0 3.5 4.1 3.5 5.2 
2001 3.0 5.5 6.0 6.1 6.5 
2002 4.1 5.8 8.0 6.9 7.4 
2003 5.8 4.8 5.9 6.5 7.8 
2004 4.1 3.4 5.6 5.9 8.6 
2005 3.1 3.6 7.7 6.1 9.7 
2006 4.9 4.0 6.4 6.3 7.9 
2007 3.4 4.2 6.7 5.2 8.8 
2008 2.9 5.2 5.8 4.5 8.2 
2009 4.2 5.3 6.0 5.1 5.0 
2010 3.3 4.0 6.4 5.7 9.0 
2011 4.3 4.9 3.1 5.8 7.3 
2012 2.7 6.5 5.4 4.5 6.9 
2013 4.1 3.4 4.5 5.3 5.6 
2014 3.3 3.5 4.9 7.5 10.6 
2015 3.7 3.4 2.9 6.2 6.3 
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Appendix 31 Proportion of continuous Z-drugs 
prescribing periods exceeding 30 days, by IMD 
quintile 
Proportion of Z-drug prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 50.1 42.1 41.9 40.5 45 
2001 39.3 49.3 44.5 40.9 39.9 
2002 41.7 48.6 43.4 44.6 40.9 
2003 38.8 48.1 44.6 34.8 43.3 
2004 42.4 43.8 43.8 42.6 47.5 
2005 42.2 41.2 47.1 48.6 34.1 
2006 41.7 43.9 43.8 41.0 40.7 
2007 34.8 44.1 34.6 45.1 44.3 
2008 44.7 41.9 42.8 37.5 41.1 
2009 43.1 40.3 44.8 40.9 46.3 
2010 37.7 41.0 39.4 45.0 41.7 
2011 42.0 42.1 36.9 43.8 44.6 
2012 43.7 42.8 40.0 47.7 43.6 
2013 37.5 48.1 39.3 35.9 37.2 
2014 42.2 37.5 36.8 29.5 38.2 
2015 40.3 39 37.5 33.9 32.7 
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Appendix 32 Proportion of continuous Z-drugs 
prescribing periods exceeding 6 months, by IMD 
quintile 
Proportion of Z-drug prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 6.3 8.8 9.1 7.1 7.8 
2001 9.3 17.9 15.3 8.5 10.8 
2002 11.3 11.2 12.8 9.3 9.4 
2003 8.5 7.7 10.6 8.5 14.4 
2004 9.4 9.6 10.3 10.8 17.3 
2005 8.6 12.5 11.7 14.1 12.7 
2006 9.3 11.7 15.8 9.9 11.7 
2007 12.3 12.2 12.3 12.2 14.7 
2008 10.4 9.7 11.8 10.9 13.3 
2009 11.9 11.8 11.4 11.1 13.8 
2010 9.4 10.7 9.4 12.7 11.8 
2011 12.3 9.2 10.2 15.5 18.0 
2012 14.1 10.9 13.3 14.2 15.1 
2013 9.0 12.4 10.8 12.4 17.3 
2014 13.0 13.1 9.6 11.8 17.5 
2015 11.4 11.5 14.2 14.0 8.4 
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Appendix 33 Proportion of continuous Z-drugs 
prescribing periods exceeding 12 months, by IMD 
quintile 
Proportion of Z-drug prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 2.4 4.0 1.6 3.2 2.8 
2001 4.8 7.5 5.2 3.0 4.7 
2002 3.9 5.1 5.0 5.6 3.9 
2003 3.3 3.2 6.2 4.2 6.6 
2004 4.0 3.6 2.9 4.0 6.0 
2005 4.2 6.6 5.1 5.8 5.3 
2006 4.0 3.6 8.9 4.7 4.4 
2007 3.7 5.3 3.9 5.1 8.1 
2008 4.7 3.5 6.2 3.2 6.7 
2009 5.7 5.3 6.3 3.8 6.5 
2010 3.4 3.2 3.4 6.6 5.7 
2011 5.0 3.6 5.8 7.2 10.1 
2012 5.9 5.0 7.1 6.4 7.2 
2013 4.0 5.8 4.5 5.1 11.6 
2014 6.2 6.0 5.4 4.7 7.9 
2015 3.3 4.3 8.4 8.1 3.8 
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Appendix 34 Proportion of continuous opioids 
prescribing periods exceeding 30 days, by IMD 
quintile 
 
Proportion of opioid prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 41.9 37.0 41.92 32.4 34.6 
2001 38.7 41.1 42.8 34.6 36.3 
2002 35.6 40.4 41.1 34.5 37.6 
2003 34.7 37.4 41.5 34.0 38.5 
2004 35.4 39.3 40.3 41.6 35.6 
2005 34.5 37.9 38.8 39.9 36.5 
2006 35.3 37.7 42.1 35.5 35.9 
2007 37.8 35.4 38.8 36.6 35.9 
2008 37.1 39.1 40.2 35.3 34.0 
2009 37.5 39.4 39.4 36.0 34.2 
2010 37.8 38.8 39.5 35.9 38.2 
2011 37.0 38.4 34.8 36.4 36.7 
2012 33.3 36.9 35.2 36.7 36.4 
2013 30.6 35.6 33.5 34.5 35.4 
2014 33.6 34.1 31.1 36.3 32.7 
2015 33.8 35.0 28.6 33.3 31.0 
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Appendix 35 Proportion of continuous opioids 
prescribing periods exceeding 6 months, by IMD 
quintile 
 
Proportion of Opioid prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 6.6 5.2 7.7 4.8 4.7 
2001 5.9 8.4 8.1 5.7 7.5 
2002 4.3 6.6 4.2 5.9 6.8 
2003 6.6 5.8 7.4 6.5 7.8 
2004 5.4 7.6 6.2 5.9 8.6 
2005 5.5 7.4 7.6 6.5 9.4 
2006 6.6 6.6 8.3 7.0 7.3 
2007 6.8 6.5 7.3 6.3 7.3 
2008 5.0 7.6 7.1 6.6 8.3 
2009 6.5 10.2 9.5 6.9 7.7 
2010 6.2 7.7 7.9 7.4 7.9 
2011 6.4 8.0 6.2 7.7 8.7 
2012 6.2 7.7 7.4 7.5 8.3 
2013 5.0 7.6 6.7 8.2 8.5 
2014 4.6 7.4 7.1 8.1 8.3 
2015 6.5 8.4 5.8 5.6 6.8 
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Appendix 36 Proportion of continuous opioids 
prescribing periods exceeding 12 months, by IMD 
quintile 
 
Proportion of opioid prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 2.9 2.0 2.2 1.4 1.1 
2001 1.5 3.4 3.1 2.5 1.8 
2002 1.4 3.2 2.0 2.5 2.7 
2003 3.4 1.3 2.7 3.1 4.6 
2004 1.4 2.5 3.0 1.5 3.5 
2005 2.3 1.8 3.4 3.0 3.3 
2006 3.2 3.1 2.9 2.8 2.9 
2007 2.5 2.6 2.4 2.7 2.9 
2008 1.5 2.8 2.9 2.4 3.8 
2009 1.9 3.4 4.4 2.9 3.6 
2010 1.4 2.8 3.3 3.4 3.6 
2011 1.7 3.5 2.0 3.0 4.8 
2012 2.5 3.1 3.1 3.9 3.9 
2013 2.1 4.2 2.2 3.8 3.5 
2014 0.8 4.6 3.6 4.2 3.9 
2015 1.4 2.6 1.5 1.5 2.1 
 
  
 72 
 
Appendix 37 Proportion of continuous GABAergic 
medicines prescribing periods exceeding 30 days, 
by IMD quintile 
 
Proportion of GABAergic medicines prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 39.2 31.2 72.2 64.1 65.6 
2001 56.2 47.7 63.3 65.7 57.0 
2002 58.4 66.0 63.0 58.0 66.5 
2003 66.8 74.1 70.7 66.7 68.3 
2004 71.3 69.8 68.8 67.0 60.6 
2005 71.6 66.5 80.3 68.1 68.4 
2006 65.5 62.4 67.3 65.8 66.8 
2007 68.5 63.8 62.5 63.0 77.5 
2008 65.1 68.5 68.8 64.9 69.8 
2009 72.9 66.1 70.5 68.2 62.8 
2010 70.5 71.3 69.7 72.0 63.1 
2011 62.9 67.3 64.6 69.3 59.1 
2012 61.9 62.6 59.5 64.8 58.8 
2013 58.2 58.1 63.4 59.9 53.3 
2014 56.5 54.6 62.8 59.6 56.3 
2015 54.1 56.9 56.0 57.4 56.7 
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Appendix 38 Proportion of continuous GABAergic 
medicines prescribing periods exceeding 6 
months, by IMD quintile 
 
Proportion of GABAergic medicines prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 16.7 7.9 8.2 7.8 7.8 
2001 15.4 8.8 8.4 12.5 7.9 
2002 12.2 19.6 6.8 10.4 12.9 
2003 13.9 16.1 16.5 10.3 5.5 
2004 12.5 11.3 13.2 15.0 6.1 
2005 14.1 7.0 10.2 15.4 10.0 
2006 12.2 10.9 11.9 12.6 19.7 
2007 17.0 8.4 11.1 14.6 13.7 
2008 14.8 10.6 16.5 13.7 12.3 
2009 15.4 14.4 15.3 13.1 9.4 
2010 15.4 18.3 14.2 15.5 9.7 
2011 11.6 15.0 14.3 14.5 13.1 
2012 13.3 11.9 13.6 15.3 13.6 
2013 11.9 16.7 12 17.5 12.3 
2014 14.5 11.9 12.8 16.1 14.9 
2015 8.5 13.8 12.6 10.3 14.5 
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Appendix 39 Proportion of continuous GABAergic 
medicines prescribing periods exceeding 12 
months, by IMD quintile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proportion of GABAergic medicines prescribing 
Index of multiple deprivation (IMD) quintiles 
Year 
Q1 (least 
deprived) Q2 Q3 Q4 
Q5 (most 
deprived) 
2000 0.0 2.0 3.0 4.0 7.8 
2001 6.2 3.5 4.2 8.9 2.3 
2002 1.7 6.4 3.2 1.3 4.7 
2003 5.4 3.6 5.3 1.9 4.9 
2004 0.5 2.4 4.4 3.7 3.5 
2005 2.2 0.7 4.4 5.6 2.6 
2006 6.3 4.3 4.3 4.3 5.8 
2007 5.5 2.2 3.1 4.2 2.9 
2008 4.9 3.2 5.4 4.1 4.3 
2009 3.5 5.5 4.5 5.8 3.5 
2010 6.7 7.0 4.2 5.7 5.0 
2011 2.9 7.0 5.7 4.8 4.7 
2012 4.6 3.6 2.2 4.9 6.4 
2013 5.7 7.0 4.4 7.1 3.8 
2014 3.8 5.7 3.2 5.9 6.2 
2015 1.7 4.7 3.1 2.7 5.8 
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Appendix 40 Characteristics of people prescribed 
benzodiazepines in 2014, by continuous 
prescribing period length 
Benzodiazepines 
  
Up to 3 
months  
3 to 6 
months 
6 to 12 
months 
Over 12 
months 
Mean age (years) 61.0*** 63.8* 65.6*** 62.3 
IMD quintile (%)         
I (least deprived) § 57.5 6.0 6.0 3.3 
II 56.3 6.0 6.8 3.5 
III 43.6*** 9.3** 8.3* 4.9 
IV 49.7*** 11.7*** 4.5 7.5*** 
V (most deprived 43.0*** 12.0*** 9.4** 10.6*** 
Gender (%)         
Male § 51.6 10.0 6.1 7.3 
Female 49.1 8.4* 7.5  5.1*** 
Region (%)         
North of England § 46.6 10.1 6.7 9.7 
Midlands and East of 
England 54.5*** 10.2 6.9 4.8*** 
London 51.9* 3.7*** 3.4** 7.3 
South East 53.3*** 9.6 9.2** 3.7*** 
South West 35.6*** 6.9* 5.1 5.0*** 
*  P ≤ 0.05, **  P ≤ 0.01,  *** P ≤ 0.001, § - reference category 
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Appendix 41 Characteristics of people prescribed Z-
drugs in 2014, by continuous prescribing period 
length 
Z-drugs 
  
Up to 3 
months  
3 to 6 
months 
6 to 12 
months 
Over 12 
months 
Mean age (years) 60.4*** 65.0*** 68.1*** 67.5*** 
IMD quintile (%)         
I (least deprived) § 61.7 11.8 7.2 6.2 
II 67.1* 9.1 7.6 6.0 
III 64.1 9.1 5.0* 5.4 
IV 67.8** 6.3*** 7.8 4.8 
V (most deprived 52.7*** 3.6*** 11.3** 8.0 
Gender (%)         
Male § 27.5 16.5 14.8 7.7 
Female 26.9** 17.4* 15.3 5.1** 
Region (%)         
North of England § 61.6 7.0 9.1 9.5 
Midlands and East of 
England 68.8*** 7.3 7.2 4.7*** 
London 71.6*** 6.6 7.9 5.6* 
South East 62.7 11.2*** 7.0 5.4*** 
South West 51.8*** 5.2 7.5 4.2*** 
*  P ≤ 0.05, **  P ≤ 0.01,  *** P ≤ 0.001, § - reference category 
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Appendix 42 Characteristics of people prescribed 
opioids in 2014, by continuous prescribing period 
length 
Opioids 
  
Up to 3 
months  
3 to 6 
months 
6 to 12 
months 
Over 12 
months 
Mean age (years) 61.6*** 63.3 63.8 63.1 
IMD quintile (%)         
I (least deprived) § 52.1 10.4 4.2 0.9 
II 45.4*** 10.6 3.5 4.6*** 
III 51.8 8.1** 3.8 3.6*** 
IV 55.0* 9.6 4.4 4.*** 
V (most deprived 50.5 7.3*** 5.1 3.9*** 
Gender (%)         
Male § 52.3 8.7 3.6 4.2 
Female 49.7*** 9.4 4.6** 3.3** 
Region (%)         
North of England § 53.6 8.8 5.3 4.7 
Midlands and East of 
England 52.9 9.9 3.1*** 3.6* 
London 52.4 10.1 3.8* 2.2*** 
South East 46.0*** 8.9 4.0** 3.3*** 
South West 49.9** 8.3 3.8* 2.0*** 
*  P ≤ 0.05, **  P ≤ 0.01,  *** P ≤ 0.001, § - reference category 
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Appendix 43 Characteristics of people prescribed 
GABAergic medicines in 2014, by continuous 
prescribing period length 
 
GABAergic medicines 
  
Up to 3 
months  
3 to 6 
months 
6 to 12 
months 
Over 12 
months 
Mean age (years) 59.7 60.1 63.7*** 61.1 
IMD quintile (%)         
I (least deprived) § 41.0 10.7 13.2 3.8 
II 38.1 17.7*** 7.3*** 5.6* 
III 44.0 21.1*** 12.5 3.2 
IV 41.5 19.1*** 11.6 5.9* 
V (most deprived 47.5*** 12.0 10.0** 6.2** 
Gender (%)         
Male § 43.5 15.1 8.4 6.9 
Female 42.2 16.8 12.2*** 3.9*** 
Region (%)         
North of England § 44.9 14.2 12.2 4.8 
Midlands and East of 
England 43.1 16.0 9.6* 7.4*** 
London 43.2 13.7 11.7 2.2* 
South East 41.3* 16.8* 11.0 4.4 
South West 37.4*** 23.9*** 7.3*** 4.8 
*  P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, § - reference category  
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 44 Proportion of continuous prescribing 
periods exceeding 30 days by GABAergic 
medicine type 
 
Year Gabapentin Pregabalin 
2000 55.5 - 
2001 68.5 - 
2002 68.2 - 
2003 72.6 - 
2004 71.5 60.0 
2005 75.5 56.7 
2006 73.4 54.6 
2007 72.7 59.5 
2008 74.0 62.6 
2009 74.8 63.9 
2010 75.7 60.8 
2011 71.3 58.5 
2012 68.7 57.3 
2013 62.2 57.6 
2014 59.8 62.7 
2015 58.3 61.8 
 
 
Appendix 45 Proportion of continuous prescribing 
periods exceeding 6 months by GABAergic 
medicine type 
Year Gabapentin Pregabalin 
2000 9.2 - 
2001 9.6 - 
2002 8.0 - 
2003 12.3 - 
2004 8.7 6.7 
2005 11.9 3.0 
2006 11.5 11.4 
2007 10.5 11.3 
2008 11.3 12.2 
2009 12.7 13.2 
2010 11.7 12.0 
2011 9.1 14.1 
2012 11.3 13.7 
2013 11.5 15.9 
2014 12.3 16.0 
2015 9.2 13.8 
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Appendix 46 Proportion of continuous prescribing 
periods exceeding 12 months by GABAergic 
medicine type 
 
 
 
 
Appendix 47 Gabapentin: Proportion of continuous 
prescribing periods exceeding 30 days, by age 
Year 18-40 41-60 61-80 81+ 
2000 32.0 67.5 54.3 75.0 
2001 61.8 78.3 61.3 70.6 
2002 57.4 74.7 76.1 41.9 
2003 54.1 78.0 75.8 68.4 
2004 62.2 73.9 72.4 75.5 
2005 66.2 76.4 78.5 73.2 
2006 64.0 77.8 73.5 74.6 
2007 67.5 75.8 71.0 73.5 
2008 76.4 71.9 78.1 63.0 
2009 70.0 71.7 80.1 69.5 
2010 66.9 76.6 79.2 71.6 
2011 66.7 71.6 73.5 67.3 
2012 60.1 70.2 71.3 63.1 
2013 58.5 64.6 61.0 62.6 
2014 48.9 63.5 62.9 53.2 
2015 53.2 55.4 63.0 58.4 
  
Year Gabapentin Pregabalin 
2000 0.0 - 
2001 4.1 - 
2002 2.6 - 
2003 4.0 - 
2004 2.6 0.0 
2005 4.3 0.8 
2006 3.1 4.0 
2007 3.1 2.8 
2008 4.0 3.8 
2009 3.8 4.5 
2010 3.9 4.7 
2011 3.1 5.7 
2012 3.4 4.5 
2013 4.0 6.1 
2014 4.2 7.7 
2015 1.7 5.2 
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Appendix 48 Gabapentin: Proportion of continuous 
prescribing periods exceeding 6 months, by age 
Year 18-40 41-60 61-80 81+ 
2000 4.0 17.5 6.5 0.0 
2001 2.9 10.1 10.7 11.8 
2002 5.9 8.4 9.4 6.5 
2003 9.8 10.1 15.8 10.5 
2004 8.5 4.9 11.4 13.2 
2005 11.7 9.3 14.6 10.7 
2006 17.4 8.0 11.5 15.3 
2007 9.1 11.0 8.8 15.7 
2008 5.5 11.4 10.8 18.0 
2009 9.0 12.2 11.8 23.2 
2010 5.2 11.9 12.4 17.4 
2011 7.4 6.0 11.1 14.5 
2012 9.1 8.1 14.1 14.9 
2013 9.4 10.8 11.0 17.4 
2014 6.8 11.7 13.5 16.9 
2015 12.1 8.0 8.5 12.9 
 
 
 
Appendix 49 Gabapentin: Proportion of continuous 
prescribing periods exceeding 12 months, by age 
Year 18-40 41-60 61-80 81+ 
2000 0.0 0.0 0.0 0.0 
2001 2.9 4.3 4.0 0.0 
2002 2.9 4.2 0.9 3.2 
2003 3.3 3.1 4.2 7.9 
2004 1.2 0.5 5.4 1.9 
2005 7.8 2.7 5.3 1.8 
2006 3.5 2.2 2.3 8.5 
2007 2.6 2.9 2.8 4.8 
2008 1.8 4.7 3.6 6.0 
2009 2.0 3.3 3.9 7.3 
2010 2.6 5.6 2.6 5.5 
2011 0.0 3.3 2.5 9.1 
2012 3.5 2.9 3.4 5.0 
2013 1.9 3.3 4.7 6.1 
2014 1.5 4.2 4.3 7.3 
2015 0.8 1.9 2.0 1.0 
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Appendix 50 Pregabalin: Proportion of continuous 
prescribing periods exceeding 30 days, by age 
 
Year 18-40 41-60 61-80 81+ 
2004 100.0 33.3 83.3 50.0 
2005 47.1 71.4 52.6 27.3 
2006 62.2 61.0 46.0 44.4 
2007 55.0 57.4 68.5 37.0 
2008 60.0 54.2 72.7 74.3 
2009 67.9 58.1 70.4 57.1 
2010 58.6 59.2 63.8 62.2 
2011 56.4 58.2 60.2 59.0 
2012 47.1 56.1 62.4 64.7 
2013 47.1 55.6 63.6 60.9 
2014 48.1 62.2 66.7 75.0 
2015 61.6 61.7 63.0 65.5 
 
 
Appendix 51 Pregabalin: Proportion of continuous 
prescribing periods exceeding 6 months, by age 
 
Year 18-40 41-60 61-80 81+ 
2004 0.0 0.0 16.7 0.0 
2005 5.9 4.1 1.8 0.0 
2006 13.5 10.2 13.0 5.6 
2007 13.3 9.2 12.9 11.1 
2008 10.0 10.7 16.5 8.6 
2009 4.9 14.7 14.8 14.3 
2010 5.4 14.3 12.1 16.2 
2011 9.8 13.0 17.2 16.4 
2012 15.9 9.8 16.4 16.2 
2013 8.6 17.3 17.8 16.1 
2014 13.7 14.0 18.2 19.7 
2015 13.4 14.4 14.0 13.8 
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Appendix 52 Pregabalin: Proportion of continuous 
prescribing periods exceeding 12 months, by age 
 
Year 18-40 41-60 61-80 81+ 
2004 0.0 0.0 0.0 0.0 
2005 0.0 0.0 1.8 0.0 
2006 8.1 2.5 5.0 0.0 
2007 5.0 1.4 4.0 0.0 
2008 0.0 3.4 5.8 5.7 
2009 1.2 4.1 5.6 7.1 
2010 0.0 7.2 4.3 5.4 
2011 3.8 4.5 7.3 9.8 
2012 5.8 1.8 5.2 11.8 
2013 5.0 7.8 4.4 8.0 
2014 8.4 6.5 8.3 9.2 
2015 2.7 6.6 4.3 8.6 
 
 
Appendix 53 Proportion of continuous prescribing 
periods exceeding 30 days, by GABAergic 
medicine type and gender 
 
  Gabapentin Pregabalin 
Years Male Female Male Female 
2000 52.6 58.1 - - 
2001 68.2 68.8 - - 
2002 70.1 67.0 - - 
2003 78.6 69.7 - - 
2004 74.3 69.8 75.0 54.5 
2005 79.7 72.9 46.9 62.4 
2006 79.8 69.2 55.8 54.1 
2007 77.8 69.6 65.5 56.7 
2008 77.0 72.3 65.7 61.0 
2009 73.7 75.4 66.5 62.7 
2010 79.1 73.3 59.0 61.8 
2011 75.3 68.3 57.4 59.1 
2012 70.6 67.4 55.5 58.5 
2013 65.5 60.1 50.3 61.6 
2014 59.9 59.8 60.2 64.0 
2015 59.9 57.4 62.2 61.5 
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Appendix 54 Proportion of continuous prescribing 
periods exceeding 6 months, by GABAergic 
medicine type and gender 
 
  Gabapentin Pregabalin 
Years Male Female Male Female 
2000 3.5 14.5 - - 
2001 12.9 7.1 - - 
2002 11.1 6.2 - - 
2003 17.1 9.9 - - 
2004 10.7 7.5 0.0 9.1 
2005 13.0 11.2 2.0 3.5 
2006 11.9 11.2 14.3 10.2 
2007 10.4 10.6 13.3 10.4 
2008 12.6 10.5 16.4 10.0 
2009 11.9 13.2 16.5 11.6 
2010 11.3 11.9 12.1 11.8 
2011 9.6 8.7 13.1 14.6 
2012 11.0 11.5 12.0 14.8 
2013 10.1 12.4 15.0 16.4 
2014 10.3 13.5 19.9 13.9 
2015 9.9 8.7 14.2 13.6 
 
Appendix 55 Proportion of continuous prescribing 
periods exceeding 12 months, by GABAergic 
medicine type and gender 
 
  Gabapentin Pregabalin 
Years Male Female Male Female 
2000 0.0 0.0 - - 
2001 5.9 2.7 - - 
2002 5.1 1.0 - - 
2003 5.7 3.2 - - 
2004 2.1 2.8 0.0 0.0 
2005 5.2 3.7 0.0 1.2 
2006 5.1 1.8 2.6 4.6 
2007 3.1 3.0 3.5 2.5 
2008 4.4 3.8 6.0 2.7 
2009 3.1 4.2 6.6 3.4 
2010 4.4 3.5 5.1 4.5 
2011 2.8 3.4 3.9 6.8 
2012 2.9 3.7 3.5 5.1 
2013 3.6 4.3 5.8 6.3 
2014 4.5 4.1 13.0 4.9 
2015 2.4 1.3 6.9 4.2 
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Appendix 56 Proportion of continuous gabapentin 
prescribing periods exceeding 30 days, by IMD 
quintile 
Proportion of gabapentin prescribing 
  Index of multiple deprivation (IMD) quintiles 
Year Q1  Q2 Q3 Q4 Q5  
2000 47.4 42.9 61.3 61.5 59.1 
2001 72.0 61.4 71.4 77.1 60.5 
2002 64.9 71.4 70.8 63.4 70.9 
2003 68.8 80.2 73.5 67.3 73.7 
2004 76.3 72.1 76.1 70.7 64.6 
2005 67.7 80.6 81.2 72.9 73.9 
2006 75.7 66.0 78.3 78.7 70.2 
2007 69.6 71.0 69.9 75.5 76.4 
2008 70.0 73.3 78.8 73.0 75.1 
2009 78.4 74.5 74.9 77.2 69.6 
2010 81.6 78.7 76.7 80.8 64.5 
2011 74.8 71.8 72.9 77.3 60.3 
2012 71.1 67.5 69.5 70.6 66.1 
2013 70.9 60.8 68.3 61.4 52.6 
2014 63.3 54.6 59.3 66.1 57.5 
2015 61.0 58.2 57.0 58.4 57.5 
 
Appendix 57 Proportion of continuous gabapentin 
prescribing periods exceeding 6 months, by IMD 
quintile 
Proportion of gabapentin prescribing 
  Index of multiple deprivation (IMD) quintiles 
Year Q1  Q2 Q3 Q4 Q5  
2000 15.8 9.5 9.7 11.5 0.0 
2001 4.0 9.1 11.9 12.5 7.9 
2002 5.3 14.3 4.6 8.5 7.3 
2003 8.8 15.6 16.2 12.5 7.9 
2004 12.5 7.7 8.7 12.9 2.7 
2005 11.1 10.5 13.7 12.8 11.2 
2006 11.2 8.8 7.8 14.0 15.3 
2007 15.2 7.1 6.5 13.8 10.4 
2008 10.8 6.8 14.4 13.3 10.4 
2009 16.3 13.7 13.8 12.5 8.8 
2010 11.8 15.3 11.9 13.5 7.0 
2011 7.7 11.1 8.6 12.4 5.0 
2012 10.0 11.7 11.9 12.1 10.9 
2013 9.7 11.7 9.8 12.3 13.3 
2014 15.2 12.4 9.5 14.6 10.9 
2015 7.6 10.3 7.3 9.0 11.3 
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Appendix 58 Proportion of continuous gabapentin 
prescribing periods exceeding 12 months, by IMD 
quintile 
Proportion of gabapentin prescribing 
  Index of multiple deprivation (IMD) quintiles 
Year Q1  Q2 Q3 Q4 Q5  
2000 0.0 0.0 0.0 0.0 0.0 
2001 0.0 2.3 7.1 6.3 2.6 
2002 0.0 4.8 3.1 1.4 3.6 
2003 2.5 4.2 5.9 2.9 5.3 
2004 5.0 1.0 3.3 4.3 0.0 
2005 2.0 3.2 4.3 6.0 5.2 
2006 3.7 2.7 1.7 5.1 2.3 
2007 6.3 0.6 1.3 5.3 2.1 
2008 5.0 3.1 4.4 3.5 4.5 
2009 3.9 3.1 4.2 4.0 3.7 
2010 4.6 5.0 2.5 3.9 3.9 
2011 2.6 3.7 2.7 4.4 1.7 
2012 3.3 3.3 2.5 3.8 3.9 
2013 2.9 4.6 3.1 4.7 4.4 
2014 4.4 4.6 1.5 7.3 3.6 
2015 0.6 0.0 0.0 2.7 4.2 
 
 
Appendix 59 Proportion of continuous pregabalin 
prescribing periods exceeding 30 days, by IMD 
quintile 
Proportion of pregabalin prescribing 
  Index of multiple deprivation (IMD) quintiles 
Year Q1  Q2 Q3 Q4 Q5  
2004 33.3 100.0 100.0 100.0 33.3 
2005 57.7 50.0 66.7 66.7 41.7 
2006 54.3 61.7 56.6 47.3 51.7 
2007 57.4 65.8 58.5 48.9 69.0 
2008 75.5 60.4 59.4 62.5 59.8 
2009 72.9 66.9 57.0 61.0 62.2 
2010 61.8 62.0 60.2 58.2 61.6 
2011 55.2 65.1 57.4 59.5 55.8 
2012 59.0 66.5 53.2 55.5 53.7 
2013 59.5 55.5 57.2 59.1 56.4 
2014 59.8 61.6 67.1 66.7 57.6 
2015 60.9 66.4 65.4 57.7 59.8 
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Appendix 60 Proportion of continuous pregabalin 
prescribing periods exceeding 6 months, by IMD 
quintile 
Proportion of pregabalin prescribing 
  Index of multiple deprivation (IMD) quintiles 
Year Q1  Q2 Q3 Q4 Q5  
2004 0.0 0.0 100.0 0.0 0.0 
2005 3.8 0.0 0.0 4.8 8.3 
2006 8.7 8.3 20.8 7.3 10.3 
2007 11.1 6.8 16.9 8.0 14.1 
2008 18.9 12.1 5.8 12.5 13.0 
2009 18.8 15.3 9.7 12.7 10.4 
2010 8.8 13.4 15.0 12.1 11.0 
2011 12.7 11.6 16.2 12.0 18.2 
2012 11.5 14.6 10.9 15.9 14.7 
2013 13.5 16.8 13.9 18.2 16.8 
2014 10.7 15.1 16.1 22.2 14.5 
2015 12.2 19.8 14.2 8.0 16.4 
 
 
Appendix 61 Proportion of continuous pregabalin 
prescribing periods exceeding 12 months, by IMD 
quintile 
 
Proportion of pregabalin prescribing 
  Index of multiple deprivation (IMD) quintiles 
Year Q1 Q2 Q3 Q4 Q5  
2004 0.0 0.0 0.0 0.0 0.0 
2005 0.0 0.0 0.0 4.8 0.0 
2006 4.3 3.3 5.7 1.8 3.4 
2007 0.0 1.4 4.6 0.0 7.0 
2008 1.9 5.5 2.9 3.4 4.3 
2009 4.2 5.1 4.3 6.8 2.2 
2010 4.4 4.2 4.4 6.4 4.1 
2011 6.0 6.2 5.9 4.0 7.1 
2012 3.6 5.7 3.8 3.8 5.3 
2013 4.1 6.5 5.6 6.6 8.1 
2014 3.3 8.2 7.1 11.1 7.9 
2015 5.2 7.6 4.7 1.8 7.4 
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Appendix 62 Characteristics of people prescribed 
gabapentin in 2014, by continuous prescribing 
period length 
 
Gabapentin 
  
Up to 3 
months  
3 to 6 
months 
6 to 12 
months 
Over 12 
months 
Mean age (years) 59.9 59.5 62.7 64.1 
IMD quintile (%)         
I (least deprived) § 44.9 8.2 12.0 4.4 
II 39.5 15.6* 8.7 4.6 
III 48.7 17.6* 8.5 1.5 
IV 51.0 15.6* 8.3 7.3 
V (most deprived 50.6 10.9 9.3 3.6 
Gender (%)         
Male § 48.8 15.6 6.3 4.5 
Female 46.0 12.7 11.0* 4.1 
Region (%)         
North of England § 48.1 12.8 10.2 4.1 
Midlands and East of 
England 45.2 17.0 10.9 5.2 
London 46.0 10.8 9.5 - 
South East 46.7 10.5 8.3 5.1 
South West 49.5 21.5* 4.3 3.2 
*  P ≤ 0.05, **  P ≤ 0.01,  *** P ≤ 0.001, § - reference category  
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Appendix 63 Characteristics of people prescribed 
pregabalin in 2014, by continuous prescribing 
period length 
 
Pregabalin 
  
Up to 3 
months  
3 to 6 
months 
6 to 12 
months 
Over 12 
months 
Mean age (years) 56.6* 59.8 62.4* 59.4 
IMD quintile (%)         
I (least deprived) § 59.0 18.0 9.8 3.3 
II 48.6 21.9 8.2 8.2 
III 51.0 25.8 11.0 7.1 
IV 43.2** 20.4 13.0 11.1* 
V (most deprived 57.0 18.2 7.3 7.9 
Gender (%)         
Male § 52.6 17.2 7.7 13.0 
Female 50.9 22.9 11.0 4.9*** 
Region (%)         
North of England § 48.5 19.4 8.7 11.7 
Midlands and East of 
England 54.6 20.8 10.4 6.5 
London 52.6 19.3 3.5 10.5 
South East 54.4 21.3 12.5 4.0** 
South West 39.3 26.2 6.6 11.5 
*  P ≤ 0.05, **  P ≤ 0.01,  *** P ≤ 0.001, § - reference category 
Source: CPRD       
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Appendix 64 Total counts of sales of individual 
codeine and dihydrocodeine-containing medicines 
 
 
3/2015 to 
2/2016 
3/2016 to 
2/2017 
3/2017 to 
2/2018 
Paracetamol & codeine 7,713,634 7,133,170 7,269,506 
Paracetamol & codeine & caffeine 3,848,998 3,753,986 3,322,000 
Ibuprofen & codeine 2,223,748 2,160,476 2,254,624 
Paracetamol & dihydrocodeine 1,129,152 1,119,408 986,080 
Buclizine & paracetamol & codeine 291,948 278,772 271,008 
Aspirin & codeine 115,872 109,184 98,368 
Total 15,323,352 14,554,996 14,201,586 
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Appendix B. Evaluation of published 
estimates of dependence on prescribed 
medicine 
 
What proportion of adults in England are dependent on medicines they 
are being prescribed? 
 
Information needed 
There is concern about the extent of dependence on medicines that people are 
prescribed. To understand the scale of the problem, an estimate is needed of the 
proportion of adults in England who are dependent on (in terms of showing signs of 
addiction to) the medicines they are prescribed. With a reliable estimate of the 
proportion, an estimate of the number of people can also be extrapolated.  
 
To produce such an estimate, a large sample representative of (and therefore 
generalisable to) the wider national population is needed. Information about what 
potentially DFMs each individual in the sample was taking would need to be 
combined at the patient level with information about whether they have any indicators 
of dependence. 
 
The focus here is on four classes of medicine that have been identified as potentially 
dependence forming: opioids, benzodiazepines, Z-drugs, and GABAergic medicines. 
Ideally, prescribing that was clinically appropriate despite dependence risk would be 
excluded. For example, the risk of dependence may be secondary when managing 
pain in palliative care, or implicit when treating a person for established dependence 
with maintenance therapy. The focus here is also on medicines prescribed through 
NHS primary care, and not on those obtained either illicitly or through private practice. 
Other research has addressed the abuse and misuse of prescription medicines, for 
example through diversion. Those findings are only relevant here where they relate to 
individuals taking the medicines that have been prescribed to them. Given enormous 
international variation in health care systems, prescribing practices, and the 
epidemiology of prescription drug dependence, understanding of the context in 
England needs to be based on data from England. 
 
Information available 
From a research (and clinical) perspective, identifying dependence is complex. The 
subjective experience of signs and symptoms of dependence could be captured using 
a screening tool (where people are able and willing to report those signs openly). 
However, many of the available screening tools focus on a specific class of medicine, 
on drug misuse rather than dependence on a medication that is being taken as 
prescribed, or they take a long time, and so are costly, to administer.9  
 
                                            
9 See this paper for discussion of some available tools: Wickersham JA, Azar MM, 
Cannon CM et al. Validation of a Brief Measure of Opioid Dependence: 6The Rapid 
Opioid Dependence Screen (RODS) J Correct Health Care. 2015 21(1): 12-26. 
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Length of prescribing (at various thresholds, e.g. four, six, and 12 months) has been 
used in research as an indicator of dependence. However, not everyone prescribed to 
long-term is dependent, and some prescribed to shorter-term will be dependent. The 
Royal College of Anaesthetists produced a list of eighteen ‘indicators that suggest the 
possibility of dependence should be explored in those on a long term opioid 
prescription’.10 Indications that someone being prescribed opioids long-term might be 
dependent include: presence of psychiatric illness; concern expressed by family 
members, carers, or pharmacists; and resistance to attending appointments to review 
opioid prescribing or addiction assessment. What the list demonstrates is that length 
of prescribing alone may not be enough, and identification is not straightforward.  
 
The validity of using length of prescribing as a single proxy for dependence on 
prescribed medicines is not considered here. Instead, we briefly consider the 
statistical robustness of the following three studies as sources for estimating the 
prevalence of long-term prescribing in the adult population in England. These are 
reviewed because they are commonly quoted sources for estimates of there being 1-
1.5m people dependent, cited by the media and others to demonstrate the scale of 
the need for action. The first two papers focus on long-term prescribing (exceeding 
four and six months) of benzodiazepines around 18 years ago, the third on long-term 
term prescribing (exceeding 12 months) of benzodiazepines and Z-drugs in 2014/5. 
 
Heather et al.: Benzodiazepine prescribing in 1997-1999 exceeding six months 
A research study carried out in seven GP practices in Newcastle and North Tyneside 
in 1997-1999 identified 1,297 patients who had been prescribed benzodiazepines for 
longer than six months.11,12 These figures were subsequently scaled up (not by the 
study authors) to a projected 1.5 million people in England being prescribed 
benzodiazepines for periods exceeding six months. 
 
Representativeness of the sample: The papers present findings from a well-run 
evaluation. The sample was designed to evaluate an intervention and the selection 
criteria were not intended to produce a sample representative of the wider population. 
In personal communication one of the authors said: ‘There is no way our 2004 paper 
could be used to estimate prevalence [of long-term benzodiazepine prescribing]. 
Apart from geographical restrictions, there were several kinds of restrictions on entry 
to the study.’  
 
Exclusions: Most of the 1,297 patients identified in the trial were not considered 
suitable for an intervention aimed at reducing their long-term benzodiazepine 
prescribing. This was for a range of reasons, including because they were taking 
benzodiazepines for a serious acute illness (such as cancer) or for a medical 
                                            
https://www.rcoa.ac.uk/system/files/FPM-OA-identification-treatment.pdf  
11 Heather N, Bowie A, Ashton H, et al. Randomised controlled trial of two brief 
interventions against long-term benzodiazepine use: outcome of intervention. 
Addiction Research and Theory 2004; 12(2): 141–154.  
http://www.benzo.org.uk/amisc/rndoi.pdf 
12 Godfrey C, Heather N, Bowie A, et al. Randomised controlled trial of two brief 
interventions against long-term benzodiazepine use: Cost-effectiveness. Addiction 
Research and Theory. 2008; 16(4): 309–317.  
https://www.benzo.org.uk/amisc/rndce.pdf 
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condition (such as epilepsy). These conditions have been applied as exclusion criteria 
in subsequent research on long-term prescribing of potentially DFMs, and further 
reinforce the conclusion that the rates generated in this paper are not comparable 
with rates generated in the latter studies. 
 
Recency: While the papers were published in 2004 and 2008, it is important to note 
that they are based on data collected in 1997 to 1999, and so relate to 
benzodiazepine prescribing practice in those GP surgeries two decades ago. The 
proportion of people to be prescribed benzodiazepines has fallen in recent years and 
estimates based on data collected at that time are unlikely to reflect current 
prescribing levels. 13 
 
BBC Panorama poll: Benzodiazepine prescribing in 2000-2001 exceeding four 
months 
In 2001, Panorama commissioned a poll of about two thousand adults which found 
that 3% of the sample had been prescribed a benzodiazepine for longer than four 
months.14 Based on the 2001 adult population, this was extrapolated to a projected 
1.5 million people in England being prescribed benzodiazepines long-term (for four 
months or more).  
 
Assessing methods: Attempts have been made to obtain information about the 
sampling or survey methods, both with the polling agency (NOP) and with Panorama. 
However, no details could be located. We are therefore unable to confirm whether 
this poll was robust.  
 
Outcome definition: It is also not clear what questions survey participants were 
asked, and therefore precisely what was being measured. For example, whether the 
3% of participants were being prescribed a benzodiazepine for a period exceeding 
four months at the time of the interview, or whether these patients had been 
prescribed at that level in the previous12 months, or at some point in their life. 
Analysis of CPRD data15 has found that about 3.5% of adults had been prescribed 
benzodiazepines at some point in 2000, but that most prescribing periods were 
around 30 days or less. Irrespective of the measure used on the Panorama poll, this 
suggests that the rate generated by the poll may have been an overestimate. The poll 
also likely relied on people being aware of what medicines they were being 
prescribed, other research has found that self-reports may be inaccurate in relation to 
prescribing.16   
 
Recency: As mentioned above, other work has since found that the proportion of the 
population to be prescribed this class of medicine to have fallen since 2000/2001. 
This indicates that results from 2000-2001 are unlikely to reflect recent prescribing 
patterns. 
                                            
13 Cartagena Farias J, Porter L, McManus S, Strang J, Hickman M, Reed K, Smith N. 
(2017) Prescribing patterns in dependence forming medicines. London: NatCen. 
14 http://news.bbc.co.uk/1/hi/programmes/panorama/tranquillisers/1325909.stm 
15 Cartagena Farias J, Porter L, McManus S, Strang J, Hickman M, Reed K, Smith N. 
(2017) Prescribing patterns in dependence forming medicines. London: NatCen. 
16 https://www.sciencedaily.com/releases/2009/12/091210000845.htm  
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Davies et al.: Benzodiazepine and Z-drugs prescribing exceeding 12 months  
Analysis of data on patients registered at a number of GP surgeries in Bradford in 
2014-2015 found that the proportion of 16 to 80 year olds taking benzodiazepines 
and/or Z-drugs very long-term (for more than one year) was 0.69%.17 This figure was 
then applied by the authors to the registered NHS patient population that age in 
England. The projection was that there were between 265,000 and 295,000 patients 
age 16-80 taking benzodiazepines and/or Z-drugs long-term in England. The study 
found that 35% of all patients prescribed benzodiazepines or Z-drugs had been 
prescribed them very long term (for more than 12 months). 
 
Assessing methods: While the results of this survey are published as a paper in the 
British Journal of General Practice, relatively limited methodological detail was 
provided. For example, it is not stated how many GP surgeries were visited, and 
whether any surgeries were selected but did not take part.  
 
Exclusions are well defined, appropriate, and lean towards the rate of long-term 
prescribing generated being a conservative estimate. The results were filtered to 
exclude children and those aged 80 years and over, those in receipt of palliative care, 
those with a diagnosis of epilepsy, those with severe and enduring mental health 
issues, and those ‘with illness at the time of the survey’ (although how this latter 
exclusion was applied is not defined). 
 
Representativeness of the sample: The key issue is with the appropriateness of 
extrapolating to a national prevalence based on an unadjusted sample of patients 
living in and around one city. Considerable variation in prescribing is evident between 
clinical commissioning groups within a region, as well as between regions.18 In order 
to justify scaling estimates from one area to a national prevalence, the characteristics 
of that sample would need to be profiled so that they could be compared with the 
national profile. This is particularly relevant for those characteristics known to be 
associated with prescribing propensity, such as age, sex, ethnicity and area level 
deprivation. Weighting factors could then be applied to adjust the profile of the patient 
sample to better approximate that of the national population. Without knowing how 
representative the patient sample is of the national population, and how 
representative the GP practice sample is of GP practices nationally, it is not possible 
to establish how robust an estimate this is of long-term benzodiazepine and Z-drug 
prescribing nationally. 
 
  
                                            
17 Davies J, Rae TC, Montagu L (2017) Long-term benzodiazepine and Z-drugs use in 
England: a survey of general research. British Journal of General Practice 67(662): 
e:609-e613. 
http://bjgp.org/content/67/662/e609  
18 OpenPrescribing.net allows for variation in volume of items prescribed per 1,000 
registered patients to be charted and finds significant variation between practices, 
CCGs, and regions (Curtis et al. 2019). 
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Appendix C. Estimating the minimum 
proportion of the population prescribed 
DFM long-term in 2014 
 
Estimates of the proportion of people in primary care to have been prescribed 
dependence forming medicines long-term can be extrapolated from the prescribing 
data. It should be noted that the estimates that we could derive from the available 
data were crude, based on several assumptions, and likely to significantly 
underestimate rates. The figures presented should therefore be considered the 
minimum. The methods used to generate these estimates, and their limitations, are 
set out in Chapter 2. 
 
The proportion of people in primary care in 2014 who had been prescribed DFM long-
term varied by type of drug. Opioids had the highest prevalence of the population 
being prescribed in excess of 30 days: at least 1.8%. 1.1% of adults were prescribed 
GABAergic medicines in excess of 30 days, 0.9% were prescribed benzodiazepines 
and 0.7% were prescribed Z-drugs at this level.  
 
Very broadly, at least one person in 500 in 2014 had been continuously prescribed an 
opioid for over a year; with a similar minimum proportion prescribed benzodiazepines 
for over a year. The rates for Z-drugs and GABAergic medicines appeared to be 
lower, at a minimum of at least one person in a 1000.  
 
It should be noted that there is a lot of uncertainty in these estimates and they should 
be regarded as minimum estimates. 
 
Table 7: Minimum proportion of the population exceeding DFM continuous prescribing 
periods in 2014, by length (%) 
 
>30 days >6 months >12 months 
Benzodiazepines 0.9 0.3 0.2 
Z-drugs 0.7 0.2 0.1 
Opioids 1.8 0.4 0.2 
GABAergic medicines 1.1 0.3 0.1 
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Appendix D. Clinical Practice Research 
Datalink  
 
A full consideration of the CPRD data extract analysed can be found in the previous 
report. Some of that information is provided below for reference.  
CPRD data collection and structure 
The Clinical Practice Research Datalink (CPRD) GOLD19 is an ongoing primary care 
database of anonymised medical records. There are 701 contributing GP practices in 
the UK which includes 15.8 million patients that meet the quality criteria. From those, 
4.4 million patients are active (currently registered and/or alive)(CPRD, July 2016), 
representing approximately 6.9% of the UK population. Data collection begins when a 
patient is registered with a contributing practice. Thereafter the information recorded 
for each patient consultation or contact with the practice is uploaded to the CPRD on 
a monthly basis.  
The CPRD primary care database is a rich source of health data for research. It 
includes data on: 
• Demographics (gender and age) 
• Strategic Health Authority 
• Medical symptoms and diagnoses 
• Tests and vaccinations 
• Therapies 
• Health-related behaviours 
• Referrals to secondary care. 
• Drug prescriptions. 
 
Prescriptions are recorded by the GP using the GEMscript product code system 
(which includes the generic name of the product) with a therapy record containing the 
British National Formulary (BNF) code, daily dose, quantity prescribed, numbers of 
packs, and issue sequence (if it is a repeat prescription). Additionally, the CPRD also 
allows for the study of geographical differences using the ten former Strategic Health 
Authorities in England (SHA). 
In terms of the data structure, the CPRD is a longitudinal dataset that combines 
location information for each GP practice with the consultation record for each 
registered patient. Each consultation in the CPRD is associated with a unique patient 
identifier and a date. A patient can have several consultations over time, with each 
consultation containing all the clinical and associated therapies and referrals 
information connected to it. However, it was not possible to directly associate 
diagnoses with treatments. For example, in a single consultation, a patient may be 
diagnosed with anxiety and flu and be prescribed paracetamol, ibuprofen, gabapentin 
                                            
19 The main primary care database held by CPRD is known as GOLD (formerly GPRD). GOLD 
contains the anonymised, longitudinal medical records of patients registered with contributing 
primary care practices across the UK. 
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and diazepam with no systematic way to link each drug to each diagnosis. This 
represents a significant challenge to the management of the data within the CPRD. 
Data structure of the CPRD 
 
Arrows indicate that several diagnoses and several treatments may be present for 
each clinical encounter, but a definitive link between a specific diagnosis and a 
specific treatment is not available in the dataset. 
CPRD representativeness 
For the analysis, it was important to establish how representative the CPRD 
information was in order to know with what confidence results could be generalised to 
the wider patient population. In terms of representativeness of patients within the 
CPRD, a study concluded that patients are broadly representative of the UK general 
population in terms of age, sex and ethnicity when compared with the 2011 UK 
Census and are comparable to the Health Survey for England (HSE) for body mass 
index (BMI) distribution (Herrett et al., 2015).  
 
In terms of representation of practices, historically the CPRD has gathered data from 
practices using the Vision IT system.20 Over the last two years there has been a 
significant fall in the number of practices using Vision, and even a complete drop off 
in practices in certain geographical areas. This is attributable to some Clinical 
Commissioning Groups (CCGs) requiring different software to be used. Therefore, the 
                                            
20 Vision is an IT package designed to provide NHS patients with joined up services. It makes 
relevant information available to the whole healthcare team, intended to facilitate collaboration 
and reduce duplication of effort.  
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CPRD may not be representative of all practices in the UK based on geography and 
size. 
Profile of the CPRD extract 
The CPRD extract contains 49,999 patients who have been prescribed at least one of 
the four types of DFMs of interest at some point between 2000 and 2015. The extract 
is a geographically representative random sample of patients in England on the 
CPRD, with the proportion of patients in each area determined by the proportion of 
the overall population living there at the 2011 Census. For example, from the total 
number of patients requested in the extract, 10% are located in the South West, 10% 
are in Yorkshire and 15% are in London. See Table A.8. 
Table A.8: Geographical distribution of patients 
Region  %  N  
North East 5 2,449 
North West 13 6,651 
Yorkshire 10 4,983 
East Midlands 9 4,276 
West Midlands 11 5,284 
East of England 11 5,515 
London 15 7,709 
South East 16 8,144 
South West 10 4,988 
 Total 100 49,999 
 
As well as providing a geographically representative sample for national analysis, the 
number of patients across each of the nine regions listed above is also sufficient for 
regional analysis. It should be noted that the nature of data collection from a self-
selecting sample of GP practices does not allow for the production of probability 
weights which could account for non-response bias.  
The 49,999 patients have an associated 13,868,419 consultations distributed 
between 2000 and 2015. This is an average of 23 consultations per patient per year. 
Of those patients, 59.5% are women. The patients span a wide age range, including 
some children and some adults in their nineties and over. Median age in 2000 was 50 
years old, increasing to 52 in 2007, and 56 years in 2015.21 It is important to note that 
this increase in patients’ age over time. Some patients are included in the extract from 
2000 and continue to be prescribed over time until 2015, thereby contributing their 
own ageing effect to the age distribution of the sample. Conversely, patients who 
were first prescribed in later years contribute fewer years to the age distribution. 
                                            
21 Mean age in 2015 was 56.19 and the standard deviation was 18.71. 
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The CPRD does not contain individual level information on socioeconomic 
characteristics. However, it does contain area level deprivation based on the location 
of the GP practice which acts as a proxy measure of socioeconomic circumstances of 
the patient. Overall, the extract contained roughly similar proportions of patients at 
each decile of deprivation. 
Appendix E. Medicines included in the analysis 
Drug name Product name BNF code BNF header 
Benzodiazepines    
Temazepam Temazepam 10mg tablets 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Nitrazepam Nitrazepam 5mg tablets 4010100 Hypnotics 
Diazepam Diazepam 2mg tablets 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 5mg tablets 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Lorazepam Lorazepam 4mg/1ml solution for injection ampoules 04010201/04080200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Benzodiazepines (peri-operative) 
Temazepam Temazepam 10mg/5ml oral solution sugar free 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 1mg/1ml solution for injection ampoules and diluent 4080200 Drugs Used In Status Epilepticus 
Temazepam Temazepam 10mg capsules 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Lorazepam Lorazepam 1mg tablets 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Diazepam Diazepam 10mg tablets 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg capsules 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Clonazepam Clonazepam 500microgram tablets 4080100 Control Of Epilepsy 
Temazepam Temazepam 20mg tablets 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 2mg tablets 4080100 Control Of Epilepsy 
Diazepam Diazepam 5mg RecTubes (Wockhardt UK) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Diazepam 10mg RecTubes (Wockhardt UK) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Lorazepam Lorazepam 2.5mg tablets 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 5mg capsules 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Diazepam Diazepam 2mg/5ml oral solution 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Valium 2mg Tablet (Roche Products) 04010100/04010200 Hypnotics/Anxiolytics 
Temazepam Temazepam 20mg capsules 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Triazolam Triazolam 250microgram Tablet 4010100 Hypnotics 
Nitrazepam Nitrazepam 5mg Capsule 4010100 Hypnotics 
Flurazepam hydrochloride Dalmane 30mg capsules (Meda Pharmaceuticals) 4010201 Benzodiazepines 
Clobazam Clobazam 10mg capsules 04010200/04080100 Anxiolytics/Control Of Epilepsy 
Clobazam Clobazam 10mg tablets 4080100 Control Of Epilepsy 
Chlordiazepoxide Hydrochloride Chlordiazepoxide 10mg tablets 4010200 Anxiolytics 
Diazepam Diazepam 5mg 04010100/04010200 Hypnotics/Anxiolytics 
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Lormetazepam Lormetazepam 1mg tablets 4010100 Hypnotics 
Lormetazepam Lormetazepam 1mg Capsule 4010100 Hypnotics 
Nitrazepam Mogadon 5mg Capsule (Roche Products) 4010100 Hypnotics 
Nitrazepam Nitrazepam 10mg Tablet 4010100 Hypnotics 
Lormetazepam Lormetazepam 500microgram tablets 4010100 Hypnotics 
Diazepam Diazepam 2mg capsules 04010100/04010200 Hypnotics/Anxiolytics 
Flurazepam hydrochloride Flurazepam 15mg capsules 4010201 Benzodiazepines 
Flurazepam hydrochloride Dalmane 15mg capsules (Meda Pharmaceuticals) 4010201 Benzodiazepines 
Diazepam Tensium 10mg tablets (DDSA Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Oxazepam Oxazepam 30mg Capsule 4010200 Anxiolytics 
Oxazepam Oxazepam 15mg tablets 4010201 Benzodiazepines 
Diazepam Diazepam 10mg/2.5ml rectal solution tube 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Valium 5mg Tablet (Roche Products) 04010100/04010200 Hypnotics/Anxiolytics 
Diazepam Stesolid 5mg rectal tube (Actavis UK) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Clonazepam Clonazepam 2.5mg/ml drops sugar free 4080100 Control Of Epilepsy 
Chlordiazepoxide Hydrochloride Chlordiazepoxide 5mg tablets 4010200 Anxiolytics 
Oxazepam Oxazepam 10mg tablets 4010201 Benzodiazepines 
Loprazolam mesilate Loprazolam 1mg tablets 4010100 Hypnotics 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg tablets 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Diazepam Stesolid 10mg Rectal tubes (Dumex) 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
Diazepam Diazepam 2.5mg/1.25ml rectal solution tube 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Chlordiazepoxide hydrochloride Chlordiazepoxide 5mg tablets 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Chlordiazepoxide Hydrochloride Chlordiazepoxide 25mg tablets 4010200 Anxiolytics 
Diazepam Diazepam 5mg/2.5ml rectal solution tube 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Lorazepam Ativan 4mg/1ml solution for injection ampoules (Pfizer) 04010201/04080200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Benzodiazepines (peri-operative) 
Flurazepam hydrochloride Flurazepam 30mg capsules 4010201 Benzodiazepines 
Temazepam Temazepam planpak Capsule (Manufacturer unknown) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Temazepam Temazepam 15mg capsules 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Triazolam Triazolam 125microgram Tablet 4010100 Hypnotics 
Nitrazepam Mogadon 5mg Tablet (ICN Pharmaceuticals France S.A.) 4010100 Hypnotics 
Nitrazepam Nitrazepam 2.5mg/5ml oral suspension 4010100 Hypnotics 
Clonazepam Rivotril 2mg tablets (Roche Products) 4080100 Control Of Epilepsy 
Diazepam Diazepam 10mg suppositories 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Diazepam 5mg suppository 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
Diazepam Stesolid 10mg rectal tube (Actavis UK) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Clobazam Frisium 10mg Capsule (Aventis Pharma) 04010200/04080100 Anxiolytics/Control Of Epilepsy 
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Chlordiazepoxide Hydrochloride Chlordiazepoxide 25mg tablets 4010200 Anxiolytics 
Oxazepam Oxazepam 30mg Tablet 4010200 Anxiolytics 
Temazepam Temazepam gelthix 10mg Capsule (Pharmacia) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Librium 10mg Capsule (ICN Pharmaceuticals France S.A.) 4010200 Anxiolytics 
Diazepam Diazepam 1mg/5ml suspension 04010100/04010200 Hypnotics/Anxiolytics 
Chlordiazepoxide hydrochloride Librium 5mg Tablet (ICN Pharmaceuticals France S.A.) 4010200 Anxiolytics 
Diazepam Diazepam 5mg/5ml oral solution 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 10mg capsules 04010100/04010200 Hypnotics/Anxiolytics 
Diazepam Diazepam 2.5mg/5ml oral suspension 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Alprazolam Alprazolam 250microgram tablets 4010201 Benzodiazepines 
Bromazepam Lexotan 3mg Tablet (Roche Products) 4010200 Anxiolytics 
Nitrazepam Nitrazepam 5mg/5ml oral suspension 4010100 Hypnotics 
Diazepam Diazepam 2mg/5ml oral solution sugar free 4010201 Benzodiazepines 
Diazepam Valium 10mg Tablet (Roche Products) 04010100/04010200 Hypnotics/Anxiolytics 
Temazepam Temazepam 30mg capsules 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Clonazepam Rivotril 500microgram tablets (Roche Products) 4080100 Control Of Epilepsy 
Medazepam Nobrium 10mg Capsule (Roche Products) 4010200 Anxiolytics 
Medazepam Medazepam 10mg Capsule 4010200 Anxiolytics 
Medazepam Nobrium 5mg Capsule (Roche Products) 4010200 Anxiolytics 
Alprazolam Xanax 250microgram tablets (Pfizer) 4010201 Benzodiazepines 
Lorazepam Ativan 1mg Tablet (Wyeth Pharmaceuticals) 04010200/15010401 Anxiolytics/Benzodiazepines (peri-operative) 
Alprazolam Alprazolam 500microgram tablets 4010201 Benzodiazepines 
Bromazepam Lexotan 1.5mg Tablet (Roche Products) 4010200 Anxiolytics 
Diazepam Diazepam 10mg/2ml solution for injection ampoules 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Ketazolam Anxon 30mg Capsule (Beecham Research Laboratories) 4010200 Anxiolytics 
Diazepam Diazepam 10mg/2ml emulsion for injection ampoules 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Temazepam Normison 10mg Capsule (Wyeth Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Ketazolam Anxon 15mg Capsule (Beecham Research Laboratories) 4010200 Anxiolytics 
Temazepam Temazepam gelthix 20mg Capsule (Pharmacia) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Librium 5mg Capsule (ICN Pharmaceuticals France S.A.) 4010200 Anxiolytics 
Alprazolam Xanax 500microgram tablets (Pfizer) 4010201 Benzodiazepines 
Diazepam Diazepam 10mg/5ml oral suspension 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Clonazepam Clonazepam 2mg/5ml oral solution sugar free 4080100 Control Of Epilepsy 
Lorazepam Lorazepam 500micrograms/5ml oral suspension 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Diazepam Diazemuls 10mg/2ml emulsion for injection ampoules (Actavis UK) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Clobazam Frisium 10mg tablets (Sanofi) 4080100 Control Of Epilepsy 
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Clonazepam Clonazepam 500micrograms/5ml oral suspension 4080100 Control Of Epilepsy 
Temazepam Temazepam 10mg/5ml Oral solution (Generics (UK)) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Nitrazepam Nitrados 5mg Tablet (Rorer Pharmaceuticals) 4010100 Hypnotics 
Chlordiazepoxide Hydrochloride Librium 100mg Injection (Roche Products) 4010200 Anxiolytics 
Diazepam Valium 5mg/ml Injection (Roche Products) 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
Diazepam Diazepam rectubes 20mg Rectal tubes (C P Pharmaceuticals) 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
Clonazepam Rivotril 2.5mg/1ml drops (Imported (Switzerland)) 4080100 Control Of Epilepsy 
Clobazam Clobazam 5mg/5ml oral suspension 4080100 Control Of Epilepsy 
Chlordiazepoxide hydrochloride Librium 10mg Tablet (ICN Pharmaceuticals France S.A.) 4010200 Anxiolytics 
Clonazepam Clonazepam 500micrograms/5ml solution sugar free 4080100 Control Of Epilepsy 
Lorazepam Ativan 2.5mg Tablet (Wyeth Pharmaceuticals) 04010200/15010401 Anxiolytics/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Librium 5mg capsules (Meda Pharmaceuticals) 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Lormetazepam Noctamid 1mg Tablet (Schering Health Care) 4010100 Hypnotics 
Diazepam Diazepam 2.5mg RecTubes (Wockhardt UK) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Valium 5mg Capsule (Roche Products) 04010100/04010200 Hypnotics/Anxiolytics 
Nitrazepam Mogadon 5mg tablets (Meda Pharmaceuticals) 4010100 Hypnotics 
Bromazepam Bromazepam 3mg tablets 4010200 Anxiolytics 
Diazepam Valium 2mg Capsule (Roche Products) 04010100/04010200 Hypnotics/Anxiolytics 
Temazepam Temazepam 10mg gel-fill capsules 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Valium 10mg Suppository (Roche Products) 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
  CHLORDIAZEPOXIDE 0 Unknown 
Temazepam Temazepam gelthix 30mg Capsule (Pharmacia) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Clobazam Clobazam 10mg/5ml oral suspension 4080100 Control Of Epilepsy 
Diazepam Diazepam 2mg/5ml oral solution sugar free (Actavis UK) 4010201 Benzodiazepines 
Amitriptyline 
Hydrochloride/Chlordiazepoxide 
Amitriptyline 12.5mg / Chlordiazepoxide 5mg capsules 4030100 Tricyclic And Related Antidepressant Drugs 
Lormetazepam Loramet 1mg Capsule (Wyeth Pharmaceuticals) 4010100 Hypnotics 
Temazepam Normison 20mg Capsule (Wyeth Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Medazepam Medazepam 5mg Capsule 4010200 Anxiolytics 
  CHLORDIAZEPOXIDE 0 Unknown 
Bromazepam Bromazepam 1.5mg tablets 4010200 Anxiolytics 
Temazepam Temazepam gelthix 15mg Capsule (Pharmacia) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Loprazolam mesilate Dormonoct 1mg Tablet (Hoechst Marion Roussel) 4010100 Hypnotics 
Ketazolam Ketazolam 15mg Capsule 4010200 Anxiolytics 
Diazepam Diazepam 20mg rectal tubes 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
Nitrazepam Somnite 2.5mg/5ml oral suspension (Norgine Pharmaceuticals) 4010100 Hypnotics 
Flurazepam hydrochloride Paxane 30mg Capsule (M A Steinhard) 4010100 Hypnotics 
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Chlordiazepoxide hydrochloride Librium 10mg capsules (Meda Pharmaceuticals) 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Chlordiazepoxide Hydrochloride Chlordiazepozide 100mg injection 4010200 Anxiolytics 
Oxazepam Oxanid 10mg Tablet (M A Steinhard) 4010200 Anxiolytics 
Prazepam Centrax 10mg Tablet (Parke-davis Research Laboratories) 4010200 Anxiolytics 
Clonazepam Rivotril 1mg/1ml concentrate for solution for injection ampoules (Roche Products) 4080200 Drugs Used In Status Epilepticus 
Temazepam Temazepam 10mg/5ml oral solution sugar free (Rosemont Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Nitrazepam Surem 5mg Capsule (Galen) 4010100 Hypnotics 
Chlordiazepoxide hydrochloride Tropium 5mg capsules (Dr Reddy's Laboratories (UK)) 04010201/10020200 Benzodiazepines/Skeletal Muscle Relaxants 
  CHLORDIAZEPOXIDE 0 Unknown 
Diazepam Diazepam 2mg Tablet (Crosspharma) 04010100/04010200 Hypnotics/Anxiolytics 
Ketazolam Ketazolam 30mg Capsule 4010200 Anxiolytics 
Diazepam Valium 5mg Suppository (Roche Products) 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
Diazepam Evacalm 5mg Tablet (Unimed Pharmaceuticals) 04010100/04010200 Hypnotics/Anxiolytics 
Chlordiazepoxide hydrochloride Chlordiazepoxide 5mg Tablet (DDSA Pharmaceuticals) 4010200 Anxiolytics 
Temazepam Euhypnos forte 20mg Capsule (Pharmacia) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg tablets (Ranbaxy (UK)) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Tropium 5mg tablets (Dr Reddy's Laboratories (UK)) 04010201/10020200 Benzodiazepines/Skeletal Muscle Relaxants 
Diazepam Valium 2mg/5ml Oral solution (Roche Products) 04010100/04010200 Hypnotics/Anxiolytics 
Temazepam Temazepam 20mg Tablet (Wyeth Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Temazepam Temazepam 20mg tablets (IVAX Pharmaceuticals UK) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Valclair 10mg suppositories (Durbin Plc) 0 Unknown 
Chlordiazepoxide Hydrochloride Librium 25mg Tablet (ICN Pharmaceuticals France S.A.) 4010200 Anxiolytics 
Diazepam Diazepam 5mg tablets (Actavis UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Temazepam Temazepam 20mg gel-fill capsules 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 10mg/2ml solution for injection ampoules (Wockhardt UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 250micrograms/5ml oral solution 4080100 Control Of Epilepsy 
Temazepam Temazepam 10mg/5ml oral solution sugar free (A A H Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg/5ml oral solution (Sandoz) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Solis 5mg Capsule (Galen) 04010100/04010200 Hypnotics/Anxiolytics 
Lorazepam Lorazepam 1mg tablets (Teva UK) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Temazepam Temazepam 10mg Tablet (Wyeth Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg tablets (A A H Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 10mg/2ml solution for injection ampoules (Hameln Pharmaceuticals) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Temazepam Temazepam 10mg tablets (IVAX Pharmaceuticals UK) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 5mg/2.5ml rectal solution tube (Sandoz) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Diazepam 5mg/5ml oral solution (Sandoz) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
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Lormetazepam Lormetazepam 500microgram tablets (A A H Pharmaceuticals) 4010100 Hypnotics 
Diazepam Diazepam 10mg tablets (Mylan) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Temazepam Temazepam 10mg tablets (A A H Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg tablets (Teva UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg tablets (Mylan) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 10mg tablets (Ranbaxy (UK)) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Lormetazepam Lormetazepam 500microgram tablets (Genus Pharmaceuticals) 4010100 Hypnotics 
Temazepam Temazepam 10mg tablets (Teva UK) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Nitrazepam Nitrazepam 5mg tablets (A A H Pharmaceuticals) 4010100 Hypnotics 
Diazepam Diazepam 5mg tablets (Teva UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 2mg/5ml oral solution sugar free (Rosemont Pharmaceuticals) 4080100 Control Of Epilepsy 
Temazepam Temazepam 10mg tablets (Mylan) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Lormetazepam Lormetazepam 1mg tablets (Mylan) 4010100 Hypnotics 
Diazepam Diazepam 2mg tablets (Actavis UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Lormetazepam Lormetazepam 1mg Tablet (Wyeth Pharmaceuticals) 4010100 Hypnotics 
Nitrazepam Nitrazepam 5mg tablets (Wockhardt UK) 4010100 Hypnotics 
Diazepam Diazepam 2mg Tablet (Regent Laboratories) 04010100/04010200 Hypnotics/Anxiolytics 
Temazepam Temazepam 20mg tablets (Mylan) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 10mg/2.5ml rectal solution tube (Sandoz) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Diazepam 5mg tablets (Mylan) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 5mg tablets (A A H Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Lormetazepam Lormetazepam 500microgram tablets (Mylan) 4010100 Hypnotics 
Diazepam Diazepam 2mg tablets (IVAX Pharmaceuticals UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 5mg Tablet (Crosspharma) 04010100/04010200 Hypnotics/Anxiolytics 
Nitrazepam Nitrazepam 5mg tablets (Teva UK) 4010100 Hypnotics 
Lormetazepam Lormetazepam 1mg tablets (Genus Pharmaceuticals) 4010100 Hypnotics 
Nitrazepam Nitrazepam 5mg Tablet (DDSA Pharmaceuticals) 4010100 Hypnotics 
Nitrazepam Nitrazepam 5mg tablets (Mylan) 4010100 Hypnotics 
Diazepam Diazepam 10mg tablets (Actavis UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg Tablet (Berk Pharmaceuticals) 04010100/04010200 Hypnotics/Anxiolytics 
Diazepam Diazepam 5mg Tablet (Berk Pharmaceuticals) 04010100/04010200 Hypnotics/Anxiolytics 
Chlordiazepoxide hydrochloride Chlordiazepoxide 5mg Capsule (DDSA Pharmaceuticals) 4010200 Anxiolytics 
Nitrazepam Nitrazepam 5mg Tablet (Berk Pharmaceuticals) 4010100 Hypnotics 
Lorazepam Lorazepam 2.5mg tablets (Teva UK) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 5mg capsules (A A H Pharmaceuticals) 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Lorazepam Lorazepam 1mg tablets (Mylan) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
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Diazepam Atensine 10mg Tablet (Rorer Pharmaceuticals) 04010100/04010200 Hypnotics/Anxiolytics 
Temazepam Temazepam 20mg Tablet (Pharmacia) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Oxazepam Oxazepam 10mg tablets (A A H Pharmaceuticals) 4010201 Benzodiazepines 
Temazepam Euhypnos 10mg/5ml Oral solution (Pharmacia) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Nitrazepam Remnos 10mg Tablet (DDSA Pharmaceuticals) 4010100 Hypnotics 
Lorazepam Lorazepam 1mg/5ml oral suspension 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Clobazam Clobazam 2.5mg capsules 4080100 Control Of Epilepsy 
Lorazepam Lorazepam 1mg/5ml oral solution 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Diazepam Diazepam 5mg Rectal tubes (Hillcross Pharmaceuticals) 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
Temazepam Temazepam 10mg Capsule (Berk Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Temazepam Temazepam 20mg Capsule (Berk Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Lorazepam Lorazepam 1mg tablets (Genus Pharmaceuticals) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Chlordiazepoxide Hydrochloride Chlordiazepoxide 25mg Tablet (DDSA Pharmaceuticals) 4010200 Anxiolytics 
Clobazam Clobazam 25mg/5ml oral solution 4080100 Control Of Epilepsy 
Nitrazepam Nitrazepam 5mg tablets (Actavis UK) 4010100 Hypnotics 
Lorazepam Lorazepam 1mg tablets (Arrow Generics) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Oxazepam Oxazepam 15mg tablets (A A H Pharmaceuticals) 4010201 Benzodiazepines 
Temazepam Temazepam 10mg Tablet (IVAX Pharmaceuticals UK) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Oxazepam Oxazepam 10mg tablets (Actavis UK) 4010201 Benzodiazepines 
Oxazepam Oxazepam 10mg Tablet (IVAX Pharmaceuticals UK) 4010200 Anxiolytics 
Oxazepam Oxazepam 10mg tablets (Genus Pharmaceuticals) 4010201 Benzodiazepines 
Temazepam Temazepam 10mg Tablet (Pharmacia) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg Capsule (Approved Prescription Services) 4010200 Anxiolytics 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg Capsule (IVAX Pharmaceuticals UK) 4010200 Anxiolytics 
Chlordiazepoxide hydrochloride Chlordiazepoxide 5mg capsules (Actavis UK) 04010201/10020200 Benzodiazepines/Skeletal Muscle Relaxants 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg capsules (Actavis UK) 04010201/10020200 Benzodiazepines/Skeletal Muscle Relaxants 
Loprazolam mesilate Loprazolam 1mg tablets (Zentiva) 4010100 Hypnotics 
Oxazepam Oxazepam 15mg Tablet (IVAX Pharmaceuticals UK) 4010200 Anxiolytics 
Oxazepam Oxazepam 15mg tablets (Actavis UK) 4010201 Benzodiazepines 
Chlordiazepoxide hydrochloride Chlordiazepoxide 5mg Capsule (Approved Prescription Services) 4010200 Anxiolytics 
Diazepam Diazepam 10mg tablets (Teva UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg Capsule (DDSA Pharmaceuticals) 4010200 Anxiolytics 
Diazepam Diazepam 10mg tablets (A A H Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Temazepam Temazepam 20mg Capsule (Hillcross Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 10mg Suppository (Sinclair IS Pharma Plc) 04010200/04080200 Anxiolytics/Drugs Used In Status Epilepticus 
Temazepam Temazepam 20mg tablets (A A H Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
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Temazepam Temazepam 20mg tablets (A A H Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Temazepam Temazepam 10mg Capsule (Hillcross Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Temazepam Temazepam 10mg Capsule (Hillcross Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Triazolam Triazolam 0.25mg Tablet (Berk Pharmaceuticals) 4010100 Hypnotics 
Triazolam Triazolam 0.25mg Tablet (Berk Pharmaceuticals) 4010100 Hypnotics 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg Tablet (DDSA Pharmaceuticals) 4010200 Anxiolytics 
Diazepam Diazepam 5mg/5ml oral solution (A A H Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Lorazepam Lorazepam 2.5mg tablets (Genus Pharmaceuticals) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 5mg tablets (A A H Pharmaceuticals) 04010201/10020200 Benzodiazepines/Skeletal Muscle Relaxants 
Midazolam Midazolam Oral solution 04080200/15010401 Drugs Used In Status Epilepticus/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Tropium 10mg tablets (Dr Reddy's Laboratories (UK)) 04010201/10020200 Benzodiazepines/Skeletal Muscle Relaxants 
Clonazepam Clonazepam 500microgram/5ml Oral solution (Rosemont Pharmaceuticals) 4080100 Control Of Epilepsy 
Diazepam Diazepam 2mg Tablet (M & A Pharmachem) 04010100/04010200 Hypnotics/Anxiolytics 
Diazepam Diazepam 5mg tablets (Ranbaxy (UK)) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg capsules (A A H Pharmaceuticals) 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Diazepam Diazepam 5mg tablets (Sandoz) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Temazepam Temazepam 10mg tablets (Actavis UK) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Temazepam Temazepam 10mg tablets (Genus Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg tablets (Almus Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Midazolam Midazolam 2.5mg/ml oral solution 15010401 Benzodiazepines (peri-operative) 
Lorazepam Lorazepam 1mg tablets (Sandoz) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Temazepam Temazepam 20mg tablets (Genus Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Clobazam Clobazam 10mg/5ml oral solution 4080100 Control Of Epilepsy 
Clobazam Clobazam 5mg/5ml oral solution 4080100 Control Of Epilepsy 
Lorazepam Lorazepam 500micrograms/5ml oral solution 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Triazolam Triazolam (roi) 125microgram Tablet 4010100 Hypnotics 
Diazepam Diazepam 10mg tablets (IVAX Pharmaceuticals UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Temazepam Temazepam 20mg tablets (Teva UK) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Oxazepam Oxazepam 15mg tablets (Genus Pharmaceuticals) 4010201 Benzodiazepines 
Nitrazepam Nitrazepam 5mg tablets (Ranbaxy (UK)) 4010100 Hypnotics 
Temazepam Temazepam 20mg tablets (Actavis UK) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 5mg tablets (IVAX Pharmaceuticals UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 500micrograms/5ml oral solution 4080100 Control Of Epilepsy 
Clobazam Clobazam 25mg/5ml oral suspension 4080100 Control Of Epilepsy 
Lormetazepam Lormetazepam 1mg/5ml oral suspension 4010100 Hypnotics 
Clonazepam Clonazepam 500micrograms/5ml oral solution sugar free 4080100 Control Of Epilepsy 
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Midazolam Midazolam 10mg/1ml oromucosal solution pre-filled oral syringes 0 Unknown 
Midazolam Midazolam 5mg/0.5ml oromucosal solution pre-filled syringes 4080200 Drugs Used In Status Epilepticus 
Temazepam Temazepam 10mg tablets (Sandoz) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 2mg/5ml oral solution sugar free 4080100 Control Of Epilepsy 
Clobazam Clobazam 4mg/5ml oral solution 4080100 Control Of Epilepsy 
Diazepam Diazepam 10mg/5ml oral solution 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Clobazam Clobazam 2.5mg/5ml oral solution 4080100 Control Of Epilepsy 
Midazolam Epistatus 10mg/1ml oromucosal solution (Special Products) 4080200 Drugs Used In Status Epilepticus 
Diazepam Diazepam 10mg/2ml solution for injection ampoules (A A H Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Midazolam Epistatus 7.5mg/0.75ml oromucosal solution pre-filled oral syringes (Special Products) 4080200 Drugs Used In Status Epilepticus 
  Diazepam 2mg/5ml oral suspension 4010201 Benzodiazepines 
Clobazam Clobazam 4mg/5ml oral suspension 4080100 Control Of Epilepsy 
Clobazam Clobazam 2.5mg/5ml oral suspension 4080100 Control Of Epilepsy 
Clobazam Clobazam 100mg/5ml oral suspension 4080100 Control Of Epilepsy 
Midazolam Epistatus 10mg/1ml oromucosal solution pre-filled oral syringes (Special Products) 4080200 Drugs Used In Status Epilepticus 
Clonazepam Clonazepam 500microgram tablets (Phoenix Healthcare Distribution) 4080100 Control Of Epilepsy 
Diazepam Diazepam 2mg/5ml oral solution sugar free (A A H Pharmaceuticals) 4010201 Benzodiazepines 
Diazepam Diazepam 2.5mg/5ml oral solution 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Clonazepam Clonazepam 2mg tablets (Sigma Pharmaceuticals Plc) 4080100 Control Of Epilepsy 
Midazolam Midazolam 7.5mg/0.75ml oromucosal solution pre-filled syringes 4080200 Drugs Used In Status Epilepticus 
Diazepam Diazepam 10mg Tablet (M & A Pharmachem) 04010100/04010200 Hypnotics/Anxiolytics 
Midazolam Epistatus 5mg/0.5ml oromucosal solution pre-filled oral syringes (Special Products  4080200 Drugs Used In Status Epilepticus 
Clobazam Tapclob 5mg/5ml oral suspension (Martindale Pharmaceuticals) 04010201/04080100 Benzodiazepines/Control Of Epilepsy 
Triazolam Triazolam 0.125mg Tablet (Berk Pharmaceuticals) 4010100 Hypnotics 
Clobazam Clobazam 10mg/5ml oral suspension sugar free 04010201/04080100 Benzodiazepines/Control Of Epilepsy 
Bromazepam Bromazepam 3mg tablets 4010000 Hypnotics And Anxiolytics 
Temazepam Temazepam 10mg/5ml oral solution sugar free (Focus Pharmaceuticals) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Midazolam Midazolam 10mg/1ml oromucosal solution pre-filled oral syringes 15010401 Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg tablets (Wockhardt UK) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Lorazepam Lorazepam 5mg/5ml oral solution 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Clobazam Tapclob 10mg/5ml oral suspension (Martindale Pharmaceuticals) 04010201/04080100 Benzodiazepines/Control Of Epilepsy 
Temazepam Temazepam 10mg tablets (F.Maltby & Sons) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Temazepam Temazepam 10mg tablets (Ethigen) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Lorazepam Lorazepam 2.5mg tablets (Sandoz) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Clobazam Frisium 10mg tablets (Waymade Healthcare Plc) 4080100 Control Of Epilepsy 
Clonazepam Clonazepam 250micrograms/5ml oral suspension 4080100 Control Of Epilepsy 
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Diazepam Diazepam 5mg tablets (Waymade Healthcare Plc) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 5mg tablets (Sovereign Medical) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 312.5micrograms/5ml oral suspension 4080100 Control Of Epilepsy 
Clonazepam Clonazepam 500microgram tablets (A A H Pharmaceuticals) 4080100 Control Of Epilepsy 
Diazepam Diazepam 10mg/5ml oral solution (AM Distributions (Yorkshire)) 04010201/04080200/10020200/15010401/54140000 Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning 
Diazepam Diazepam 5mg/5ml oral solution (AM Distributions (Yorkshire)) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 500microgram tablets (Almus Pharmaceuticals) 4080100 Control Of Epilepsy 
Diazepam Diazepam 5mg tablets (DE Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Clobazam Clobazam 5mg/5ml oral suspension (Special Order) 4080100 Control Of Epilepsy 
Temazepam Temazepam 20mg tablets (Sandoz) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 5mg tablets (Arrow Generics) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Lorazepam Lorazepam 1mg tablets (A A H Pharmaceuticals) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Clonazepam Clonazepam 500microgram tablets (Actavis UK) 4080100 Control Of Epilepsy 
  Nitrazepam 2mg/5ml oral suspension 4010100 Hypnotics 
Lorazepam Lorazepam 5mg/5ml oral suspension 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Diazepam Diazepam 10mg tablets (Almus Pharmaceuticals) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg tablets (A A H Pharmaceuticals) 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Diazepam Diazepam 2mg tablets (Sovereign Medical) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Temazepam Temazepam 20mg Tablet (Lagap) 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Clobazam Clobazam 7.5mg/5ml oral suspension 4080100 Control Of Epilepsy 
Diazepam Diazepam 2mg tablets (Waymade Healthcare Plc) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Lormetazepam Noctamid 0.5mg Tablet (Schering Health Care) 4010100 Hypnotics 
Temazepam Temazepam 30mg gel-fill capsules 04010100/15010401 Hypnotics/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg tablets (Phoenix Healthcare Distribution) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Diazepam Diazepam 2mg tablets (Alliance Healthcare (Distribution)) 04010201/04080200/04080300/10020200/15010401 Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative) 
Chlordiazepoxide hydrochloride Chlordiazepoxide 10mg tablets (Phoenix Healthcare Distribution) 04010201/04105000/10020200 Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants 
Clonazepam Clonazepam 5mg/5ml oral suspension 4080100 Control Of Epilepsy 
Lorazepam Lorazepam 1mg tablets (Genesis Pharmaceuticals) 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Nitrazepam Nitrazepam 10mg/5ml oral suspension 4010100 Hypnotics 
Lorazepam Lorazepam 2mg/5ml oral suspension 04010201/15010401 Benzodiazepines/Benzodiazepines (peri-operative) 
Clobazam Clobazam 5mg/5ml oral suspension sugar free (A A H Pharmaceuticals) 04010201/04080100 Benzodiazepines/Control Of Epilepsy 
Clonazepam Clonazepam 10mg/5ml oral solution 4080100 Control Of Epilepsy 
GABAergics    
Gabapentin Gabapentin 100mg capsules 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 25mg capsules 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 75mg capsules 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
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Gabapentin Gabapentin 300mg capsules 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg tablets 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 5mg dispersible tablets sugar free 4080100 Control Of Epilepsy 
Vigabatrin Vigabatrin 500mg tablets 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 200mg tablets 4080100 Control Of Epilepsy 
Vigabatrin Vigabatrin 500mg oral powder sachets sugar free 4080100 Control Of Epilepsy 
Lamotrigine Lamictal 25mg tablets (GlaxoSmithKline UK) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 400mg capsules 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 100mg tablets 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 600mg tablets 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg dispersible tablets sugar free 4080100 Control Of Epilepsy 
Lamotrigine Lamictal 100mg dispersible tablets (GlaxoSmithKline UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 100mg dispersible tablets sugar free 4080100 Control Of Epilepsy 
Gabapentin Neurontin 300mg capsules (Pfizer) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 2mg dispersible tablets sugar free 4080100 Control Of Epilepsy 
Pregabalin Lyrica 75mg capsules (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Pregabalin Pregabalin 150mg capsules 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 50mg capsules 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 200mg capsules 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 100mg capsules 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 300mg capsules 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamictal 50mg tablets (GlaxoSmithKline UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamictal 100mg tablets (GlaxoSmithKline UK) 4080100 Control Of Epilepsy 
Pregabalin Lyrica 100mg capsules (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Pregabalin Lyrica 50mg capsules (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Pregabalin Lyrica 200mg capsules (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Gabapentin Gabapentin 800mg tablets 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Neurontin 100mg capsules (Pfizer) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamictal 200mg tablets (GlaxoSmithKline UK) 4080100 Control Of Epilepsy 
Pregabalin Lyrica 300mg capsules (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Vigabatrin Sabril 500mg tablets (Sanofi) 4080100 Control Of Epilepsy 
Lamotrigine Lamictal 25mg dispersible tablets (GlaxoSmithKline UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamictal 5mg dispersible tablets (GlaxoSmithKline UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg dispersible tablets sugar free 4080100 Control Of Epilepsy 
Gabapentin Neurontin 400mg capsules (Pfizer) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
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Pregabalin Lyrica 150mg capsules (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Pregabalin Lyrica 25mg capsules (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Vigabatrin Vigabatrin 125mg capsules 4080100 Control Of Epilepsy 
Gabapentin Neurontin 600mg tablets (Pfizer) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Vigabatrin Sabril 500mg oral powder sachets (Sanofi) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 250mg/5ml oral solution 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
  TIAGABINE 0 Unknown 
Lamotrigine Lamictal 2mg dispersible tablets (GlaxoSmithKline UK) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 400mg/5ml oral suspension 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Teva UK) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Neurontin 800mg tablets (Pfizer) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets (Actavis UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 100mg tablets (Actavis UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets (Mylan) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 100mg capsules (Teva UK) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 100mg capsules (A A H Pharmaceuticals) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (A A H Pharmaceuticals) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 600mg tablets (Teva UK) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg dispersible tablets sugar free (Arrow Generics) 4080100 Control Of Epilepsy 
Pregabalin Pregabalin 225mg capsules 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Pregabalin Lyrica 225mg capsules (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Lamotrigine Lamotrigine 50mg tablets (Actavis UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets (Teva UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 100mg tablets (Teva UK) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 250mg/5ml oral suspension 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 600mg tablets (A A H Pharmaceuticals) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 250mg/5ml Oral solution (Boots Pharmaceuticals) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg Suppository 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg tablets (Teva UK) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 100mg capsules (Sandoz) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg tablets (IVAX Pharmaceuticals UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets (Fannin UK) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Mylan) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Sandoz) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg dispersible tablets sugar free (A A H Pharmaceuticals) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets (Arrow Generics) 4080100 Control Of Epilepsy 
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Pregabalin Lyrica 150mg capsules (Lexon (UK)) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Lamotrigine Lamotrigine 25mg tablets (Accord Healthcare) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets (A A H Pharmaceuticals) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Ranbaxy (UK)) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
  Pregabalin 20mg/ml oral solution sugar free 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Lamotrigine Lamictal 25mg tablets (DE Pharmaceuticals) 4080100 Control Of Epilepsy 
Lamotrigine Lamictal 25mg tablets (Lexon (UK)) 4080100 Control Of Epilepsy 
  Lyrica 20mg/ml oral solution (Pfizer) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Pregabalin Lyrica 50mg capsules (Waymade Healthcare Plc) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Gabapentin Gabapentin 300mg capsules (Actavis UK) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 300mg/5ml oral solution 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 5mg dispersible tablets sugar free (Actavis UK) 4080100 Control Of Epilepsy 
  Gabapentin 50mg/ml oral solution sugar free 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Almus Pharmaceuticals) 0 Unknown 
Gabapentin Gabapentin 300mg capsules (Bristol Laboratories) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets (Bristol Laboratories) 4080100 Control Of Epilepsy 
  Pregabalin 150mg/5ml oral solution 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg dispersible tablets sugar free (Tillomed Laboratories) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 100mg capsules (Mylan) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Neurontin 300mg capsules (Dowelhurst) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Arrow Generics) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg tablets (Alliance Healthcare (Distribution)) 4080100 Control Of Epilepsy 
  Gabapentin 600mg/5ml oral solution 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 100mg capsules (Actavis UK) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 400mg capsules (Almus Pharmaceuticals) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 300mg/5ml oral suspension 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 100mg capsules (Zentiva) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 100mg tablets (A A H Pharmaceuticals) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 100mg tablets (Alliance Healthcare (Distribution)) 4080100 Control Of Epilepsy 
Vigabatrin Vigabatrin 500mg/5ml oral solution 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 600mg tablets (Zentiva) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
  Gabapentin 400mg/5ml oral solution 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 100mg dispersible tablets sugar free (Teva UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg dispersible tablets sugar free (Teva UK) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg tablets (A A H Pharmaceuticals) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg tablets (Alliance Healthcare (Distribution)) 4080100 Control Of Epilepsy 
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Lamotrigine Lamotrigine 100mg dispersible tablets sugar free (A A H Pharmaceuticals) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 200mg tablets (A A H Pharmaceuticals) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Creo Pharma) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamictal 25mg dispersible tablets (Lexon (UK)) 4080100 Control Of Epilepsy 
  Pregabalin 75mg/5ml oral solution 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 200mg tablets (Waymade Healthcare Plc) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg/5ml oral suspension 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Waymade Healthcare Plc) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg tablets (Accord Healthcare) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 100mg tablets (Accord Healthcare) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 200mg tablets (Accord Healthcare) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 50mg tablets (Sigma Pharmaceuticals Plc) 4080100 Control Of Epilepsy 
Pregabalin Rewisca 75mg capsules (Consilient Health) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Rewisca 50mg capsules (Consilient Health) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Rewisca 300mg capsules (Consilient Health) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Rewisca 150mg capsules (Consilient Health) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Rewisca 100mg capsules (Consilient Health) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Rewisca 200mg capsules (Consilient Health) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Rewisca 25mg capsules (Consilient Health) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Rewisca 225mg capsules (Consilient Health) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Zentiva) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 50mg capsules (A A H Pharmaceuticals) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Alzain 25mg capsules (Dr Reddy's Laboratories (UK)) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Alzain 100mg capsules (Dr Reddy's Laboratories (UK)) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Lamotrigine Lamotrigine 25mg dispersible tablets sugar free (Actavis UK) 4080100 Control Of Epilepsy 
Pregabalin Pregabalin 100mg capsules (A A H Pharmaceuticals) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Alzain 300mg capsules (Dr Reddy's Laboratories (UK)) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Alzain 225mg capsules (Dr Reddy's Laboratories (UK)) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Alzain 150mg capsules (Dr Reddy's Laboratories (UK)) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Alzain 75mg capsules (Dr Reddy's Laboratories (UK)) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Alzain 50mg capsules (Dr Reddy's Laboratories (UK)) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Alzain 200mg capsules (Dr Reddy's Laboratories (UK)) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Gabapentin Gabapentin 600mg tablets (DE Pharmaceuticals) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 150mg/5ml oral suspension 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 300mg capsules (Alliance Healthcare (Distribution)) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Gabapentin Gabapentin 50mg/ml oral solution sugar free (Alliance Healthcare (Distribution)) 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
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Pregabalin Lyrica 75mg capsules (Waymade Healthcare Plc) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Pregabalin Lyrica 150mg capsules (Sigma Pharmaceuticals Plc) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Lamotrigine Lamotrigine 100mg tablets (Kent Pharmaceuticals) 4080100 Control Of Epilepsy 
Gabapentin Gabapentin 100mg/5ml oral solution 04070300/04080100 Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 75mg capsules (Teva UK) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Pregabalin 25mg capsules (Teva UK) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Lecaent 50mg capsules (Actavis UK) 04030000/04080100 Antidepressant Drugs/Control Of Epilepsy 
Pregabalin Pregabalin 50mg capsules (Accord Healthcare) 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Pregabalin Pregabalin 50mg capsules (Sandoz) 04030000/04070300/04080100 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy 
Pregabalin Lyrica 75mg capsules (Stephar (U.K.)) 04030000/04070300/04080100/06010500 Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy 
Lamotrigine Lamictal 50mg tablets (DE Pharmaceuticals) 4080100 Control Of Epilepsy 
Lamotrigine Lamotrigine 5mg/5ml oral solution 4080100 Control Of Epilepsy 
Opioids    
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules 4070200 Opioid Analgesics 
Pentazocine Lactate Fortral 30mg/ml Injection (Sterwin Medicines) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml linctus 3090100 Cough Suppressants 
Codeine phosphate Codeine 30mg tablets 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Zydol 50mg capsules (Grunenthal) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 10mg/5ml oral solution 4070200 Opioid Analgesics 
Codeine phosphate Codeine 25mg/5ml oral solution 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Pethidine Hydrochloride Pethidine 25mg tablet 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine 10mg/ml injection 4070200 Opioid Analgesics 
Buprenorphine Hydrochloride Buprenorphine HCl 300micrograms injection 4070200 Opioid Analgesics 
Pentazocine hydrochloride Pentazocine 50mg capsules 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulfate 100mg/50ml solution for infusion vials 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 200microgram sublingual tablets sugar free 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Pethidine Hydrochloride Pethidine 50mg/ml injection 4070200 Opioid Analgesics 
Morphine Sulphate Morphine 15mg Suppository 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate MST Continus 10mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Morphine sulfate MST Continus Suspension 20mg granules sachets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 50microgram/ml Injection 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Fentanyl Fentanyl 25micrograms/hour transdermal patches 4070200 Opioid Analgesics 
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Codeine Phosphate Codeine 30mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/5ml oral solution unit dose vials sugar free 4070200 Opioid Analgesics 
Morphine Sulphate Morphine 30mg Suppository 4070200 Opioid Analgesics 
Tramadol hydrochloride/ 
Paracetamol 
Tramacet 37.5mg/325mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg modified-release capsules 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 1mg/ml Injection 4070200 Opioid Analgesics 
Fentanyl Durogesic 25micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 50micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate Oramorph 10mg/5ml oral solution (Boehringer Ingelheim) 4070200 Opioid Analgesics 
  Migraleve tablets (McNeil Products) 04070200/04070401 Opioid Analgesics/Treatment Of Acute Migraine 
Buclizine hydrochloride/ 
Paracetamol/ Codeine 
phosphate 
Migraleve Pink tablets (McNeil Products) 04070200/04070401 Opioid Analgesics/Treatment Of Acute Migraine 
Codeine phosphate Codeine 15mg/5ml linctus sugar free 3090100 Cough Suppressants 
Dihydrocodeine tartrate Dihydrocodeine 60mg modified-release tablets 4070200 Opioid Analgesics 
Pentazocine hydrochloride Pentazocine 25mg tablets 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg tablets 4070200 Opioid Analgesics 
Codeine phosphate Codeine 3mg/5ml linctus paediatric sugar free 3090100 Cough Suppressants 
Methadone hydrochloride Methadone 1mg/ml oral solution 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate MST Continus 30mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine 50mg/ml injection 4070200 Opioid Analgesics 
Morphine sulfate Oramorph sr 10mg Tablet (Boehringer Ingelheim) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 400microgram sublingual tablets sugar free 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Diamorphine Hydrochloride Diamorphine 10mg Injection (Manufacturer unknown) 4070200 Opioid Analgesics 
Meptazinol hydrochloride Meptazinol 200mg tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg soluble tablets sugar free 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Temgesic 200microgram sublingual tablets (RB Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Zydol SR 100mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 50mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Df118 40mg Tablet (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Sevredol 10mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Dextromoramide tartrate Dextromoramide 5mg tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 100mg modified-release capsules 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 100mg modified-release tablets 4070200 Opioid Analgesics 
Dextromoramide tartrate Palfium 5mg tablets (Roche Products) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 10mg tablets 4070200 Opioid Analgesics 
Morphine sulfate MST Continus 5mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
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Codeine phosphate Galcodine 3mg/5ml Oral solution (Thornton & Ross) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Morphine sulfate MST Continus Suspension 60mg granules sachets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate MST Continus 60mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 100micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Morphine sulfate Oramorph 10mg/5ml oral solution unit dose vials (Boehringer Ingelheim) 4070200 Opioid Analgesics 
Codeine Phosphate Codeine phosphate 15mg/5ml diabetic oral solution 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 40mg tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 150mg modified-release capsules 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol 24 Modified-release tablet 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol 24 Modified-release tablet 4070200 Opioid Analgesics 
Fentanyl Durogesic 50micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine hydrochloride 5mg powder for injection solution 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Hydromorphone 2.6mg capsules 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Hydromorphone 1.3mg capsules 4070200 Opioid Analgesics 
Tramadol hydrochloride Zydol SR 200mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 2mg/5ml linctus 3090100 Cough Suppressants 
Tramadol Hydrochloride Tramadol 12 Modified-release tablet 4070200 Opioid Analgesics 
Methadone hydrochloride Physeptone 5mg tablets (Martindale Pharmaceuticals) 03090100/04070200/04105200 Cough Suppressants/Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate Sevredol 10mg/5ml oral solution (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 12 20mg Modified-release capsule 4070200 Opioid Analgesics 
Codeine phosphate Galcodine 15mg/5ml linctus (Thornton & Ross) 3090100 Cough Suppressants 
Oxycodone hydrochloride Oxycodone 10mg capsules 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 10mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 400microgram lozenges 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 12 50mg Modified-release capsule 4070200 Opioid Analgesics 
Fentanyl Durogesic 75micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Morphine hydrochloride Morphine hydrochloride 15mg suppositories 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine hydrochloride 30mg powder for injection solution 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine hydrochloride 10mg powder for injection solution 4070200 Opioid Analgesics 
Morphine sulfate Morphine 10mg modified-release tablets 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 600microgram lozenges 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 800microgram lozenges 4070200 Opioid Analgesics 
Morphine sulfate MST Continus 15mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine tartrate/Cyclizine 
tartrate 
Cyclimorph 10 solution for injection 1ml ampoules (AMCo) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/5ml oral solution 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 10mg modified-release tablets 4070200 Opioid Analgesics 
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Buprenorphine Transtec 35micrograms/hour transdermal patches (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate MST Continus 100mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 10mg modified-release capsules 4070200 Opioid Analgesics 
Buprenorphine Transtec 52.5micrograms/hour transdermal patches (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 8mg sublingual tablets sugar free 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Zydol SR 150mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Buprenorphine Transtec 70micrograms/hour transdermal patches (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Subutex 8mg sublingual tablets (RB Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Tramadol 200mg modified-release capsules 4070200 Opioid Analgesics 
Morphine sulfate Sevredol 20mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 120mg modified-release tablets 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 20mg/ml oral solution sugar free 4070200 Opioid Analgesics 
Fentanyl Fentanyl 75micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Morphine sulfate Sevredol 50mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone Hydrochloride Oxycodone hydrochloride 10mg/ml injection 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 5mg tablets 03090100/04070200/04105200 Cough Suppressants/Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Diamorphine Hydrochloride Diamorphine hydrochloride 500mg powder for injection solution 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine hydrochloride 100mg powder for injection solution 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 2mg sublingual tablets sugar free 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Oxycodone hydrochloride OxyNorm 5mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol 
hydrochloride/Paracetamol 
Tramadol 37.5mg / Paracetamol 325mg tablets 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 20mg modified-release tablets 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 5mg/5ml oral solution sugar free 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 40mg modified-release tablets 4070200 Opioid Analgesics 
Morphine sulfate Morphine 20mg modified-release granules sachets sugar free 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 5mg modified-release tablets 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 5mg capsules 4070200 Opioid Analgesics 
Buprenorphine Buprenorphine 35micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 10mg/ml Injection 4070200 Opioid Analgesics 
Buprenorphine Buprenorphine 52.5micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 80mg modified-release tablets 4070200 Opioid Analgesics 
Fentanyl Durogesic DTrans 25micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Fentanyl Durogesic DTrans 50micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine 3mg/5ml oral solution 4070200 Opioid Analgesics 
Fentanyl Fentanyl 12micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 5mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
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Morphine Sulphate Morphine sulphate 12 30mg Modified-release capsule 4070200 Opioid Analgesics 
Buprenorphine Buprenorphine 10micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Buprenorphine Buprenorphine 20micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 20mg capsules 4070200 Opioid Analgesics 
Buprenorphine Buprenorphine 5micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 20mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 20mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl Durogesic DTrans 75micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 10mg/ml concentrate oral solution (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine Hydrochloride Temgesic 0.3mg/ml Injection (Reckitt Benckiser Healthcare (UK)) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Df118 10mg/5ml Oral solution (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 15mg suppositories 4070200 Opioid Analgesics 
Buprenorphine BuTrans 5micrograms/hour transdermal patches (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Hydrochloride Morphine hcl Oral solution (Thornton and Ross) 4070200 Opioid Analgesics 
Dextromoramide Tartrate Palfium 5mg/ml Injection (Roche Products) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine 100mg Injection (Manufacturer unknown) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 30mg modified-release tablets 4070200 Opioid Analgesics 
Dextromoramide tartrate Dextromoramide 10mg tablets 0 Unknown 
Diamorphine Hydrochloride Diamorphine 5mg Injection (Manufacturer unknown) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Temgesic 400microgram sublingual tablets (RB Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate MST Continus 200mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine 30mg Injection (Manufacturer unknown) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 30mg/ml Injection 4070200 Opioid Analgesics 
Pentazocine hydrochloride Fortral 25mg tablets (Zentiva) 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol 12 Modified-release tablet 4070200 Opioid Analgesics 
Meptazinol hydrochloride Meptid 200mg Tablet (Shire Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate DHC Continus 60mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 5mg/5ml Oral solution (Manufacturer unknown) 4070200 Opioid Analgesics 
Morphine hydrochloride Morphine hydrochloride 30mg suppositories 4070200 Opioid Analgesics 
Morphine sulfate Morphine 60mg modified-release tablets 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 10mg Tablet (Manufacturer unknown) 4070200 Opioid Analgesics 
Morphine sulfate Oramorph 20mg/ml concentrated oral solution (Boehringer Ingelheim) 4070200 Opioid Analgesics 
Cyclizine hydrochloride/ 
Dipipanone hydrochloride 
Diconal tablets (Amdipharm Plc) 4070200 Opioid Analgesics 
Morphine tartrate/Cyclizine 
tartrate 
Cyclimorph 15 solution for injection 1ml ampoules (AMCo) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine 500mg Injection (Manufacturer unknown) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 20mg tablets 4070200 Opioid Analgesics 
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Morphine sulfate Morphine 100mg modified-release tablets 4070200 Opioid Analgesics 
Dihydrocodeine tartrate DHC Continus 90mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate DHC Continus 120mg tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 90mg modified-release tablets 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Hydromorphone 4mg modified-release capsules 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Palladone 2.6mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Palladone SR 4mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Palladone SR 2mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate MXL 30mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate MXL 60mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate MXL 120mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate MXL 90mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zamadol SR 50mg capsules (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zamadol SR 100mg capsules (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 24 60mg Modified-release capsule 4070200 Opioid Analgesics 
Morphine sulfate Morphine 15mg modified-release tablets 4070200 Opioid Analgesics 
Morphine sulfate Morphine 5mg modified-release tablets 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Palladone 1.3mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 100mg modified-release granules sachets sugar free 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 1mg/ml oral solution sugar free 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Tramadol 100mg effervescent powder sachets sugar free 0 Unknown 
Oxycodone hydrochloride OxyNorm liquid 5mg/5ml oral solution (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 40mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone Hydrochloride Oxynorm 10mg/ml Solution for injection (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 10mg Tablet (Aurum Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 12 60mg Modified-release capsule 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 10mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 80mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Subutex 2mg sublingual tablets (RB Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Buprenorphine BuTrans 10micrograms/hour transdermal patches (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate MXL 150mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Df118 50mg/ml Injection (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Dextromoramide tartrate Palfium 10mg tablets (Roche Products) 0 Unknown 
Pentazocine Lactate Pentazocine 30mg/ml injection 4070200 Opioid Analgesics 
Morphine Anhydrous Morphine 10mg/ml Tincture 4070200 Opioid Analgesics 
Morphine sulfate Sevredol 10mg Suppository (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
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Pentazocine hydrochloride Fortral 50mg Capsule (Sanofi-Synthelabo) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone hydrochloride 30mg suppositories 0 Unknown 
Fentanyl Durogesic 100micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Meptazinol hydrochloride Meptid 100mg/1ml solution for injection ampoules (Almirall) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zydol 50mg soluble tablets (Grunenthal) 4070200 Opioid Analgesics 
Papaveretum Papaveretum 15.4mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Tramadol hydrochloride Zydol 100mg/2ml solution for injection ampoules (Grunenthal) 4070200 Opioid Analgesics 
Morphine sulfate Oramorph 30mg/5ml oral solution unit dose vials (Boehringer Ingelheim) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 10mg/ml oral solution sugar free 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 100mg/2ml solution for injection ampoules 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 75mg modified-release tablets 0 Unknown 
Tramadol hydrochloride Tramadol 50mg effervescent powder sachets sugar free 0 Unknown 
Buprenorphine Buprenorphine 70micrograms/hour transdermal patches 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 24 30mg Modified-release capsule 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 10mg/ml oral solution sugar free 4105200 Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Tramadol 50mg orodispersible tablets sugar free 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 300mg modified-release tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 400mg modified-release tablets 4070200 Opioid Analgesics 
Morphine sulfate Morcap SR 20mg capsules (Hospira UK) 0 Unknown 
Meptazinol hydrochloride Meptazinol 100mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate Morphine 200mg modified-release tablets 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 200microgram lozenges 4070200 Opioid Analgesics 
Fentanyl Durogesic DTrans 12micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Cyclizine hydrochloride/ 
Dipipanone hydrochloride 
Dipipanone 10mg / Cyclizine 30mg tablets 4070200 Opioid Analgesics 
Dextropropoxyphene Napsylate Dextropropoxyphene 60mg capsules 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 15mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate Morphine 60mg modified-release granules sachets sugar free 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg suppositories 4070200 Opioid Analgesics 
Morphine sulfate MST Continus Suspension 100mg granules sachets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine Phosphate/Ibuprofen Ibuprofen and codeine 200mg + 12.5mg Tablet 04070200/10010100 Opioid Analgesics/Non-steroidal Anti-inflammatory Drugs 
Morphine sulfate Oramorph 100mg/5ml oral solution unit dose vials (Boehringer Ingelheim) 4070200 Opioid Analgesics 
Morphine sulfate MST Continus Suspension 30mg granules sachets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Subutex 0.4mg sublingual tablets (RB Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Fentanyl citrate Actiq 200microgram lozenges with integral oromucosal applicator (Teva UK) 4070200 Opioid Analgesics 
Morphine sulfate Zomorph 10mg modified-release capsules (ProStrakan) 4070200 Opioid Analgesics 
Morphine sulfate Zomorph 30mg modified-release capsules (ProStrakan) 4070200 Opioid Analgesics 
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Morphine sulfate Morphine sulfate 20mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 30mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 60mg/2ml solution for injection ampoules 4070200 Opioid Analgesics 
Buprenorphine BuTrans 20micrograms/hour transdermal patches (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 15mg/5ml Oral solution (Manufacturer unknown) 4070200 Opioid Analgesics 
Morphine Sulphate Morcap sr 20mg Modified-release capsule (Faulding Pharmaceuticals (Dbl)) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zamadol 50mg capsules (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 24 200mg Modified-release capsule 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 100mg Modified-release capsule 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 12 100mg Modified-release capsule 4070200 Opioid Analgesics 
Morphine sulfate Zomorph 100mg modified-release capsules (ProStrakan) 4070200 Opioid Analgesics 
Methadone Hydrochloride Methadone 10mg/ml Injection 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate Morphine sulfate 30mg/5ml oral solution unit dose vials sugar free 4070200 Opioid Analgesics 
Morphine sulfate Morphine 30mg modified-release granules sachets sugar free 4070200 Opioid Analgesics 
Phenazocine Hydrobromide Phenazocine hydrobromide 5mg tablet 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramake 50mg capsules (Galen) 4070200 Opioid Analgesics 
Fentanyl Durogesic DTrans 100micrograms transdermal patches (Janssen-Cilag) 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 1.2mg lozenges 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine 10mg/5ml oral solution 4070200 Opioid Analgesics 
Papaveretum Papaveretum 7.7mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Codeine phosphate Codeine phosphate powder 50030000 Extemporaneous Item 
Morphine Sulphate Morphine sulphate 24 90mg Modified-release capsule 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Hydromorphone 2mg modified-release capsules 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine hydrochloride powder 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Hydromorphone 8mg modified-release capsules 4070200 Opioid Analgesics 
Morphine sulfate Morphine 50mg tablets 4070200 Opioid Analgesics 
Morphine sulfate Zomorph 200mg modified-release capsules (ProStrakan) 4070200 Opioid Analgesics 
Morphine sulfate Zomorph 60mg modified-release capsules (ProStrakan) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 6.75mg/5ml oral solution 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Morphine Sulphate Morphine sulphate 10mg/ml Injection 4070200 Opioid Analgesics 
Tramadol hydrochloride Zydol XL 300mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Morphine sulfate Oramorph sr 30mg Tablet (Boehringer Ingelheim) 4070200 Opioid Analgesics 
Morphine tartrate/Cyclizine 
tartrate 
Morphine tartrate 10mg/1ml / Cyclizine tartrate 50mg/1ml solution for injection 
ampoules 
4070200 Opioid Analgesics 
Tramadol hydrochloride Zydol XL 200mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Fentanyl Tilofyl 75micrograms/hour transdermal patches (Tillomed Laboratories) 4070200 Opioid Analgesics 
Nalbuphine Hydrochloride Nubain 10mg/ml Injection (Bristol-Myers Squibb Pharmaceuticals) 4070200 Opioid Analgesics 
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Pethidine hydrochloride Pethidine 100mg/2ml solution for injection ampoules 4070200 Opioid Analgesics 
Phenazocine Hydrobromide Narphen 5mg Tablet (Smith & Nephew Healthcare) 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg Tablet (Roche Products) 4070200 Opioid Analgesics 
Morphine tartrate/ Cyclizine 
tartrate 
Morphine tartrate 15mg/1ml / Cyclizine tartrate 50mg/1ml solution for injection 
ampoules 
4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 50mg/1ml solution for injection ampoules 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Dextromoramide Tartrate Dextromoramide 5mg/ml injection 4070200 Opioid Analgesics 
Pentazocine lactate Pentazocine 50mg suppositories 0 Unknown 
Morphine sulfate Oramorph sr 60mg Tablet (Boehringer Ingelheim) 4070200 Opioid Analgesics 
Methadone Hydrochloride Physeptone 10mg/ml Injection (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate MXL 200mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Sevredol 20mg/ml concentrated oral solution (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 12 200mg Modified-release capsule 4070200 Opioid Analgesics 
Fentanyl citrate Actiq 400microgram lozenges with integral oromucosal applicator (Teva UK) 4070200 Opioid Analgesics 
Morphine anhydrous/ 
Peppermint oil 
J Collis Browne's mixture (Thornton & Ross) 01020200/04070200 Other Antispasmodics/Opioid Analgesics 
Pethidine hydrochloride/ 
Promethazine hydrochloride 
Pamergan P100 solution for injection 2ml ampoules (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate SRM-RHOTARD 10mg Modified-release tablet (Pharmacia) 4070200 Opioid Analgesics 
Morphine sulfate SRM-RHOTARD 30mg Modified-release tablet (Pharmacia) 4070200 Opioid Analgesics 
Morphine sulfate Oramorph sr 100mg Tablet (Boehringer Ingelheim) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 10mg tablets 4070200 Opioid Analgesics 
Morphine sulfate Morcap SR 100mg capsules (Hospira UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphgesic SR 10mg tablets (AMCo) 4070200 Opioid Analgesics 
Dextropropoxyphene napsylate Dextropropoxyphene 60mg capsules 0 Unknown 
Morphine Sulphate Morcap sr 50mg Modified-release capsule (Faulding Pharmaceuticals (Dbl)) 4070200 Opioid Analgesics 
Pethidine hydrochloride/ 
Promethazine hydrochloride 
Pethidine 100mg/2ml / Promethazine 50mg/2ml solution for injection ampoules 4070200 Opioid Analgesics 
Nalbuphine Hydrochloride Nalbuphine hc 10mg/ml Injection 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 100mg/5ml oral solution unit dose vials sugar free 4070200 Opioid Analgesics 
Codeine Phosphate/Papaverine 
Hydrochloride/Morphine 
Hydrochloride 
Omnopon 10mg Tablet (Roche Products) 4070200 Opioid Analgesics 
Morphine sulfate Morphgesic SR 30mg tablets (AMCo) 4070200 Opioid Analgesics 
Morphine sulfate Morphgesic SR 60mg tablets (AMCo) 4070200 Opioid Analgesics 
Morphine sulfate Morphgesic SR 100mg tablets (AMCo) 4070200 Opioid Analgesics 
Codeine Phosphate/ Papaverine 
Hydrochloride/Morphine 
Hydrochloride 
Papaveretum 10mg tablet 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Palladone SR 16mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Hydromorphone 16mg modified-release capsules 4070200 Opioid Analgesics 
Tramadol hydrochloride Dromadol SR 100mg tablets (Teva UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/10ml solution for injection pre-filled syringes 4070200 Opioid Analgesics 
Levorphanol Tartrate Dromoran roche 1.5mg Tablet (Roche Products) 4070200 Opioid Analgesics 
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Tramadol hydrochloride Zamadol Melt 50mg tablets (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 30mg suppositories 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 20mg suppositories 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramake Insts 50mg sachets (Galen) 0 Unknown 
Hydromorphone hydrochloride Palladone SR 8mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Palladone SR 24mg capsules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zydol XL 400mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Methadone hydrochloride Physeptone 1mg/ml mixture sugar free (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Dromadol SR 200mg tablets (Teva UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zamadol SR 200mg capsules (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Cocaine/Diamorphine 
Hydrochloride 
Diamorphine hydrochloride and cocaine oral solution 4070200 Opioid Analgesics 
Tramadol hydrochloride Zydol XL 150mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Morphine sulfate Rhotard Morphine SR 10mg tablets (Sovereign Medical) 4070200 Opioid Analgesics 
Morphine sulfate Rhotard Morphine SR 30mg tablets (Sovereign Medical) 4070200 Opioid Analgesics 
Fentanyl Tilofyl 50micrograms/hour transdermal patches (Tillomed Laboratories) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 24 120mg Modified-release capsule 4070200 Opioid Analgesics 
Morphine sulfate Filnarine SR 30mg tablets (Teva UK) 4070200 Opioid Analgesics 
Morphine sulfate MST Continus Suspension 200mg granules sachets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 20mg/ml oral solution sugar free 4105200 Drugs Used In Substance Dependence - Opioid Dependence 
Dextromoramide Tartrate Palfium 10mg Suppository (Roche Products) 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg/5ml solution for injection ampoules 4070200 Opioid Analgesics 
Tramadol hydrochloride Dromadol SR 150mg tablets (Teva UK) 4070200 Opioid Analgesics 
Alfentanil hydrochloride Alfentanil 5mg/1ml solution for injection ampoules 15010403 Opioid Analgesics (in Anaesthesia) 
Codeine phosphate Codeine 15mg/5ml linctus (Thornton & Ross) 3090100 Cough Suppressants 
Tramadol hydrochloride Zamadol SR 150mg capsules (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diagesil 10mg Injection (Berk Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml linctus (A A H Pharmaceuticals) 3090100 Cough Suppressants 
Codeine phosphate Codeine 15mg/5ml Oral solution (Approved Prescription Services) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Methadone hydrochloride Methadose 10mg/ml oral solution concentrate (Rosemont Pharmaceuticals) 4105200 Drugs Used In Substance Dependence - Opioid Dependence 
Methadone hydrochloride Methadose 20mg/ml oral solution concentrate (Rosemont Pharmaceuticals) 4105200 Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Tramake Insts 100mg sachets (Galen) 0 Unknown 
Methadone hydrochloride Methodex 1mg/ml Mixture (Link Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine Sulphate Morcap sr 100mg Modified-release capsule (Faulding Pharmaceuticals (Dbl)) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 50mg/2ml solution for injection ampoules 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Diamorphine Hydrochloride Diaphine 100mg Injection (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Hydromorphone 24mg modified-release capsules 4070200 Opioid Analgesics 
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Alfentanil Hydrochloride Alfentanil 500micrograms/ml injection 15010403 Opioid Analgesics (in Anaesthesia) 
Morphine Sulphate Morphine sulphate 20mg/ml Injection 4070200 Opioid Analgesics 
Pethidine 
Hydrochloride/levallorphan 
Pethidine with levallorphan tartrate injection 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 1.6mg lozenges 4070200 Opioid Analgesics 
Fentanyl Citrate Sublimaze 50microgram/ml Injection (Janssen-Cilag) 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Fentanyl citrate Actiq 600microgram lozenges with integral oromucosal applicator (Teva UK) 4070200 Opioid Analgesics 
Morphine Anhydrous Nepenthe 8.4mg/ml Injection (Celltech Pharma Europe) 4070200 Opioid Analgesics 
Codeine Phosphate Codeine phosphate with other ingredient pastilles 3090100 Cough Suppressants 
Dextromoramide Tartrate Palfium 10mg/ml Injection (Roche Products) 4070200 Opioid Analgesics 
Pentazocine lactate Fortral 50mg suppositories (Sterwin Medicines) 0 Unknown 
Dextropropoxyphene napsylate Doloxene 60mg Capsule (Eli Lilly and Company) 4070200 Opioid Analgesics 
Fentanyl citrate Actiq 1.6mg lozenges with integral oromucosal applicator (Teva UK) 4070200 Opioid Analgesics 
Methadone hydrochloride Physeptone 1mg/ml mixture (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate Filnarine SR 10mg tablets (Teva UK) 4070200 Opioid Analgesics 
Morphine sulfate Filnarine SR 100mg tablets (Teva UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Dromadol XL 300mg tablets (IVAX Pharmaceuticals UK) 4070200 Opioid Analgesics 
Fentanyl citrate Actiq 800microgram lozenges with integral oromucosal applicator (Teva UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zamadol 24hr 200mg modified-release tablets (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Filnarine SR 60mg tablets (Teva UK) 4070200 Opioid Analgesics 
  OXYCODONE 0 Unknown 
Tramadol hydrochloride Zamadol 24hr 150mg modified-release tablets (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 24 150mg Modified-release capsule 4070200 Opioid Analgesics 
Fentanyl Tilofyl 100micrograms/hour transdermal patches (Tillomed Laboratories) 4070200 Opioid Analgesics 
Methadone hydrochloride Metharose 1mg/ml oral solution sugar free (Rosemont Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine Sulphate Moraxen 35mg Rectal tampon (Schwarz Pharma) 4070200 Opioid Analgesics 
Alfentanil Hydrochloride Rapifen 100microgram/ml Paediatric injection (Janssen-Cilag) 15010403 Opioid Analgesics (in Anaesthesia) 
Diamorphine Hydrochloride Diamorphine hydrochloride bpc 1973 3mg/5ml oral solution 4070200 Opioid Analgesics 
Tramadol hydrochloride Zamadol 24hr 300mg modified-release tablets (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Dextromoramide Tartrate Dextromoramide 10mg suppository 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diaphine 10mg Injection (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 200mg modified-release granules sachets sugar free 4070200 Opioid Analgesics 
Methadone hydrochloride Physeptone 10mg/1ml solution for injection ampoules (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Dromadol SR 75mg tablets (IVAX Pharmaceuticals UK) 0 Unknown 
Pethidine Hydrochloride Pethidine 50mg/ml Injection (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 5mg/5ml oral solution 4070200 Opioid Analgesics 
Fentanyl citrate Actiq 1.2mg lozenges with integral oromucosal applicator (Teva UK) 4070200 Opioid Analgesics 
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Methadone hydrochloride Methadone 2mg/5ml Oral solution (Martindale Pharmaceuticals) 3090100 Cough Suppressants 
Tramadol hydrochloride Tramadol 50mg capsules (IVAX Pharmaceuticals UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate powder 04070200/50030000 Opioid Analgesics/Extemporaneous Item 
Methadone hydrochloride Methadone 2mg/5ml linctus (Thornton & Ross) 3090100 Cough Suppressants 
Morphine Sulphate Morphine sulphate rapiject 1mg/ml Injection (International Medication Systems (UK)) 4070200 Opioid Analgesics 
Morphine Anhydrous Morphine 8.4mg/ml elixir 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine powder 50000000 Ingredients 
Diamorphine Hydrochloride Diaphine 30mg Injection (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 1mg/ml oral solution sugar free (Rosemont Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Levorphanol Tartrate Levorphanol 1.5mg Tablet 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diagesil 500mg Injection (Berk Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine 10mg/5ml Oral solution (Manufacturer unknown) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine hydrochloride 3mg/5ml oral solution 4070200 Opioid Analgesics 
Fentanyl Tilofyl 25micrograms/hour transdermal patches (Tillomed Laboratories) 4070200 Opioid Analgesics 
Tramadol hydrochloride Dromadol XL 200mg tablets (IVAX Pharmaceuticals UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Dromadol XL 150mg tablets (IVAX Pharmaceuticals UK) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine 50mg/ml Injection (Auden McKenzie (Pharma Division)) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Wockhardt UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Pentazocine lactate Pentazocine 30mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Pentazocine lactate Pentazocine 60mg/2ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulfate 30mg/30ml solution for infusion vials 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Actavis UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Dromadol XL 400mg tablets (IVAX Pharmaceuticals UK) 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 100mg/10ml solution for injection ampoules 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg Tablet (Roche Products) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (IVAX Pharmaceuticals UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 15mg/5ml oral solution 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg Capsule (Generics (UK)) 4070200 Opioid Analgesics 
Methadone hydrochloride Methex 1mg/ml Mixture (Generics (UK)) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Alfentanil hydrochloride Rapifen 5mg/ml Concentrate for solution for infusion (Janssen-Cilag) 15010403 Opioid Analgesics (in Anaesthesia) 
Oxycodone hydrochloride OxyNorm 10mg/1ml solution for injection ampoules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 3mg/5ml linctus paediatric (Thornton & Ross) 0 Unknown 
Tramadol hydrochloride Zamadol 24hr 400mg modified-release tablets (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine anhydrous Opium tincture 0 Unknown 
Diamorphine Hydrochloride Diagesil 5mg Injection (Berk Pharmaceuticals) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine 100mg/2ml Injection (Roche Products) 4070200 Opioid Analgesics 
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Diamorphine hydrochloride Diamorphine 5mg powder for solution for injection ampoules (Novartis) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 10mg/1ml solution for injection ampoules 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Methadone Hydrochloride Methadone 35mg/ml Injection 4105200 Drugs Used In Substance Dependence - Opioid Dependence 
Codeine phosphate Codeine 15mg/5ml linctus sugar free (A A H Pharmaceuticals) 3090100 Cough Suppressants 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Wockhardt UK) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 1mg/ml oral solution (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Pethidine Hydrochloride/ 
Promethazine Hydrochloride 
Promethazine hydrochloride 50mg with pethidine 100mg/2ml injection 03040102/04070200 Sedating Antihistamines/Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (IVAX Pharmaceuticals UK) 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol sr 150mg Modified-release tablet (Winthrop Pharmaceuticals) 4070200 Opioid Analgesics 
Ethylmorphine hydrochloride Collins 1.5mg/5ml elixir (Collins Elixir Co) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine Oral solution (Berk Pharmaceuticals) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml linctus sugar free (Pinewood Healthcare) 3090100 Cough Suppressants 
Codeine phosphate Codeine 15mg/5ml Oral solution (Celltech Pharma Europe) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml linctus sugar free (Thornton & Ross) 3090100 Cough Suppressants 
Codeine phosphate Codeine 15mg/5ml Oral solution (William Ransom) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml Oral solution (Rusco) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Tramadol sr 100mg Modified-release tablet (Winthrop Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol sr 200mg Modified-release tablet (Winthrop Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (A A H Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine Oral solution (Co-operative) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (A A H Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Actavis UK) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml Oral solution (Nucare Plc) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Wockhardt UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/5ml oral solution (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine hydrochloride 10mg Injection (Hillcross Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Actavis UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Teva UK) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Actavis UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Genus Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Mylan) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg Tablet (Berk Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 30mg/ml Injection (Celltech Pharma Europe) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 10mg powder for solution for injection ampoules (Novartis) 4070200 Opioid Analgesics 
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Diamorphine hydrochloride Diamorphine 30mg powder for solution for injection ampoules (Novartis) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Kent Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (PLIVA Pharma) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 20mg/2ml solution for injection ampoules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 20mg/2ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulfate 50mg/50ml solution for infusion vials 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Temgesic 300micrograms/1ml solution for injection ampoules (RB Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Fentanyl citrate Fentanyl 100micrograms/2ml solution for injection ampoules 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Oxycodone hydrochloride Oxycodone 10mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol 24 Modified-release tablet 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramquel SR 100mg capsules (Beechmere Pharmaceuticals) 4070200 Opioid Analgesics 
Alfentanil hydrochloride Alfentanil 1mg/2ml solution for injection ampoules 15010403 Opioid Analgesics (in Anaesthesia) 
Methadone hydrochloride Methadone 20mg/2ml solution for injection ampoules 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Tradorec XL 200mg tablets (Paladin Labs Europe) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tradorec XL 100mg tablets (Paladin Labs Europe) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 25mg/5ml oral solution (Thornton & Ross) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Larapam SR 100mg tablets (Sandoz) 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 500micrograms/10ml solution for injection ampoules 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Fentanyl Matrifen 25micrograms/hour transdermal patches (Teva UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tradorec XL 300mg tablets (Paladin Labs Europe) 4070200 Opioid Analgesics 
Fentanyl Matrifen 100micrograms/hour transdermal patches (Teva UK) 4070200 Opioid Analgesics 
Alfentanil hydrochloride Alfentanil 5mg/10ml solution for injection ampoules 15010403 Opioid Analgesics (in Anaesthesia) 
Fentanyl Matrifen 50micrograms/hour transdermal patches (Teva UK) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 50mg/5ml solution for injection ampoules 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Mabron 200mg modified-release tablets (Morningside Healthcare) 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol 50mg modified-release tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Zydol SR 50mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramquel SR 50mg capsules (Beechmere Pharmaceuticals) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 5mg/ml oral solution 0 Unknown 
Tramadol hydrochloride Tramadol 150mg modified-release tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 200mg modified-release tablets 4070200 Opioid Analgesics 
Alfentanil hydrochloride Alfentanil 0.1% nasal spray 4070200 Opioid Analgesics 
Methadone hydrochloride Physeptone 50mg/1ml solution for injection ampoules (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Methadone hydrochloride Physeptone 50mg/1ml solution for injection ampoules (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Methadone hydrochloride Methadone 35mg/3.5ml solution for injection ampoules 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Pethidine hydrochloride Pethidine 50mg/1ml solution for injection ampoules (AMCo) 4070200 Opioid Analgesics 
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Fentanyl Fentalis Reservoir 100micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Fentanyl Fentalis Reservoir 25micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Tramadol hydrochloride Mabron 100mg modified-release tablets (Morningside Healthcare) 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol (roi) Tablet 4070200 Opioid Analgesics 
Fentanyl Fentalis Reservoir 50micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Fentanyl Matrifen 12micrograms/hour transdermal patches (Teva UK) 4070200 Opioid Analgesics 
Fentanyl Mezolar Matrix 12micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Fentanyl Osmach 50micrograms/hour transdermal patches (Teva UK) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 40micrograms/dose transdermal system 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg capsules 4070200 Opioid Analgesics 
Fentanyl Mezolar Matrix 25micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Pentazocine Lactate Pentazocine 30mg/ml Injection (Sterwin Medicines) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine 25mg Tablet (Roche Products) 4070200 Opioid Analgesics 
Remifentanyl hydrochloride Remifentanil 1mg powder for solution for injection vials 15010403 Opioid Analgesics (in Anaesthesia) 
Tramadol hydrochloride Larapam SR 200mg tablets (Sandoz) 4070200 Opioid Analgesics 
Buprenorphine Hydrochloride/ 
Naloxone Hydrochloride 
Naloxone hc 2mg + 8mg Tablet 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Fentanyl Mezolar Matrix 75micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Fentanyl Matrifen 75micrograms/hour transdermal patches (Teva UK) 4070200 Opioid Analgesics 
Fentanyl Fentalis Reservoir 75micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Teva UK) 4070200 Opioid Analgesics 
Alfentanil hydrochloride Rapifen 1mg/2ml solution for injection ampoules (Janssen-Cilag) 15010403 Opioid Analgesics (in Anaesthesia) 
Tramadol hydrochloride Tramadol 50mg Capsule (Tillomed Laboratories) 4070200 Opioid Analgesics 
Fentanyl Mezolar Matrix 100micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zamadol 100mg/2ml solution for injection ampoules (Meda Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramquel SR 200mg capsules (Beechmere Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate DF 118 Forte 40mg tablets (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Galcodine 3mg/5ml linctus paediatric (Thornton & Ross) 3090100 Cough Suppressants 
Fentanyl Osmach 100micrograms/hour transdermal patches (Ratiopharm UK) 4070200 Opioid Analgesics 
Fentanyl Mezolar Matrix 50micrograms/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Fentanyl Osmach 25micrograms/hour transdermal patches (Teva UK) 4070200 Opioid Analgesics 
Dextromoramide tartrate Palfium 5mg Tablet (IDIS World Medicines) 4070200 Opioid Analgesics 
Methadone hydrochloride Eptadone 1mg/ml oral solution (Dee Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Ibuprofen/Codeine phosphate Solpadeine Migraine Ibuprofen & Codeine tablets (Omega Pharma) 04070200/10010100 Opioid Analgesics/Non-steroidal Anti-inflammatory Drugs 
Fentanyl citrate Fentanyl 100microgram sublingual tablets sugar free 4070200 Opioid Analgesics 
Naloxone Hydrochloride/ 
oxycodone Hydrochloride 
Oxycodone 10mg / Naloxone 5mg modified-release tablets 4070200 Opioid Analgesics 
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Naloxone Hydrochloride/ 
oxycodone Hydrochloride 
Targinact 10mg/5mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Naloxone hydrochloride/ 
Oxycodone hydrochloride 
Targinact 20mg/10mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Naloxone hydrochloride 
/Oxycodone hydrochloride 
Oxycodone 20mg / Naloxone 10mg modified-release tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Marol 100mg modified-release tablets (Morningside Healthcare) 4070200 Opioid Analgesics 
Fentanyl citrate Abstral 100microgram sublingual tablets (ProStrakan) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Zentiva) 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 200microgram sublingual tablets sugar free 4070200 Opioid Analgesics 
Tramadol hydrochloride Marol 200mg modified-release tablets (Morningside Healthcare) 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 100microgram buccal tablets sugar free 4070200 Opioid Analgesics 
Fentanyl citrate Effentora 100microgram buccal tablets (Teva UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Marol 150mg modified-release tablets (Morningside Healthcare) 4070200 Opioid Analgesics 
Fentanyl citrate Abstral 200microgram sublingual tablets (ProStrakan) 4070200 Opioid Analgesics 
Tramadol hydrochloride Nobligan retard 100mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Fentanyl citrate Abstral 800microgram sublingual tablets (ProStrakan) 4070200 Opioid Analgesics 
Tramadol hydrochloride Maxitram SR 200mg capsules (Chiesi) 4070200 Opioid Analgesics 
Meptazinol hydrochloride Meptid 200mg tablets (Almirall) 4070200 Opioid Analgesics 
Fentanyl citrate Effentora 200microgram buccal tablets (Teva UK) 4070200 Opioid Analgesics 
Fentanyl citrate Abstral 400microgram sublingual tablets (ProStrakan) 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 200microgram buccal tablets sugar free 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramulief SR 100mg tablets (AMCo) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramulief SR 200mg tablets (AMCo) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramulief SR 150mg tablets (AMCo) 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 400microgram sublingual tablets sugar free 4070200 Opioid Analgesics 
Fentanyl Citrate Effentora 400microgram buccal tablets (Teva UK) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 10mg/5ml oral solution (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Niche Generics) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 2mg sublingual tablets sugar free (Teva UK) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Buprenorphine hydrochloride Buprenorphine 8mg sublingual tablets sugar free (Teva UK) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Pethidine hydrochloride Pethidine 50mg tablets (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Maxitram SR 100mg capsules (Chiesi) 4070200 Opioid Analgesics 
Tramadol hydrochloride Maxitram SR 50mg capsules (Chiesi) 4070200 Opioid Analgesics 
Alfentanil Hydrochloride Rapifen 500microgram/ml Injection (Janssen-Cilag) 15010403 Opioid Analgesics (in Anaesthesia) 
Fentanyl citrate Effentora 600microgram buccal tablets (Teva UK) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 300micrograms/1ml solution for injection ampoules 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
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Fentanyl citrate Abstral 600microgram sublingual tablets (ProStrakan) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 30mg modified-release capsules 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 400microgram buccal tablets sugar free 4070200 Opioid Analgesics 
Naloxone Hydrochloride/ 
oxycodone Hydrochloride 
Oxycodone 5mg / Naloxone 2.5mg modified-release tablets 4070200 Opioid Analgesics 
Naloxone Hydrochloride/ 
oxycodone Hydrochloride 
Targinact 5mg/2.5mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone Hydrochloride Oxycodone 50mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Almus Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 50mg/1ml solution for injection ampoules (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride/ 
Naloxone hydrochloride 
Oxycodone 40mg / Naloxone 20mg modified-release tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramquel SR 150mg capsules (Beechmere Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Maxitram SR 150mg capsules (Chiesi) 4070200 Opioid Analgesics 
Tramadol hydrochloride Larapam SR 150mg tablets (Sandoz) 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 300microgram sublingual tablets sugar free 4070200 Opioid Analgesics 
Fentanyl citrate Effentora 800microgram buccal tablets (Teva UK) 4070200 Opioid Analgesics 
Oxycodone hydrochloride/ 
Naloxone hydrochloride 
Targinact 40mg/20mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 50micrograms/dose nasal spray 4070200 Opioid Analgesics 
Fentanyl Osmach 75micrograms/hour transdermal patches (Teva UK) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml Oral solution (Thornton & Ross) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Fentanyl Citrate Abstral 300microgram sublingual tablets (ProStrakan) 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 600microgram sublingual tablets sugar free 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets (Wockhardt UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine Oral solution (Family Health) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Teva UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Pethidine Hydrochloride Pethidine 100mg/2ml Injection (C P Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Teva UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Methadone hydrochloride Methadone 1mg/ml oral solution (Rosemont Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine hydrochloride Morphine hcl 15mg Suppository (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulphate 10mg Suppository (Aurum Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulphate 15mg Suppository (Celltech Pharma Europe) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 1mg/ml Mixture (Macarthy Medical) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Methadone hydrochloride Methadone 1mg/ml Mixture (Macarthy Medical) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Diamorphine hydrochloride Diamorphine 30mg powder for solution for injection ampoules (Wockhardt UK) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 30mg powder for solution for injection ampoules (Wockhardt UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/1ml solution for injection ampoules (Martindale) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 100mg modified-release tablets (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl Victanyl 100micrograms/hour transdermal patches (Actavis UK) 4070200 Opioid Analgesics 
 131 
 
Buprenorphine Hydrochloride/ 
Naloxone Hydrochloride 
Naloxone hc 500micrograms + 2mg Tablet 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Pentazocine lactate Fortral 30mg/1ml solution for injection ampoules (Zentiva) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Df118 30mg Tablet (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride/ 
Paracetamol 
Tramadol 37.5mg / Paracetamol 325mg effervescent tablets sugar free 4070200 Opioid Analgesics 
Tramadol hydrochloride/ 
Paracetamol 
Tramacet 37.5mg/325mg effervescent tablets (Grunenthal) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate 10mg Modified-release capsule 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 800microgram sublingual tablets sugar free 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 600microgram buccal tablets sugar free 4070200 Opioid Analgesics 
Fentanyl Victanyl 75micrograms/hour transdermal patches (Actavis UK) 4070200 Opioid Analgesics 
Fentanyl Osmanil 75micrograms/hour transdermal patches (Zentiva) 4070200 Opioid Analgesics 
Fentanyl Osmanil 25micrograms/hour transdermal patches (Zentiva) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine 50mg/ml intramuscular injection (Roche Products) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml Oral solution (Actavis UK) 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Tramadol 150mg modified-release tablets (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 10mg powder for solution for injection ampoules (Wockhardt UK) 4070200 Opioid Analgesics 
Fentanyl Citrate Instanyl 100micrograms/dose nasal spray (Takeda UK) 4070200 Opioid Analgesics 
Fentanyl Osmanil 50micrograms/hour transdermal patches (Zentiva) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol sr 50mg Capsule (Hillcross Pharmaceuticals) 4070200 Opioid Analgesics 
Methadone Hydrochloride Methadone Oral solution 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/1ml suspension for injection vials 4070200 Opioid Analgesics 
Alfentanil hydrochloride Rapifen Intensive Care 5mg/1ml solution for injection ampoules (Janssen-Cilag) 15010403 Opioid Analgesics (in Anaesthesia) 
Codeine phosphate Codeine phosphate Oral solution (William Ransom) 01040200/04070200 Antimotility Drugs/Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Zentiva) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Ranbaxy (UK)) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Fentanyl Citrate Instanyl 200micrograms/dose nasal spray (Takeda UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 100mg modified-release capsules 4070200 Opioid Analgesics 
Morphine sulfate Morphine 200mg modified-release capsules 4070200 Opioid Analgesics 
Alfentanil hydrochloride Rapifen 5mg/10ml solution for injection ampoules (Janssen-Cilag) 15010403 Opioid Analgesics (in Anaesthesia) 
Methadone hydrochloride Eptadone 5mg/ml oral solution (Dee Pharmaceuticals) 0 Unknown 
Fentanyl citrate Sublimaze 500micrograms/10ml solution for injection ampoules (Janssen-Cilag) 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Fentanyl citrate Sublimaze 500micrograms/10ml solution for injection ampoules (Janssen-Cilag) 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Tramadol hydrochloride Mabron 150mg modified-release tablets (Morningside Healthcare) 4070200 Opioid Analgesics 
Fentanyl Osmanil 12micrograms/hour transdermal patches (Zentiva) 4070200 Opioid Analgesics 
Fentanyl Victanyl 50micrograms/hour transdermal patches (Actavis UK) 4070200 Opioid Analgesics 
Pentazocine lactate Fortral 60mg/2ml solution for injection ampoules (Zentiva) 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 200micrograms/dose nasal spray 4070200 Opioid Analgesics 
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Pethidine Hydrochloride Pethidine injection 4070200 Opioid Analgesics 
Fentanyl Citrate PecFent 100micrograms/dose nasal spray (ProStrakan) 4070200 Opioid Analgesics 
Fentanyl Osmanil 100micrograms/hour transdermal patches (Zentiva) 4070200 Opioid Analgesics 
Fentanyl Victanyl 25micrograms/hour transdermal patches (Actavis UK) 4070200 Opioid Analgesics 
Fentanyl citrate Instanyl 50micrograms/dose nasal spray (Takeda UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 60mg modified-release capsules 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 30mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 60mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 15mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 15mg modified-release tablets 4070200 Opioid Analgesics 
Tapentadol hydrochloride Tapentadol 200mg modified-release tablets 4070200 Opioid Analgesics 
Tapentadol hydrochloride Tapentadol 50mg tablets 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 30mg modified-release tablets 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 120mg modified-release tablets (Napp Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 100micrograms/dose nasal spray 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 60mg modified-release tablets 4070200 Opioid Analgesics 
Tapentadol hydrochloride Palexia 50mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Tapentadol hydrochloride Palexia SR 50mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Tapentadol Hydrochloride Tapentadol 100mg modified-release tablets 4070200 Opioid Analgesics 
Tapentadol Hydrochloride Tapentadol 150mg modified-release tablets 4070200 Opioid Analgesics 
Tapentadol Hydrochloride Palexia SR 100mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Tapentadol Hydrochloride Tapentadol 50mg modified-release tablets 4070200 Opioid Analgesics 
Tapentadol hydrochloride Palexia 75mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Tapentadol Hydrochloride Palexia SR 150mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Oxycodone Hydrochloride Oxycodone 120mg modified-release tablets 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 200mg modified-release capsules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl citrate PecFent 400micrograms/dose nasal spray (ProStrakan) 4070200 Opioid Analgesics 
Tapentadol hydrochloride Tapentadol 75mg tablets 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 800microgram buccal tablets sugar free 4070200 Opioid Analgesics 
Fentanyl Fencino 12micrograms/hour transdermal patches (DB Ashbourne) 4070200 Opioid Analgesics 
Fentanyl Fencino 50micrograms/hour transdermal patches (DB Ashbourne) 4070200 Opioid Analgesics 
Methadone hydrochloride Physeptone 20mg/2ml solution for injection ampoules (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol Hydrochloride Tramadol 100mg/ml oral drops 4070200 Opioid Analgesics 
Tramadol hydrochloride Zeridame SR 150mg tablets (Actavis UK) 4070200 Opioid Analgesics 
Fentanyl Fencino 75micrograms/hour transdermal patches (DB Ashbourne) 4070200 Opioid Analgesics 
Fentanyl Fencino 100micrograms/hour transdermal patches (DB Ashbourne) 4070200 Opioid Analgesics 
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Tapentadol hydrochloride Palexia SR 200mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Fentanyl Fencino 25micrograms/hour transdermal patches (DB Ashbourne) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets (Ranbaxy (UK)) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Papaveretum Omnopon 15.4mg/ml Injection (Roche Products) 4070200 Opioid Analgesics 
Morphine sulfate Filnarine SR 200mg tablets (Teva UK) 4070200 Opioid Analgesics 
Tapentadol Hydrochloride Tapentadol 250mg modified-release tablets 4070200 Opioid Analgesics 
Fentanyl Fentanyl 75micrograms/hr Transdermal patch (Sandoz) 4070200 Opioid Analgesics 
Tapentadol hydrochloride Palexia SR 250mg tablets (Grunenthal) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/10ml solution for injection Minijet pre-filled syringes (UCB) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine hydrochloride 10mg Injection (Approved Prescription Services) 4070200 Opioid Analgesics 
Diamorphine Hydrochloride Diamorphine hydrochloride 30mg Injection (Hillcross Pharmaceuticals) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 1mg/ml oral solution sugar free (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate Morphine 90mg modified-release capsules 4070200 Opioid Analgesics 
Fentanyl Citrate Fentanyl 400micrograms/dose nasal spray 4070200 Opioid Analgesics 
Tramadol Hydrochloride Tramadol (roi) Tablet 4070200 Opioid Analgesics 
Morphine sulfate Morphine 150mg modified-release capsules 4070200 Opioid Analgesics 
Codeine phosphate Codeine phosphate 15mg Tablet (Wockhardt UK) 01040200/04070200 Antimotility Drugs/Opioid Analgesics 
Morphine sulfate Morphine 120mg modified-release capsules 4070200 Opioid Analgesics 
Codeine phosphate Codeine phosphate 30mg Tablet (Wockhardt UK) 01040200/04070200 Antimotility Drugs/Opioid Analgesics 
Morphine sulfate M-eslon 10mg Capsule (Trinity Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Ranbaxy (UK)) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Codeine Phosphate Codeine phosphate oral solution 01040200/03090100 Antimotility Drugs/Cough Suppressants 
Tramadol hydrochloride Tramadol 200mg modified-release tablets (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 100mg/2ml solution for injection ampoules (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Almus Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Almus Pharmaceuticals) 0 Unknown 
Pethidine hydrochloride Pethidine 100mg/2ml solution for injection ampoules (Actavis UK) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets (Actavis UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 5mg powder for solution for injection vials (Teva UK) 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 100micrograms/2ml solution for injection ampoules (Martindale Pharma) 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Diamorphine hydrochloride Diamorphine 5mg powder for solution for injection ampoules 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 5mg powder for solution for injection vials 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 10mg powder for solution for injection ampoules 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 30mg powder for solution for injection ampoules 4070200 Opioid Analgesics 
Fentanyl Durogesic DTrans 50micrograms transdermal patches (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
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Diamorphine hydrochloride Diamorphine 10mg powder for solution for injection vials 4070200 Opioid Analgesics 
Diamorphine Diamorphine 30mg powder for solution for injection vials 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 100mg powder for solution for injection ampoules 4070200 Opioid Analgesics 
Diamorphine Diamorphine 100mg powder for solution for injection vials 4070200 Opioid Analgesics 
Codeine phosphate Codeine 3mg/5ml linctus paediatric 0 Unknown 
Tramadol hydrochloride Marol 150mg modified-release tablets (Teva UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Marol 100mg modified-release tablets (Teva UK) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 5mg modified-release tablets (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 20mg modified-release tablets (Lexon (UK)) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 20mg/2ml solution for injection ampoules (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 5mg capsules (Lexon (UK)) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/1ml solution for injection ampoules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 5mg capsules (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Subutex 2mg sublingual tablets (Lexon (UK)) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Codeine phosphate Codeine phosphate 15mg Tablet (Celltech Pharma Europe) 01040200/04070200 Antimotility Drugs/Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Alliance Healthcare (Distribution)) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/1ml solution for injection ampoules (UCB Pharma) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Bristol Laboratories) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets (A A H Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Fentanyl Fentanyl 12micrograms/hour transdermal patches (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 10mg/1ml solution for injection ampoules (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 10mg modified-release tablets (Mawdsley-Brooks & Company) 4070200 Opioid Analgesics 
Tramadol hydrochloride Marol 200mg modified-release tablets (Teva UK) 4070200 Opioid Analgesics 
Fentanyl Durogesic DTrans 12micrograms transdermal patches (Mawdsley-Brooks & Company) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 100mg modified-release capsules (Alliance Healthcare (Distribution)) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 25micrograms/hour transdermal patches (Phoenix Healthcare Distribution) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Alliance Healthcare (Distribution)) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 20mg capsules (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 10mg/1ml solution for injection ampoules (Mawdsley-Brooks & Company) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Bristol Laboratories) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 10mg capsules (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 80mg modified-release tablets (Mawdsley-Brooks & Company) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Bristol Laboratories) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Fentanyl citrate Fentanyl 100micrograms/2ml solution for injection ampoules (AMCo) 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Oxycodone hydrochloride Longtec 5mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Longtec 10mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
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Oxycodone hydrochloride Longtec 40mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 100mg/10ml solution for injection ampoules (Alliance Healthcare  4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Bristol Laboratories) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyNorm 10mg capsules (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Accord Healthcare) 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 10mg modified-release tablets (Lexon (UK)) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Kent Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine 25mg/5ml oral solution (A A H Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Sigma Pharmaceuticals Plc) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Tramadol 100mg modified-release capsules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Hydromorphone hydrochloride Hydromorphone 10mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 5mg/5ml solution for injection ampoules 4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 10mg modified-release tablets (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Longtec 20mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 10mg powder for solution for injection vials (Teva UK) 4070200 Opioid Analgesics 
Morphine hydrochloride Morphine hydrochloride 10mg/5ml oral solution (Special Order) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 10mg powder for solution for injection ampoules (Actavis UK) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets (Alliance Healthcare (Distribution)) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Ibuprofen/Codeine phosphate Ibuprofen and codeine 200mg+12.8mg Tablet (Almus Pharmaceuticals) 04070200/10010100 Opioid Analgesics/Non-steroidal Anti-inflammatory Drugs 
Morphine sulfate Morphine 10mg modified-release tablets (Sigma Pharmaceuticals Plc) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine oral liquid 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/1ml solution for injection ampoules (Hameln 
Pharmaceuticals) 
4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg/1ml solution for injection ampoules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine phosphate 60mg Tablet (Wockhardt UK) 01040200/04070200 Antimotility Drugs/Opioid Analgesics 
Morphine Sulphate Morphine sulphate Capsule 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg modified-release capsules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine capsule 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Kent Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 30mg suppositories (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate Oral solution 4070200 Opioid Analgesics 
Oxycodone hydrochloride Longtec 80mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg tablets (Actavis UK) 4070200 Opioid Analgesics 
Buprenorphine Transtec 52.5micrograms/hour transdermal patches (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 50micrograms/hour transdermal patches (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morcap SR 50mg capsules (Hospira UK) 0 Unknown 
Morphine sulfate Morphine 20mg modified-release capsules 0 Unknown 
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Diamorphine hydrochloride Diamorphine 500mg powder for solution for injection ampoules 4070200 Opioid Analgesics 
Nalbuphine hydrochloride Nubain 10mg/1ml solution for injection ampoules (Bristol-Myers Squibb 
Pharmaceuticals) 
0 Unknown 
Codeine phosphate Codeine 15mg tablets (Phoenix Healthcare Distribution) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Morphine sulfate Morphine sulfate 50mg/50ml solution for infusion vials (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Dihydrocodeine Tartrate Dihydrocodeine 10mg tablets 03090100/04070200 Cough Suppressants/Opioid Analgesics 
Diamorphine Diamorphine 500mg powder for solution for injection vials 4070200 Opioid Analgesics 
Fentanyl Fentanyl 100micrograms/hour transdermal patches (Phoenix Healthcare Distribution) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 1mg/ml oral solution sugar free (Thornton & Ross) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate Morphine sulphate 15mg/ml Injection (Celltech Pharma Europe) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine 50mg/ml Injection (Roche Products) 4070200 Opioid Analgesics 
Pethidine Hydrochloride Pethidine 10mg/ml Injection (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg Capsule (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg/1ml solution for injection ampoules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine Sulphate Morphine sulphate Injection 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/2ml solution for injection ampoules 4070200 Opioid Analgesics 
Tramadol hydrochloride Zamadol SR 200mg capsules (Lexon (UK)) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 50mg/50ml solution for infusion vials (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Phoenix Healthcare Distribution) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Alfentanil Hydrochloride Alfentanil 5mg/5ml buccal spray 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxylan 10mg modified-release tablets (Chanelle Medical UK) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 25micrograms/hour transdermal patches (Sigma Pharmaceuticals Plc) 4070200 Opioid Analgesics 
Buprenorphine BuTrans 5micrograms/hour transdermal patches (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/5ml oral solution (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Almus Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg tablets (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxylan 10mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxylan 20mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets (Teva UK) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Buprenorphine hydrochloride Prefibin 8mg sublingual tablets (Sandoz) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Codeine phosphate Codeine 30mg tablets (Waymade Healthcare Plc) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Morphine sulfate Morphine sulfate 15mg/1ml solution for injection ampoules (UCB Pharma) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 15mg/1ml solution for injection ampoules (Wockhardt UK) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 10mg/5ml oral solution 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 5mg/5ml oral solution 4070200 Opioid Analgesics 
Oxycodone hydrochloride Lynlor 20mg capsules (Actavis UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Zeridame SR 100mg tablets (Actavis UK) 4070200 Opioid Analgesics 
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Codeine phosphate Codeine 15mg/5ml linctus sugar free (DE Pharmaceuticals) 3090100 Cough Suppressants 
Pethidine hydrochloride Pethidine 50mg/5ml solution for injection ampoules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Lynlor 5mg capsules (Actavis UK) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 2mg sublingual tablets sugar free (A A H Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Diamorphine hydrochloride Diamorphine 10mg tablets (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg suppositories (Martindale Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg modified-release capsules (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxylan 20mg modified-release tablets (Chanelle Medical UK) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 3mg/5ml oral solution 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 1mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg tablets (Alliance Healthcare (Distribution)) 4070200 Opioid Analgesics 
Buprenorphine BuTrans 10micrograms/hour transdermal patches (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
  Generic Migraleve tablets 04070200/04070401 Opioid Analgesics/Treatment Of Acute Migraine 
Methadone sulfate Morphine sulfate 5mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Oxycodone hydrochloride Lynlor 10mg capsules (Actavis UK) 4070200 Opioid Analgesics 
Morphine hydrochloride Morphine hydrochloride 10mg/5ml oral solution 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml linctus sugar free (Kent Pharmaceuticals) 3090100 Cough Suppressants 
Fentanyl citrate Fentanyl 400microgram buccal films sugar free 4070200 Opioid Analgesics 
  BuTrans 20micrograms/hour transdermal patches (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Methadone Methadone 100mg capsules 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Buprenorphine Hapoctasin 70micrograms/hour transdermal patches (Actavis UK) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 200microgram buccal films sugar free 4070200 Opioid Analgesics 
Buprenorphine Hapoctasin 52.5micrograms/hour transdermal patches (Actavis UK) 4070200 Opioid Analgesics 
Fentanyl  Fentanyl 37.5microgram/hour transdermal patches 4070200 Opioid Analgesics 
Fentanyl Mezolar Matrix 37.5microgram/hour transdermal patches (Sandoz) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/5ml oral solution (Alliance Healthcare (Distribution)) 4070200 Opioid Analgesics 
Buprenorphine Transtec 35micrograms/hour transdermal patches (Mawdsley-Brooks & Company) 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 100micrograms/2ml solution for injection ampoules (A A H Pharmaceuticals) 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Oxycodone hydrochloride Shortec 10mg capsules (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 2mg sublingual tablets sugar free (Actavis UK) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg tablets (Ranbaxy (UK)) 4070200 Opioid Analgesics 
Buclizine hydrochloride/ 
Paracetamol/Codeine 
phosphate 
Generic Migraleve Pink tablets 04070200/04070401 Opioid Analgesics/Treatment Of Acute Migraine 
Buprenorphine hydrochloride Tephine 200microgram sublingual tablets (Sandoz) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Alfentanil hydrochloride Alfentanil 500micrograms/1ml solution for injection ampoules 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Morphine sulfate Morphine sulfate 5mg/10ml solution for injection ampoules 4070200 Opioid Analgesics 
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Tramadol hydrochloride Tramadol 50mg modified-release capsules (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Shortec 5mg capsules (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Shortec 20mg capsules (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine Hapoctasin 35micrograms/hour transdermal patches (Actavis UK) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxylan 40mg modified-release tablets (Chanelle Medical UK) 4070200 Opioid Analgesics 
Remifentanyl hydrochloride Remifentanil 5mg powder for solution for injection vials 15010403 Opioid Analgesics (in Anaesthesia) 
Fentanyl Fentanyl 25micrograms/hour transdermal patches (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
  Codeine 30mg suppositories 4070200 Opioid Analgesics 
  Morphine 0.1% in Intrasite gel 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 500micrograms/5ml oral solution 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Waymade Healthcare Plc) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 5mg powder for solution for injection ampoules (Actavis UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tilodol SR 200mg tablets (Sandoz) 4070200 Opioid Analgesics 
  Tapentadol 20mg/ml oral solution sugar free 4070200 Opioid Analgesics 
Fentanyl Fentanyl 25micrograms/hour transdermal patches (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Buprenorphine Transtec 35micrograms/hour transdermal patches (Sigma Pharmaceuticals Plc) 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone 5mg capsules 03090100/04070200/04105200 Cough Suppressants/Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate Morphine sulfate 5mg/5ml oral solution 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (DE Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Codeine phosphate Codeine 15mg/5ml linctus (Waymade Healthcare Plc) 3090100 Cough Suppressants 
  Opiodur 12micrograms/hour transdermal patches (Pfizer) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets (Waymade Healthcare Plc) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Buprenorphine hydrochloride Tephine 400microgram sublingual tablets (Sandoz) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Fentanyl Fentanyl 12micrograms/hour transdermal patches (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 50mg/50ml solution for infusion vials (Alliance Healthcare 
(Distribution)) 
4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Phoenix Healthcare Distribution) 4070200 Opioid Analgesics 
Fentanyl Mylafent 75micrograms/hour transdermal patches (Mylan) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 30mg/1ml solution for injection ampoules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine 30mg modified-release tablets (Sigma Pharmaceuticals Plc) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/1ml solution for injection ampoules (Wockhardt UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 50mg/50ml solution for infusion vials (Torbay Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Morningside Healthcare) 4070200 Opioid Analgesics 
  Recivit 267microgram sublingual tablets (Grunenthal) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 100mg/50ml solution for infusion vials (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Tapentadol hydrochloride Palexia 20mg/ml oral solution (Grunenthal) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Sigma Pharmaceuticals Plc) 4070200 Opioid Analgesics 
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Oxycodone hydrochloride Reltebon 40mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Reltebon 20mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 20mg/2ml solution for injection ampoules 4070200 Opioid Analgesics 
Oxycodone hydrochloride Reltebon 10mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Reltebon 5mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 2.5mg/5ml solution for injection ampoules 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (DE Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Oxycodone hydrochloride Reltebon 80mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 200microgram sublingual tablets sugar free (A A H Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine hydrochloride Morphine hydrochloride 1mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Methadone hydrochloride Methadone hydrochloride powder 50030000 Extemporaneous Item 
Buprenorphine hydrochloride Buprenorphine 4mg sublingual tablets sugar free 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol 
hydrochloride/Paracetamol 
Tramacet 37.5mg/325mg tablets (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 6mg sublingual tablets sugar free 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Buprenorphine hydrochloride Buprenorphine 8mg sublingual tablets sugar free (Zentiva) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Tramadol hydrochloride Tramadol 100mg modified-release capsules (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 12micrograms/hour transdermal patches (Phoenix Healthcare Distribution) 4070200 Opioid Analgesics 
Pethidine hydrochloride Pethidine 50mg/1ml solution for injection ampoules (Alliance Healthcare 
(Distribution)) 
4070200 Opioid Analgesics 
Oxycodone hydrochloride OxyContin 40mg modified-release tablets (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Reltebon 30mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 133microgram sublingual tablets sugar free 4070200 Opioid Analgesics 
Fentanyl citrate Fentanyl 2.5mg/50ml solution for infusion vials 04070200/15010403 Opioid Analgesics/Opioid Analgesics (in Anaesthesia) 
Morphine sulfate Morphine sulfate 10mg/1ml solution for injection ampoules (DE Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 1mg suppositories 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 10mg/5ml oral solution (Actavis UK) 4070200 Opioid Analgesics 
Codeine phosphate Codeine phosphate powder (Martindale Pharmaceuticals) 50030000 Extemporaneous Item 
Buprenorphine hydrochloride Subutex 2mg sublingual tablets (DE Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Oxycodone hydrochloride Reltebon 60mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg modified-release capsules (J M McGill) 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 10mg/5ml oral solution (Waymade Healthcare Plc) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 15mg tablets (Crescent Pharma) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Oxycodone hydrochloride Oxylan 5mg modified-release tablets (Chanelle Medical UK) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 400microgram sublingual tablets sugar free (Teva UK) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Oxycodone hydrochloride Reltebon 15mg modified-release tablets (Actavis UK) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Longtec 30mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 2mg/5ml oral solution 4070200 Opioid Analgesics 
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Oxycodone hydrochloride Longtec 15mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol 
hydrochloride/Paracetamol 
Tramadol 37.5mg / Paracetamol 325mg tablets (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 100mg modified-release capsules (Ennogen Healthcare) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Longtec 60mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 100mg modified-release capsules (Icarus Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg/1ml solution for injection ampoules (Alliance Healthcare (Distribution)) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Sigma Pharmaceuticals Plc) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Morphine sulfate Morphine sulfate 50mg/1ml solution for injection ampoules 4070200 Opioid Analgesics 
Morphine sulfate Morphine sulfate 50mg/5ml solution for injection ampoules 4070200 Opioid Analgesics 
  Longtec 120mg modified-release tablets (Qdem Pharmaceuticals) 4070200 Opioid Analgesics 
Buprenorphine hydrochloride Gabup 8mg sublingual tablets (Martindale Pharmaceuticals) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
Morphine sulfate Morphine sulfate 10mg/10ml solution for injection ampoules 4070200 Opioid Analgesics 
Tramadol hydrochloride Maneo 100mg modified-release tablets (Mylan) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Oxycodone 5mg/5ml oral solution sugar free (Wockhardt UK) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Crescent Pharma) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Buprenorphine hydrochloride Buprenorphine 2mg sublingual tablets sugar free (Sigma Pharmaceuticals Plc) 04070200/04105200 Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence 
  Mylafent 12micrograms/hour transdermal patches (Mylan) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 30mg tablets (Mawdsley-Brooks & Company) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg capsules (Kent Pharmaceuticals) 4070200 Opioid Analgesics 
Codeine phosphate Codeine 60mg tablets (DE Pharmaceuticals) 01040200/03090100/04070200 Antimotility Drugs/Cough Suppressants/Opioid Analgesics 
Fentanyl Mylafent 50micrograms/hour transdermal patches (Mylan) 4070200 Opioid Analgesics 
Diamorphine hydrochloride Diamorphine 5mg powder for solution for injection ampoules (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Abtard 30mg modified-release tablets (DB Ashbourne) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Abtard 20mg modified-release tablets (DB Ashbourne) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 100micrograms/hour transdermal patches (A A H Pharmaceuticals) 4070200 Opioid Analgesics 
Fentanyl Fentanyl 267microgram sublingual tablets sugar free 4070200 Opioid Analgesics 
Dihydrocodeine tartrate Dihydrocodeine 30mg/5ml oral solution 4070200 Opioid Analgesics 
Oxycodone hydrochloride Abtard 40mg modified-release tablets (DB Ashbourne) 4070200 Opioid Analgesics 
Oxycodone hydrochloride Abtard 80mg modified-release tablets (DB Ashbourne) 4070200 Opioid Analgesics 
Tramadol hydrochloride Tramadol 50mg modified-release capsules (Cubic Pharmaceuticals) 4070200 Opioid Analgesics 
Z-drugs    
Zopiclone Zopiclone 7.5mg tablets 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg tablets 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 5mg tablets 4010100 Hypnotics 
Zolpidem tartrate Stilnoct 5mg tablets (Sanofi) 4010100 Hypnotics 
Zopiclone Zimovane 7.5mg tablets (Sanofi) 4010100 Hypnotics 
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Zolpidem tartrate Stilnoct 10mg tablets (Sanofi) 4010100 Hypnotics 
Zopiclone Zimovane LS 3.75mg tablets (Sanofi) 4010100 Hypnotics 
Zopiclone Zileze 3.75 tablets (Opus Pharmaceuticals) 4010100 Hypnotics 
Zaleplon Sonata 10mg capsules (Meda Pharmaceuticals) 4010100 Hypnotics 
Zaleplon Zaleplon 10mg capsules 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 10mg tablets 4010100 Hypnotics 
Zaleplon Zaleplon 5mg capsules 4010100 Hypnotics 
Zaleplon Sonata 5mg capsules (Meda Pharmaceuticals) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg/5ml oral suspension 4010100 Hypnotics 
Zopiclone Zileze 7.5 tablets (Opus Pharmaceuticals) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (Actavis UK) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg tablets (Actavis UK) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 5mg Tablet (Winthrop Pharmaceuticals) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg tablets (IVAX Pharmaceuticals UK) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg tablets (Mylan) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 10mg tablets (A A H Pharmaceuticals) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 5mg tablets (A A H Pharmaceuticals) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (IVAX Pharmaceuticals UK) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (Mylan) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 10mg tablets (Mylan) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (PLIVA Pharma) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg tablets (A A H Pharmaceuticals) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg tablets (Teva UK) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (Teva UK) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (Kent Pharmaceuticals) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg tablets (Kent Pharmaceuticals) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 10mg tablets (IVAX Pharmaceuticals UK) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 5mg tablets (Teva UK) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 5mg tablets (IVAX Pharmaceuticals UK) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 10mg Tablet (Winthrop Pharmaceuticals) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (A A H Pharmaceuticals) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 10mg tablets (Teva UK) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (Sandoz) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg/5ml oral solution 4010100 Hypnotics 
Zopiclone Zimovane 7.5mg tablets (Lexon (UK)) 4010100 Hypnotics 
Zopiclone Zopiclone 3.75mg tablets (Almus Pharmaceuticals) 4010100 Hypnotics 
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Zopiclone Zopiclone 7.5mg/5ml oral suspension 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg/5ml oral solution 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (Sigma Pharmaceuticals Plc) 4010100 Hypnotics 
Zolpidem tartrate Zolpidem 10mg tablets (Zentiva) 4010100 Hypnotics 
Zopiclone Zopiclone 7.5mg tablets (Phoenix Healthcare Distribution) 4010100 Hypnotics 
 
